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A note to the reader 
 
With the aim of making this thesis easier to digest, 
I have split the introduction into two parts: 
i) An introduction to the theory of mass spectrometry, and 
ii) An introduction into the field of structural biology. 
Finally, the materials and methods section of this thesis is listed in 
the order that they arise throughout this study. 
 
Thank you 
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M   Met   methionine   131.040 Da 
N   Asn   asparagine   114.042 Da 
P   Pro   proline    97.052 Da 
Q   Gln   glutamine   128.058 Da 
R   Arg   arginine   156.101 Da 
S   Ser   serine    87.032 Da 
T   Thr   threonine   101.047 Da 
V   Val   valine    99.068 Da 
W   Trp   tryptophan   186.079 Da 
Y   Tyr   tyrosine   163.063 Da 
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Abstract 
Protein aggregation is responsible for a vast array of life-threatening protein based diseases as 
well as being an economic hurdle in biopharmaceutical development and manufacturing. 
Monoclonal antibodies represent the fastest growing class of biotherapeutics, with 53 
antibodies in late phase clinical trials as of late 2015. Antibodies serve as ideal therapeutics 
due to their exquisite specificity and favourable safety profile. However, further therapeutic 
antibody development is hamstringed by uncontrolled self-association and aggregation which 
can occur at all stages of biotherapeutic development. Therefore, there is an urgent need for 
methods to dissect the mechanisms that drive uncontrolled self-association and protein 
aggregation. 
This thesis presents techniques which were applied to address the identification of aggregated 
material of a therapeutically relevant monoclonal antibody, and to characterise the 
mechanism responsible for driving oligomerisation. A combination of mass spectrometric 
techniques were employed to visualise the oligomeric species. Ion mobility spectrometry 
coupled to nanoelectrospray ionisation mass spectrometry was utilised to identify the 
oligomeric species formed under native conditions and to define the oligomers in terms of 
their mass and collision cross-sectional area.  
To characterise the regions responsible for driving oligomer formation, chemical cross-
linking was employed to capture the oligomeric species in solution which were then analysed 
using tandem mass spectrometry. The initial dimer interaction was modelled using distance 
restraints obtained from the chemical cross-linking results and a model proposed that explains 
the oligomerisation events, and how runaway polymerisation can occur at higher 
concentrations.  
Finally, a powerful in vivo assay in the E. coli periplasm was developed to differentiate 
between aggregation and non-aggregation-prone sequences using single chain variable 
fragments (scFv) of the antibodies studied. The results presented demonstrate the applicability 
of the assay to molecules relevant to the biopharmaceutical sector; as an upstream platform 
for the identification of aggregation-prone sequences, prior to antibody production and 
development. 
 2 
Overall, the work presented within this thesis describes techniques that can be successfully 
applied to define the mechanism that underpins the self-association of a therapeutically-
relevant monoclonal antibody. Furthermore, the study presents a novel in vivo assay that can 
be used to identify aggregation-prone sequences, and to develop them further by mutagenesis, 
which could be useful in protein development in the biopharmaceutical sector.
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1 Introduction I: The theory of mass spectrometry 
1.1 A brief history of mass spectrometry 
Mass spectrometry (MS) is an analytical technique that is used to study charged ions in the 
gas phase and measure them based upon their mass-to-charge ratio (m/z). It is a technique 
that is used primarily to analyse the mass of ions, but has been extended more recently to give 
in depth information on composition, as well as structure. For a sample to be analysed by MS 
it must first be introduced into the gas phase, which is achieved in the first stage of a mass 
spectrometer. The different stages of a mass spectrometer can be simplified and separated into 
ionisation, mass analysers and detection (Figure 1.1).  
 
Figure 1.1: Schematic of sample analysis by use of mass spectrometry. A sample is introduced 
whereupon it is ionised and the ions separated in the mass analyser according to their m/z 
ratio. These ions are then measured by the detector where computer software can convert the 
data into a mass spectrum. 
 
Modern mass spectrometers and their application have evolved a tremendous amount over 
the past century since their first use to measure the mass of an electron by J.J. Thomson in 
1897 (Thomson, 1897). Thomson discovered that cathode rays, Lenard rays at the time, 
travelled at a speed much faster than one would expect for a particle of that size. He deduced 
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that these negatively charged particles were 1,000 times lighter than the mass of a proton. 
Thomson denoted these particles as corpuscles, which were later renamed as electrons as G.S. 
Stoney had suggested before Thomson had ever made his discovery (Stoney, 1894). Thomson 
was awarded the Nobel Prize in physics for the “great merits of his theoretical and 
experimental investigations on the conduction of electricity by gases”.  The first detection of 
elemental isotopes was also discovered by Thomson in 1913 (Thomson, 1913). Using magnetic 
and electric fields to manipulate the beam path of a stream of neon gas, he noticed the 
appearance of two distinct patches on the photographic plate used for detection. They 
concluded that there must be in fact two beams with different masses to give rise to the results 
observed, this was the first discovery of Ne-20 and Ne-22. This initial use of mass 
spectrometry was further developed by Aston who continued to measure isotopes of various 
different elements and proposed the “whole number system”; a system whereby the mass of 
all elements are whole number multiples of the mass of a proton, e.g. oxygen being 16 Da 
(Aston, 1935).  In 1922, Aston was awarded the Nobel Prize in chemistry “for his discovery, 
by means of his mass spectrograph, of isotopes, in a large number of non-radioactive elements, 
and for his enunciation of the whole-number rule”. 
 
1.2 Ionisation 
Ionisation can be achieved by a variety of methods whereupon the sample is analysed by merit 
of its m/z ratio. Ions of different m/z are separated from one another before the abundance of 
each ion is finally recorded by the detector.  Modern day applications of mass spectrometry 
range from the analysis of small chemicals through to intact bio-molecules. The analysis of 
complex bio-molecules was limited at first, however, due to the methodologies used in sample 
ionisation. The first main breakthrough in this field was the development of fast atom 
bombardment (FAB) (Barber et al., 1981). FAB works by striking a sample containing a non-
volatile surface matrix with high voltage atoms of an inert gas (typically argon or xenon).  The 
sample in the matrix is then energised as the inert gas is neutralised when it collides with the 
surface and the protein ions are ejected in the form of [M+H]+. FAB is a relatively “soft” 
ionisation technique in that it the energies impacted on the sample do not cause any 
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fragmentation of the analyte. The technique is not ideal, however, since samples have to first 
be embedded in a matrix that is commonly made from glycerol or 3-nitrobenzyl alcohol.  
 
1.2.1 Soft ionisation techniques 
Native MS had its real breakthrough from the developments of the soft ionisation techniques 
matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI) which 
result in no fragmentation of the analyte, and therefore is capable of retaining non-covalent 
interactions upon transition into the gas phase.  
MALDI (Karas et al., 1985) first requires the analyte of interest to be mixed with a matrix, 
usually aromatic acids in nature (Fitzgerald et al., 1993), that is then spotted down onto a 
metal plate and left to crystallise together. Once co-crystallised, the samples are irradiated 
with a UV laser (337 nm) where ablation and desorption of the analyte from the matrix occurs 
(Knochenmuss, 2006) (Figure 1.2). The charged analytes, typically singly charged (in the form 
of [M+H]+) are then introduced to the source of the mass spectrometer. Although suited for 
small peptides and proteins, MALDI is not necessarily the best choice for large biomolecules 
due to the energy that is imparted on the sample from the laser irradiation. Furthermore, the 
co-crystallisation of the sample with the acid based matrix is not ideal for retaining non-
covalent interactions and so ESI tends to be preferred for the analysis of larger proteins 
because of its ability to maintain such interactions for analysis in the gas phase.  
 
Figure 1.2: Schematic of the MALDI ionisation process. Samples are co-crystallised with the 
matrix onto a MALDI plate. A UV laser at 337 nm is used to irradiate the matrix where sample 
ablation and desorption from the matrix occurs. The gas phase matrix undergoes charge 
transfer to protonate the ions. 
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ESI is an ionisation technique that takes place at atmospheric pressure and is seen as the most 
gentle of ionisation methods since many more non-covalent interactions are retained. 
Furthermore, the technique has been shown to be applicable to a wide range of proteins from 
a few hundred Da to multiple MDa (Bothner and Siuzdak, 2004, Van Berkel et al., 2000, 
Kaddis et al., 2007, Snijder et al., 2013). The electrospray process occurs as a capillary, 
containing a sample of interest, has a high potential applied across it and an electrode placed 
at the entrance of the mass spectrometer. As the voltage is applied across the capillary, a 
Taylor cone is formed at the front of the charged sample-containing solvent (Figure 1.3).  
 
Figure 1.3: Mechanism of ionisation using electrospray ionisation. Upon applying a voltage 
between the capillary and the entrance of the instrument, a Taylor cone is formed from the 
build-up of charge at the end of the capillary where fine charged droplets are ejected.  
 
The sample is then ejected in the form of an aerosol from the end of the filament formed by 
the Taylor cone (Taylor, 1964). The highly charged droplets in this aerosol contain the sample 
of interest. The droplets then decrease in size due to desolvation with the aid of a nebulising 
gas (typically nitrogen), at the front of the instrument. To further assist the desolvation 
process, a drying gas is sprayed orthogonally to the path of the droplets as they are attracted 
to the negatively charged source of the instrument (when working in positive ion mode). As 
the size of these droplets decrease, they experience an increase of columbic repulsion to a 
point where coulombic fission occurs due to the droplet reaching the Rayleigh limit (Taflin 
et al., 1989). From this stage, it is somewhat controversial as to how the proteins have the 
charge from the droplet deposited on their surface. There are two well accepted models for 
what happens to the droplets from this point onward, the charged residue model (CRM) (Dole 
et al., 1968) and the ion evaporation model (IEM) (Iribarne and Thomson, 1976) (Figure 1.4).  
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Figure 1.4: Schematic showing the different mechanisms of charge transfer onto the sample. 
The individual charged droplets decrease in size until the Raleigh limit is reached, and 
Coulombic fission of the droplets occurs. IEM = ion evaporation model, CRM = charged 
residue model and CEM = chain ejection model.  
 
 
The CRM is a model that is expected to hold with large polar samples such as proteins and 
other bio-molecules. This model states that as the droplets continue to decrease in size, they 
reach a stage where protons are ejected via the ion evaporation model (IEM) to prevent 
further coulombic fission occurring. It is believed that the proteins remain near the centre of 
the droplets so that they can maximise their interactions at the water interface and the charges 
are transferred onto positively charged side-chain residues by charge carriers during the final 
moments of the process. The IEM proposed by Iribarne and Thomson proposes that as the 
droplets decrease in size, they come to a state where the charge across the surface of the 
droplet is enough to eject the analyte carrying protons. As the CRM is believed to hold true 
for proteins and larger molecules, there is literature that provides evidence that the IEM is 
the method of ionisation of small molecules (Kebarle and Verkerk, 2009, Znamenskiy et al., 
2003). A third model has recently been proposed for the mechanism of ionisation for 
intrinsically disordered proteins, the chain ejection model (CEM) (Konermann et al., 2012). 
The CEM suggests that a region of the peptide chain is expelled from the droplet, since the 
disordered protein/peptide is unlikely remain at the centre of the desolvating droplet, as stated 
by the CRM. Therefore this model has some similarities with the IEM in that it states that a 
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small region of the protein is expelled as a charged species from the droplet, sequentially 
followed by the rest of the protein until it is fully released into the gas phase. 
The electrospray process was improved further in the field of native MS by the introduction 
of nanoelectrospray technology (nESI). With the use of volatile buffers (typically ammonium 
salts), this new technology allowed for slower flow rates (Wilm and Mann, 1996, Juraschek 
et al., 1999) meaning that a few microliters of sample could be sprayed from a nESI source for 
hours. Lower flow rates and lower voltage potentials applied (~1 kV) allowed for smaller 
droplets to form at the end of the capillary, made from borosilicate glass often coated with 
gold or palladium. These smaller droplets enhance the desolvation process and, due to lower 
energies, have greater capacity to retain the non-covalent interactions between bio-
molecules. The work on ESI resulted in John Fenn (Whitehouse et al., 1989) being awarded 
the Nobel Prize in 2002 along with Koichi Tanaka (Tanaka et al., 1988), who developed laser 
desorption ionisation, for “their development of soft desorption ionisation methods for mass 
spectrometric analyses of biological macromolecules”. 
 
1.3 Mass analysers 
Mass analysers function by separating ions created in the source of the instrument based on 
the m/z ratio. There are various different types of analysers: quadrupoles, time of flight (ToF), 
ion trapping and ion cyclotron resonance (ICR) analysers. Each of the different mass analysers 
outperform others in unique aspects and therefore the type of mass analyser chosen is 
dependent on the function required. Mass analysers are normally characterised by their 
resolving power, sensitivity, mass limitation and accuracy. 
The resolving power of a mass analyser is an important characteristic and is typically 
measured in two ways. The mass resolution is defined by the capacity of the analyser to 
separate two peaks, close on the m/z scale. First, resolution can be defined as the distance a 
single peak covers on the m/z scale at half of its maximum height (Δm/z) otherwise known as 
its full width at half maximum (FWHM) (Hoffmann and Stroobant, 2001) (Figure 1.5a). The 
second definition is peaks are said to be resolved (for different types of analysers) when the 
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valley between two adjacent peaks (Δm/z) lies below a percentage threshold of the previous 
peak (Figure 1.5b). This threshold is distinct for different analysers. For a ToF analyser this is 
50 % whereas an orbitrap (ion trap) analyser allows a percentile maximum of 10 %. 
 
Figure 1.5: Schematic showing the different definitions of mass resolution. (a) Mass resolution 
is defined as the full width at half maximum of a given peak and (b) mass resolution of two 
peaks at a percentile, set by the analyser, of the peak maximum. 
 
Sensitivity is a characteristic that is measured across an entire instrument with regards to ion 
loss at different stages throughout the instrument. However, it is measured as percentage of 
ions that reach the detector compared with the amount of ions created at the source. The mass 
limitation of an instrument, or mass range, is the full m/z scale at which an analyser can 
measure and separate ions. The mass limitation/range differs greatly for different analysers, a 
quadrupole analyser for example has a relatively low mass range whereas a ToF has a, 
theoretically, infinite mass limitation. 
Lastly, the mass accuracy of a detector is measured in parts per million (ppm) and is defined 
as: 
𝑀𝑎𝑠𝑠 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = (
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 − 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑚𝑎𝑠𝑠
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠
) 𝑥 106 
Equation 1.1 
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This measures how much the experimental mass of an ion diverges from its theoretical mass. 
An example of this is if an analyser has a mass accuracy of 10 ppm, we would expect the 
observed mass of a sample of predicted 1,000 Da to be within ±0.01 Da. 
 
1.3.1 Quadrupole analysers 
A quadrupole analyser (Miller and Denton, 1986, Paul, 1990, Dawson, 2013) exploits the 
resonating trajectory of ions at a particular m/z and uses this to separate them. The quadrupole 
consists of four metal (or metal coated, ceramic) rods, two pairs that sit perpendicular to each 
other (Figure 1.6).  
 
Figure 1.6: Schematic of a quadrupole analyser. The potentials of the rod pairs can be set to 
only allow transmission of ions of a given m/z. The voltages of the different rod pairs are 
altered to allow the transmission of ions of increasing m/z, which builds up the mass spectrum.  
 
These pairs have electrical potentials applied to them, both a direct current (DC) potential 
and oscillating radio-frequency (RF) potential. The rod pairs are arranged so that each pair 
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has an opposite polarity applied to it. Depending on the potentials applied to the poles at any 
given time, this dictates whether an ion of a given m/z will transmit through the analyser and 
reach the detector. The quadrupole is a scanning analyser and so allows ions of particular m/z 
through to the detector sequentially to build up a mass spectrum. Whether an ion with a 
certain m/z has a stable trajectory through the analyser is dependent on the potential applied 
to the poles at that given time which is defined by: 
𝜑𝑇 = 𝐷𝐶 + 𝑅𝐹𝑐𝑜𝑠𝜈𝑡 
Equation 1.2 
And: 
−𝜑𝑇 = −(𝐷𝐶 + 𝑅𝐹𝑐𝑜𝑠𝜈𝑡) 
Equation 1.3 
where φT is the total potential, DC is the strength of the direct current, RF the oscillating 
frequency, ν is the frequency and t is time. 
As the ions pass through the analyser in the z plane, their motions in the x and y plane are 
influenced independently depending on the strength of the potentials impacted on the ions. 
If their trajectory in either of these planes is unstable, particularly due to the fields 
implemented by the oscillating potential, the ion will collide with the charged rod and be 
neutralised; therefore never reaching the detector. Simplistically, lighter ions experience a 
larger effect from the oscillating RF field and heavier ions are impacted largely from the DC 
voltage applied (March, 1997). The stability of an ion can be expressed in separate stability 
diagrams in terms of their x-z and y-z trajectories (Figure 1.7a). As mentioned, the voltages 
across the quadrupole are then increased linearly while maintaining the same ratio between 
the RF and DC potentials. This linear trend between the RF and DC values, can be plotted to 
illustrate how ions of different masses are detected over the range of potentials (Figure 1.7b).  
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Figure 1.7: Stability diagrams for a quadrupole analyser. (a) Stability diagrams can be drawn 
to show the stability of an ion in the different planes of the rod pairs. The top image shows 
an unstable ion in the x-z plane while the bottom diagram shows an ion stable in both planes. 
(b) Stability areas are plotted against the RF and DC voltages, where the voltages are increased 
while maintaining a constant ratio between them. The blue line indicates a high resolution 
mode where ions close in mass can be detected, however m1 is missed. The purple line shows 
a lower resolution mode where m1 is resolved but now m2 and m3 are not, due to the 
overlapping profiles. The red line indicates where the quadrupole acts as a linear ion guide, 
when only and RF voltage is applied with no DC voltage. Figures redrawn from (Hoffmann 
and Stroobant, 2001). 
 
Only when an ion has a stable trajectory, in both the x-z and y-z planes, and intersects the 
lines shown in Figure 1.7b is the ion able to pass through the analyser and reach the detector. 
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These lines plotted (Figure 1.7b) also highlight a quadrupole’s resolution power, where the 
steeper the gradient of the line (while keeping the ratios constant) corresponds to greater 
resolution. This is shown for the blue and purple lines where the only the purple line allows 
the detection of all three ions (m1, m2 and m3). However, the resolving power between m2 and 
m3 is reduced compared with the blue line. Finally, when only a RF potential is applied (DC 
= 0, red line) the resolving power of the analyser is lost and allows the transmission of all ions 
to the detector.  
 
1.3.2 Time-of-flight (ToF) analysers 
The ToF analyser is ideal due to its exquisite mass range. ToF analysers calculate an ion’s m/z 
by measuring the time taken for an ion to transfer a field-free region after being accelerated 
by an applied field (Stephens, 1946). The time taken for an ion to reach the detector is based 
on two parameters, (1) the mass and (2) the charge of the ion. The mass of an ion is responsible 
for its final velocity since all ions experience the same amount of kinetic energy (EK) per 
charge found on the ion since: 
𝑣2 =  
2𝐸𝐾
𝑚
 
Equation 1.4 
where v = velocity, Ek = kinetic energy and m = mass 
Therefore, ions of larger mass will travel more slowly, ultimately taking a longer time to reach 
the detector. The m/z of an ion can be calculated from the time taken to traverse the analyser 
by starting with the potential energy (EP) of an ion which is directly related to its charge (z) 
and the strength of the electric field (V): 
𝐸𝑃 = 𝑧𝑉 
Equation 1.5 
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As the charged particle is accelerated into the flight tube, the potential energy is converted 
into kinetic energy and rearranging Equation 1.4 gives: 
𝐸𝐾 =  
1
2
𝑚𝑣2 
Equation 1.6 
as energy is conserved (EP = EK), we can combine equations Equation 1.5 and Equation 1.6: 
𝑧𝑉 =  
1
2
𝑚𝑣2 
Equation 1.7 
since velocity is related to distance and time (v = d/t), we can substitute the value of velocity 
as: 
𝑧𝑉 =
1
2
𝑚 (
𝐿
𝑡
)
2
 
Equation 1.8 
where L is the length of the flight tube (in m) and t is the flight time of the ion (s). This can 
now be re-arranged to give: 
𝑡2 =
𝑚
𝑧
(
𝐿2
2𝑉
) 
Equation 1.9 
Modern ToF analysers have been modified to accommodate some of the problems with 
resolution that linear ToFs had due to the natural differences of isobaric ions formed as a result 
of the electrospray process. The properties that result in these isobaric ions are the kinetic 
energy distribution, resulting in isobaric ions with a different initial energy from the source, 
and thus different velocity. The spatial distribution of isobaric ions results from ions being 
formed at even slightly different regions in the source, which will experience different voltage 
potentials for different lengths of time and therefore impacts their final velocities. Finally 
there is the temporal distribution which results in isobaric ions being formed at different 
times, therefore reaching the detector at different times as a consequence.  
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To accommodate for these natural and unavoidable phenomena which result in poor 
resolution, there are two methods that can be applied to restore high resolving power. By 
applying a delayed voltage pulse (delayed pulse extraction) immediately before the field-free 
region of the ToF this corrects the velocities and flight times and ultimately, the resolution. 
A second method for increasing ToF resolution is by using a reflectron ToF analyser. 
For linear ToF analysers, the introduction of delayed pulse extraction (Wiley and McLaren, 
1955, Brown and Lennon, 1995) increased the resolution since all ions experience a delayed 
accelerating voltage that allows for the slower isobaric ions to catch up with their faster 
counter parts (Figure 1.8). 
 
Figure 1.8: Schematic showing continuous pulse extraction against delayed pulse extraction. 
(a) Continuous pulse extraction of isobaric ions results the orange ion entering the field-free 
region with more energy (i) and therefore then travel the field-free region quicker (ii) and 
will reach the detector first (iii) resulting in poor resolution. (b) Delayed pulse extraction 
showing that two ions have (i) different energies, however upon applying a voltage, (ii) the 
blue ion experiences a greater pull and therefore is able to catch up in the field-free region 
(iii) and the two ions reach the detector at the same time (iv) resulting in greater resolution.  
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In a linear ToF, the isobaric ions that have higher energies have a greater velocity by the time 
that they reach the field-free region and so the ions reach the detectors at different times, 
resulting in the poor resolution. By having a delay before the pulse to accelerate the ions into 
the field-free region of the analyser, the slower isobaric ions experience a greater effect when 
the field is applied compared with the faster ions. This enhanced potential imparted on the 
slower ions increases their velocity in such a way that they catch-up with the isobaric ions 
and so reach the detector at the same time, increasing resolution.  
The reflectron (Mamyrin et al., 1973, Mamyrin, 2001) is a number of ring electrodes stacked 
together so that they essentially function as an ion-mirror, repelling ions towards a detector 
perpendicularly placed from the ion beam (Figure 1.9). As the isobaric ions are accelerated 
towards the reflectron, the higher velocity ions will reach the reflectron first and penetrate 
the ion mirror further before being repelled back. As a result, the overall flight path for the 
higher energy isobaric ions is longer which gives time for the lower energy ions to catch-up 
and overtake them. Ions are then accelerated again as they leave the reflectron towards the 
detector. The ions reach their initial velocities again that allow for all ions to reach the 
detector at the same time. 
 
Figure 1.9: Schematic of the reflectron ToF analyser. Isobaric ions generated in the source 
with different energy potentials will travel faster and therefore penetrate further into the 
reflectron (blue) compared with the slower ions (orange). This results in the blue ion having 
a longer flight path, which due to its higher velocity, reaches the detector at the same time. 
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1.3.3 Orthogonal-acceleration ToF analysers 
Coupling the ToF analyser with the pulsed ion extraction provided the perfect marriage 
between using ToF analysers and nESI methodology. Since ToF analysers need precise 
ionisation times this previously could not be achieved. The orthogonal acceleration ToF, 
developed in the late 1980’s (Guilhaus et al., 2000), showed that it was possible to bring the 
two technologies together. The idea behind the orthogonal ToF was to take a continuous ion 
beam (as formed from nESI) and create pulsed packets of ions, with precisely defined times 
that could be introduced into a reflectron ToF (Figure 1.10). 
 
Figure 1.10: Schematic of an orthogonal ToF analyser. Resolution of different mass ions is 
increased by combining the delayed pulse extraction from the pusher with a reflectron.  
 
By using a pusher source that sits perpendicular to the ion beam path and applying an electric 
potential at set time periods, packets of ions (in a field-free region) can be pushed towards the 
start of the reflectron. As the ions are pushed in the field-free region, they enter an 
accelerating field where they are propelled towards the reflectron and detector, retaining the 
high mass resolution previously mentioned with the reflectron ToF and pulsed extraction. 
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This orthogonal set up became paramount as it allowed for the introduction of another 
analyser before the ToF which became crucial for tandem mass spectrometry analysis. This 
kind of tandem geometry is now standard in many commercial instruments such as the 
Waters Q-ToF set up (Figure 1.11) that was used for the majority of the work presented in 
this thesis. 
 
Figure 1.11: Schematic of the Synapt G1 instrument used in this study. This instrument 
consists of two mass analysers: a quadrupole and a delayed pulse reflectron ToF. The G1 
instrument also allows for a travelling wave ion mobility spectrometry (TWIMS) with the 
inclusion of a travelling wave ion mobility cell for enhanced ion separation.  
 
1.3.4 Ion trapping analysers 
The most common form of ion trapping analysers is the orbitrap (Makarov, 2000, Hu et al., 
2005). The orbitrap is a modification of the traditional ion trap analyser that was designed in 
the early 1920’s (Kingdon, 1923). An orbitrap analyser works by trapping ions based on their 
attractions to an electrically charged spindle and their flight paths which is stabilised by the 
centrifugal forces they experience as they cycle around this spindle (Figure 1.12). FT-ICR 
analysers are also trapping analysers except that they also use a magnetic field to trap the ions 
in the analyser (Marshall and Hendrickson, 2002). The analysers are then detected by 
inducing a charge that is measured by a set of electrodes as the ions travel past them as a 
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current. This signal then has to be Fourier transformed to produce a mass spectrum for the 
sample.  
 
Figure 1.12: Schematic of an orbitrap ion trapping analyser. The trapping analyser functions 
by trapping ions by their attraction to the electrically charged spindle while separating them 
out based upon their different velocities.  
 
1.4 Ion detection 
The final stage of a mass spectrometer is detection of the ions after they have been separated 
by whatever analysers used in that instrument. There are a few types of ion detectors which 
are routinely used in most commercial instruments. 
Ion detectors often take advantage of electron multipliers in order to amplify the signal 
received by the detector. An electron multiplier works by creating an electron cascade, 
through secondary emission, that is used to generate a mass spectrum after an ion has reached 
the detector (Hoffmann and Stroobant, 2001). There are various different types of electron 
multiplier detection systems; the most common of these is the microchannel plate (MCP) 
detector (Dubois et al., 1999) (Figure 1.13). 
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Figure 1.13: Schematic of the MCP electron multiplier detector. (a)  The MCP Is made up 
from multiple continuous dynode detectors over a short distance to increase the precision of 
flight times. (b) Once an ion hits the dynode, this causes an electron cascade to occur 
increasing the signal reached at the end of the detector. Once a channel has been struck by 
an ion, it must recharge before it can be struck again.  
 
The MCP is a continuous dynode electron multiplier in the form of a metal plate which 
consists of many small channels through the detector (Matsuura et al., 1985). As ions hit the 
wall of one of these channels, an electron is produced. This collision with the surface of the 
channel creates an electron cascade which increases the amount of electrons emitted with 
each impact. This increases the strength of the signal by several orders of magnitude before 
they reach the detector.  The microchannel then needs time to recharge before it can detect 
another signal. 
 
1.5 Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) utilises the power of two mass analysers within one 
instrument. By fitting a collision cell between two mass analysers, an ion can be selected 
(precursor ion) in the first analyser, fragmented in the collision cell and these fragmented 
products (product ions) are then analysed by the second mass analyser. This type of MS can 
be applied to small molecules (Kind and Fiehn, 2010) right up to large protein systems in order 
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to study the individual sub-units within a larger complex (Sharon, 2010). A typical MS/MS 
experiment yields: 
𝑃𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟 𝑖𝑜𝑛 → 𝑃𝑟𝑜𝑑𝑢𝑐𝑡 𝑖𝑜𝑛𝑠 + 𝑁𝑒𝑢𝑡𝑟𝑎𝑙 𝑙𝑜𝑠𝑠𝑒𝑠 
To fragment an ion, a variety of methods are now available including collision-induced 
dissociation (CID) (Jennings, 1968), electron-capture dissociation (ECD) (Zubarev et al., 
1998), electron-transfer dissociation (ETD) (Syka et al., 2004) and surface-induced 
dissociation (SID) (Mabud et al., 1985). Each of these different methods of fragmentation have 
their own advantages, for example ETD does not fragment/cleave post-translational 
modifications (PTM) on the protein and therefore is an attractive technique for PTM mapping 
and profiling (Kim and Pandey, 2012). The most well studied and used method of 
fragmentation however is CID.  
In the Waters Synapt G1 instrument (Figure 1.11), CID occurs as an ion is accelerated into a 
collision cell after mass selection in the quadrupole analyser. Both the trap and transfer cells 
before and after the IMS cell of the instrument can act as collision cells. These collision cells 
are filled with an inert gas that the selected ions collide with as they enter the cell. These 
collisions cause some of the kinetic energy of the ion to convert to vibrational energy which 
spreads throughout the ion. If the vibrational energy is large enough then it will cause a break 
in the peptide backbone of the ion and fragmentation occurs. The fragmentation that occurs 
has a predictable pattern based upon the type of mechanism used to form the product ions. 
CID fragmentation occurs through the breaking of a protein/peptide across the peptide bond. 
This cleavage yields two ions that are named the b- and y- ions, the N-terminal and C-
terminal fragments respectively (Figure 1.14). These fragments then undergo further rounds 
of collisions and sequential cleavages across the amide bonds yielding signals in the acquired 
mass spectra that correspond to the peptide but differ by one amino acid either side. As the 
mass of each amino acid is known, the data can be analysed and used to build up the peptide 
sequence from the peaks that correspond to the mass of the next amino acid in the sequence.  
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Figure 1.14: Schematic of a pentapeptide showing the different fragmentation patterns that 
can occur. Figure adapted from (Roepstorff and Fohlman, 1984). 
 
As CID produces b- and y- ions, the other forms of fragmentation give rise to other product 
ion types. ETD and ECD for example yield c- and z- ions and the fragmentation event occurs 
on much faster timescales due to the mechanism of cleavage. The different types of 
fragmentation and their characteristics are shown in the table below (Table 1.1). 
Table 1.1: Table of different fragmentation methodologies. 
Fragmentation type Timescale Product ions produced 
Collision-induced dissociation (CID) Slow b- and y- ions 
Electron-transfer dissociation (ETD) Fast c- and z- ions 
Electron-capture dissociation (ECD) Fast c- and z- ions 
Surface-induced dissociation (SID) Slow b- and y- ions 
Charge-transfer dissociation (CTD) Fast a- and x- ions 
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Depending on the data one wishes to acquire and what question they are wishing to address, 
there are a variety of different MS/MS experiments that can be performed depending on the 
scanning mode chosen.  
 
1.5.1 MS/MS scanning modes 
The different scanning modes used in MS/MS experiments allow for the acquisition of distinct 
data that can answer biological questions from a range of viewpoints. There are four main 
types of scan modes used which are summarised below (Louris et al., 1985) (Figure 1.15): 
I. Product ion scan: A parent ion is selected using the first analyser in the mass 
spectrometer by virtue of its m/z ratio and then fragments in a collision cell. All 
product ions from this fragmentation are then analysed by the second mass 
analyser.  
II. Precursor ion scan: Instead of the parent ion being selected, a specific product ion is 
selected in the second mass analyser. All precursor ions are allowed to traverse 
through the first analyser and undergo fragmentation in the collision cell. This 
technique is commonly used with multiple quadrupole instruments since the 
second analyser is also needed for selection.  
III. Neutral loss scan: As with precursor ion scan, this technique is also not applicable to 
ToF analysers and so is common again with multiple quadrupole instruments. Both 
analysers are used to scan through a range of ions except the second analyser is 
looking for a specific loss in mass (from the neutral loss) during its scan. Only ions 
that correspond to the loss of mass in the second analyser reach the detector.  
IV. Selected reaction monitoring (SRM): Unlike the other reaction modes, SRM does 
not consist of a scan step and instead selects for a specific reaction. Ions are only 
detected by the second detector if the precursor that was selected gives the correct 
reaction being monitored for. One advantage to SRM is an increase in sensitivity 
due to fact it enables the focus on selected ions for longer timescales with both 
analysers, removing any need for scans as well as no interference from background 
ions. 
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Figure 1.15: Illustration highlighting the different MS/MS scanning modes. Product ion scan 
involves isolating a precursor ion for fragmentation and scanning the products. Precursor ion 
scan allows fragmentation of all precursor ions and analysing for a selected product ion. The 
neutral loss scanning mode scans both the precursor and products while looking for a given 
mass loss. Selected reaction monitoring isolates a precursor for fragmentation and using the 
second analyser to isolate for a given product ion expected from the fragmentation. Figure 
redrawn and adapted form (Shepherd, 2012). 
 
1.5.2 Collisional activation of protein complexes 
As well as gaining sequence information, native-intact proteins and protein complexes can be 
activated in order to elucidate information about their higher order structure. Various studies 
have used collisional activation to understand protein complex assembly and structure 
(Benesch, 2009, Sharon, 2010, Zhou et al., 2008). Two main approaches have been used: CID, 
and more recently, SID. Both work on the same principal of using collisional energy to 
destabilise a protein complex until a subunit is ejected. The advantage of SID, when compared 
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with CID, is the retention of a native-like conformation of the ejected monomer (Dongre et 
al., 1996) (Figure 1.16).  
 
Figure 1.16: Schematic showing the mechanism of CID versus SID. (a) CID activation of a 
complex results in an unfolded monomer ejection. (b) SID activation results in ejection of a 
folded monomer, allowing determination of complex assembly. The surface used for SID is 
typically an alkanethiolate monolayer that has been self-assembled on a gold surface 
(Wysocki et al., 2008b). 
 
The use of CID often results in a protein unfolding and gathering more charge as it is being 
ejected from the complex. By contrast, SID results in a more symmetrical charge state 
distribution after the collision and ion mobility has been used in conjunction with SID to 
show that the ejected protein remains in a native-like conformation. These techniques can be 
used to probe the quaternary structure of protein complexes and reveal structural information 
(Wysocki et al., 2008a, Wysocki et al., 2008b, Blackwell et al., 2011, Zhou et al., 2013). 
 
1.6 Ion mobility spectrometry (IMS) mass spectrometry 
To further aid in yielding higher resolution structural information about proteins and protein 
complexes, mass spectrometry can be combined with ion mobility spectrometry (IMS) as an 
extra dimension of separation. So far, measuring ions has only been discussed in terms of their 
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m/z ratio. IMS-MS adds an extra scope of measurement by monitoring an ion’s drift time (tD) 
as well as its m/z. IMS works by separating ions based on their physical size and dimensions 
as well as the amount of charges the ion carries. The ions are pulled through a neutral buffer 
gas filled cell and will have different velocities, due to collisions with the gas molecules, which 
can be related to their shape and size via their rotationally averaged collision cross-sectional 
area (CCS). These experiments are carried out in a drift cell region of the instrument of which 
there are generally two types: a linear drift tube and a travelling wave (TW) device.  
 
1.6.1 Linear drift tube IMS 
A linear drift tube is the simplest form of IMS and information regarding a protein’s size and 
shape can be directly related to its measured tD. Ions are introduced into a drift tube under a 
constant electric field to which the ions are pulled through. As the ions traverse the cell they 
collide with the buffer gas which impedes their mobility (Figure 1.17). Different ions 
experience different levels of retardation based on their overall size and shape.  
 
Figure 1.17: Schematic of a linear drift tube used for IMS separation. (a) Illustration of the 
drift cell showing the injection of buffer gas in the opposite direction of the electric field, 
resulting in collision with the ions. (b) Plot of the drift time against ion intensity showing the 
differences in drift time of the two ions due to the additional collisions with the buffer gas of 
the larger ion (blue).  
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As stated previously, the CCS of a protein or analyte can be directly measured from the time 
it takes to traverse the buffer gas filled cell. Where the mobility, K, of an ion is related to its 
velocity, vi, and the electric field, E. 
𝐾 =  
𝑣𝑖
𝐸
 
Equation 1.10 
As the length, L, of the drift tube is known, and the drift time, tD, can be measured, this gives: 
𝐾 =
𝐿
𝑡𝐷𝐸
 
Equation 1.11 
In order to standardise the equation, to allow for the comparison of results, the reduced 
mobility of an ion is reported. The reduced mobility of an ion (K0) is normalized for standard 
pressure and temperature, P (760 torr) and T (273.2 K) respectively. 
𝐾𝑜 = 𝐾
273.2
𝑇
𝑃
760
 
Therefore, 
𝐾0 =  
𝐿
𝑡𝐷𝐸
273.2
𝑇
𝑃
760
 
Equation 1.12 
where L is the length of the drift tube and E is the electrical field. This is aided by the Mason-
Schamp equation which relates the mobility of an ion to its CCS (Ω) (Mason and Schamp, 
1958).  
𝐾 = (
3𝑧𝑒
16𝑁
) (
2𝜋
𝜇𝑘𝐵𝑇
)
1
2 1
𝛺
 
Equation 1.13 
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where z is the charge state of the analyte, e is elementary charge (1.6022x10-19 C), N is the 
density of the buffer gas used in the drift tube, µ is the reduced mass between the ion and 
the buffer gas and kB is the Boltzmann constant (1.381x10-23 JK-1). By substituting for 
reduced mobility (Equation 1.12) and re-arranging the equation for CCS (Ω) we can 
achieve. 
𝛺 =  
(18𝜋)
1
2
16
𝑧𝑒
(𝑘𝐵𝑇)
1
2
[
1
𝑚𝑖
+
1
𝑚𝑛
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝑡𝐷𝐸
𝐿
 
Equation 1.14 
where mi and mn are the mass of the ion and the buffer gas used, respectively. As mentioned 
above, we can clearly see from Equation 1.14 that a larger cross-section correlates with a 
longer drift time since the length (L) of the drift tube remains constant.  
 
1.6.2 Travelling wave ion mobility spectrometry 
The majority of modern mass spectrometers no longer use a linear drift tube, due to the ion 
losses suffered, and one other method of ion mobility instruments have adopted is the use of 
travelling wave ion mobility spectrometry (TWIMS) (Pringle et al., 2007, Giles et al., 2011). 
An example of a modern instrument that is equipped with a TWIMS device is the Waters 
Synapt mass spectrometer which was used for the work presented in this thesis (Figure 1.18). 
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Figure 1.18: Schematic of the Synapt G1 instrument, highlighting the TWIMS device located 
between the two mass analysers.  
 
In the Synapt instruments, the TWIMS device is situated between a quadrupole and ToF 
analyser which allows the selection of precursor ions which may or may not be collisionally 
activated in the trap region.  The region made up of the trap, TWIMS and transfer of these 
instruments is known as the “TriWave” section; each of these cells are made up of a series of 
ring electrodes called travelling wave ion guides (TWIGS). 
A series of ring electrodes are used to make up the TWIGS to which different electric 
potentials are applied in order to guide the ions through to the ToF analyser. A constant RF 
potential is applied to the electrodes which aids in confining the ions and minimises any ion 
loss. A DC voltage is applied to the first electrode in the series and moves from one ring 
electrode to the next sequentially which is where the “travelling wave” term is derived. 
Without this travelling wave potential, the ions would remain static in the TWIG due to the 
radially confining RF voltages applied (Figure 1.19a). For the TWIMS region, the TWIGS are 
surrounded in a cell which is filled with a neutral buffer gas, typically nitrogen or argon. Here, 
as the travelling wave pushes the ions along through the TWIG they collide with the neutral 
buffer gas and their mobility becomes retarded. An ion with a large enough cross-section 
becomes impeded to such an extent that it falls behind the travelling wave and therefore must 
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wait for the subsequent wave to push it further along the cell (Figure 1.19b). Using the 
premise that the ions are separated on mobility through the cell by their CCS, this process can 
be tuned by applying different DC voltages superimposed on the TWIG which is also termed 
the wave height. 
 
Figure 1.19: Illustration of the TWIMS device and its mechanism of separating ions based on 
their CCS. (a) Ring electrode with different electrical potentials prevent ions transmitting 
without the help of an additional travelling wave. (b) Low mobility ions (orange) collide with 
the buffer gas more frequently and so roll over the back of the wave and must await additional 
wave to reach the end of the device. While high mobility ions (blue) can ride the wave to the 
end of the device.  
 
As the ions are now being propelled through the TWIMS cell, the previous method of 
calculating the CCS based upon an ions tD no longer applies. In the absence of a uniform 
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electric field, the difficulty in establishing the CCS of an analyte of interest increases. To 
address this, a calibration approach is adopted by taking proteins with known cross-sections 
using a linear drift tube from a database that has been provided by the Bush group (Bush et 
al., 2010). 
The previous equation (Equation 1.14) used for calculating CCS values can be modified in 
order to account for the non-uniform electric field: 
𝛺 =  
(18𝜋)
1
2
16
𝑧𝑒
(𝑘𝐵𝑇)
1
2
[
1
𝑚𝑖
+
1
𝑚𝑛
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝑋𝑡𝐷
𝑦 
Equation 1.15 
where X and y are correction factors for the electric field applied in the TWIMS device and 
its non-uniform and non-linear existence, respectively. Furthermore, the reduced cross-
section (Ω’) value which is independent of mass and charge can be expressed by dividing the 
above equation by reduced mass ([
1
𝑚𝑖
+
1
𝑚𝑛
]) and charge (ze): 
𝛺′ =  
(18𝜋)
1
2
16
1
(𝑘𝐵𝑇)
1
2
760
𝑃
𝑇
273.2
1
𝑁
𝑋𝑡𝐷
𝑦 
Equation 1.16 
After the correction for charge and reduced mass along with the correction factors, a series 
of constant factors remain and the equation can now be further simplified by uniting these 
constants as one new constant (X’): 
𝛺′ =  𝑋′𝑡𝐷
𝑦 
Equation 1.17 
This new simplified equation is now in the form of y = axb and can be plotted as such. By 
plotting the reduced cross-section (Ω’) against tD a calibration curve can be created for 
proteins of known CCS values from linear drift tube measurements (Ruotolo et al., 2008). 
From this calibration, we can then estimate the reduced cross-section for unknown species 
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and proteins of interest; for which CCS values can then be established by multiplying by 
charge and reduced mass as had previously been removed from the procedure: 
𝛺 =  𝑧𝑒 [
1
𝑚𝑖
+
1
𝑚𝑛
]
1
2
𝛺′ 
Equation 1.18 
With the plethora of structural information that is now available through the protein 
databank (PDB), it is now routine to compare the measured CCS against a theoretically 
derived CCS value – if a 3D structure of your protein of interest is available.  
 
1.6.3 Theoretical CCS estimations 
The information obtained from the cross-section of an analyte of interest is often insufficient 
alone to derive useful structural information. As mentioned, it is now commonplace to 
compare experimental results to theoretical CCS projections and to analyse the extent to 
which the results are in agreement. Furthermore, theoretical CCS estimations are extremely 
useful in model generation. The ability to calculate the theoretical CCS of a potential model 
and compare the results with an experimental result has not only aided in oligomer 
extension/formation (Smith et al., 2010), but has also supplied invaluable assistance in 
establishing the structure of protein complexes (Ruotolo et al., 2005). Alternatively, the 
measured CCS of a protein can be compared directly with its theoretically determined value 
from the PDB in order to establish whether the ion has retained a native-like structure, or 
whether it has adopted an alternative structure in the gas-phase. 
The most common method for generating theoretical CCS values of a system is the use of the 
MOBCAL program, developed by Martin F. Jarrold (Mesleh et al., 1996, Shvartsburg, 1996). 
The main criticism of the MOBCAL system is how computational intensive the trajectory 
method (TM) (Mesleh et al., 1996) can be, which is widely known to be the most accurate 
prediction method. Advancements in the field, however, have led to the generation of other 
programs to calculate the CCS of proteins in a fraction of the time taken by MOBCAL. The 
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recently developed IMPACT software (Marklund et al., 2015) has the ability to calculate the 
CCS of a submitted structure in a matter of seconds. As well as the IMPACT software, there 
has also been a recent modified projection approximation algorithm reported that has results 
comparable to the accuracy of the trajectory method, yet is much less computationally 
demanding (Benesch and Ruotolo, 2011). Briefly, these programs calculate the 2D projection 
of a submitted structure as a snapshot at one angle. The structure is then rotated around 
various different angles in order to build up a rotationally averaged collision cross-section, as 
it is accepted that the ions tumble randomly through the mass spectrometer. The different 
methods that contribute to accuracy and computing time all use this premise except that they 
differ on how they treat the gas molecules. 
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2 Introduction II: Structural biology and the role of 
mass spectrometry in understanding protein 
complex assembly 
2.1 Protein folding, misfolding and aggregation 
In order for a protein to function, a protein must fold correctly to adopt its correct three-
dimensional structure. Since it was discovered by Anfinsen in the 1960’s that ribonuclease A 
can refold after denaturation into a thermodynamically stable and functional state (Anfinsen 
et al., 1961), the question arose of how proteins are able to do this on a biologically relevant 
timescale? For a protein to randomly sample all possible conformations before adopting its 
native fold would take an immense amount of time, even for small proteins. Therefore, it was 
concluded that the information directing the folding of a protein must be contained within a 
protein’s primary amino acid sequence (Levinthal, 1969). This paradox, of how proteins fold 
on a biologically relevant timescale, was first proposed by Levinthal, who suggested that 
specific and controlled mechanisms exist, in the forms of folding pathways, to reduce the time 
it takes for a protein to achieve its native fold. Through the rapid formation of local 
interactions, leading to a stable core or nucleus, the number of total conformations that need 
to be sampled decreases, aiding the correct minimum energy structure to be reached on an 
appropriate timescale.  
This folding process is often interpreted as an energy landscape (Dill and Chan, 1997). The 
energy landscape presents a series of structural assemblies that may be sampled en route to a 
protein reaching its native fold, transitioning from a high-energy and unfolded state to its 
low-energy native conformation. These energy landscapes are plotted as the internal free 
energy of a protein conformation versus the potential conformational space, or entropy. In an 
idealised world, the amount of internal free-energy decreases linearly with the amount of 
conformational space available to the system until the native fold is reached, in this case, with 
rapid folding kinetics (Figure 2.1).  
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Figure 2.1: Idealised folding landscape. The internal free energy is represented on the vertical 
axis with the entropy represented by the width of the folding landscape. Figure redrawn and 
adapted from (Bartlett and Radford, 2009). 
 
In reality however, the energy landscapes that proteins must traverse are very different 
(Figure 2.2) (Vendruscolo et al., 2003, Brockwell and Radford, 2007, Jahn and Radford, 2008). 
There are many intermediate states, en route to the native state, which can adopted where 
intra- and inter-molecular interactions can occur. These intermediate states give rise to a 
‘rough’ energy landscape, where there are various high energy barriers with local low energy 
troughs a protein must navigate through to reach its conformation. Folding proteins are 
constantly in exchange between these intermediate states (Jahn and Radford, 2008), with 
small fluctuation’s in a proteins conformation occurring in, and around, the minimal energy 
native fold, as well as intermediate folds. These intermediate states can be seen as ‘on-
pathway’ conformations, forming local, intramolecular interactions that aid the folding into 
the native conformation. However as Figure 2.2 shows, there are also low energy minima that 
can be reached in a misfolded conformation. The event in which a protein adopts non-native 
low-energy conformations forms the basis for protein misfolding; where significant 
reorganisation of the protein is required in order to reach the native state (Kim et al., 2013).  
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Figure 2.2: Schematic of protein folding energy landscape showing protein folding and 
aggregation.  Unfolded polypeptide chains (blue lines) fold towards the low energy state by 
forming intra-molecular contacts. By contrast, inter-molecular contacts can lead to oligomers 
and aggregates being formed. Figure redrawn and adapted from (Jahn and Radford, 2008). 
 
Various properties can increase the potential of a protein to become trapped in non-native or 
aggregation prone conformations. Destabilising factors in the proteins amino acid sequence, 
such as mutations of key residues, or even changes in the cellular environment in vivo can 
result in an increased propensity for proteins to adopt these intermediate species (Knowles et 
al., 2014). In these misfolded states, the hydrophobic core of the protein may be perturbed to 
an extent where hydrophobic residues are exposed and are able to form incorrect intra-
molecular contacts, or in worse case scenarios, interact with other misfolded monomers and 
result in the formation of aggregates.  
As well as misfolded and partially unfolded proteins leading to aggregation, small fluctuations 
in the native state can lead to regions of a protein becoming exposed that have the potential 
to drive aggregation (Dobson, 2003) (Figure 2.3). Therefore, tight regulation of the protein 
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folding process is required. However, while there are chaperones present in vivo to assist the 
folding process and proteolytic systems in place to remove any misfolded species (Goldberg, 
2003, Ellgaard and Helenius, 2003, Hingorani and Gierasch, 2014, Balchin et al., 2016, 
Gruebele et al., 2016), over-expression of misfolded proteins overload these systems, 
increasing the likelihood of protein misfolding and aggregation regardless.  
 
Figure 2.3: Schematic showing the protein folding pathway and the oligomers that can be 
formed en route to the native state. Figure redrawn and adapted from (Dobson, 2003). 
 
Thus, it is imperative that techniques are available which are able to identify even small, 
transient fluctuations in a protein’s conformation. Furthermore, it is important to be able to 
characterise these conformations once their presence is identified. Mass spectrometry is 
ideally suited to such analyses, able to determine protein conformations even in complex 
mixtures of species with a plethora of orthogonal techniques available.  
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2.2 Mass spectrometry in structural biology 
The gold standard techniques for elucidating the structure of proteins and protein complexes 
are X-ray crystallography and NMR spectroscopy, yielding high resolution structures in 
atomic detail. Recently, advances in cryo-electron microscopy (EM) have resulted in cryo-
EM yielding structures that are approaching atomic resolution (currently 1.8 Å (Merk et al., 
2016)), close to that of crystallography, which has achieved resolutions of around 1 – 1.4 Å 
for relatively large proteins (~140 kDa) (Lubkowski et al., 2003) and even better (< 1 Å) for 
smaller proteins (10-15 kDa) (Antonyuk et al., 2011). However, the techniques above have 
limits to the systems they can analyse; crystallography can often encounter trouble when 
working with dynamic samples, while NMR has an upper limit on the size of proteins that 
can be studied (around 40-50 kDa for de novo structure determination). In addition, both 
techniques often require large amounts of protein and data analysis can be expensive in terms 
of time, although this latter point has been ameliorated to some extent by the development 
of software automation (Wishart, 2013). While not at the same resolving power to 
crystallography, NMR or EM, MS and its applications can reveal important information on 
the structure of a protein/protein complex (Figure 2.4). This has been expertly utilised in 
determining the mode of assembly in systems such as virus capsids (Uetrecht et al., 2011a, 
Shepherd et al., 2013) and amyloid oligomer formation (Smith et al., 2010, Young et al., 2014a, 
Woods et al., 2013), identifying novel drug targets (Hofstadler and Sannes-Lowery, 2006, 
Deng and Sanyal, 2006, Luchini et al., 2014), epitope mapping on the surface of antibodies 
(Yan et al., 2014a, Zhang et al., 2014) as well as identifying sites of aggregation (Ashcroft, 
2010, Wang et al., 2012, Bronsoms and Trejo, 2015). 
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Figure 2.4: Schematic showing the different applications of mass spectrometry for analysis of 
protein conformation.  One half of the schematic shows the application of native MS while 
the other shows the application footprinting methodologies. 
 
2.3 Characterising protein structure and conformation using mass 
spectrometry 
2.3.1 Charge state distribution is indicative of conformation 
nESI-MS analyses have shown that the initial structure or conformation of a protein, folded 
or unfolded, can be related to the amount of charges that it acquires during the ionisation 
process. It has been well established that there is a clear link between the amount of charges 
that a protein acquired during the electrospray process, versus the solvent exposed surface 
area (SASA) (Chowdhury et al., 1990). More sites for protonation become available as the 
solvent accessible surface area of a protein increases (Figure 2.5) (Chowdhury et al., 1990, 
Kaltashov and Mohimen, 2005, Heck, 2008). 
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Figure 2.5: Figure highlighting the charge state distribution of a protein in a denatured and 
native state. (a) Urease was acid denatured in 50 % (v/v) aqueous acetonitrile containing 0.1 
% (v/v) formic acid revealing a highly charged distribution of the different subunits of the 
protein. Orange = α subunit and magenta = β subunit. (b) Spectrum showing the same protein 
under native conditions showing a narrow charge state distribution. Figure taken from (Heck, 
2008). 
 
In a stable and folded state, the extent of protonation on a protein’s surface is limited due to 
the burial of amino acid side chains. This results in a protein having a narrow charge state 
distribution at low charge. Conversely the same protein, once denatured, acquires a greater 
amount of charges during ionisation and populates a larger, highly charged distribution found 
at relatively low m/z. This transpires since as the SASA of a protein increases, during 
unfolding for example, the amount of sites for protonation also increase and higher charge 
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states become dominant. A paradigm example of defining a protein’s conformation by the 
observed charge state distribution was the analysis of β2-microglobulin, where three 
conformers are observed across different pH; and interestingly, it was known that the partially 
folded state is amyloidogenic (Borysik et al., 2004). 
 
Figure 2.6: Figure showing the identification of different conformers by charge state 
distribution.  (a) Spectra of β2m acquired at different pH values. pH 6 (top) where amyloid 
propensity is low, pH 3.6 (middle) where moderate amyloid propensity is observed and pH 
2.6 (bottom) where the amyloid propensity is high. (b) Signal intensity is plotted against 
charge state. (c) Fitting of Gaussian distributions to the observed data showing that as pH 
decreases, a greater proportion of unfolded states are observed. Taken from (Borysik et al., 
2004). 
This observation of multiple conformations for a simple polypeptide chain has also been 
observed without the requirement of changing pH. Studies have shown that intrinsically 
disordered proteins are able to adopt multiple conformations under native-like conditions 
with multiple charge state distributions being observed upon ionisation (Frimpong et al., 
2010). Furthermore along with IMS-MS, a framework has been established using the charge 
state distribution and CCSs populated for a given sample in order to elucidate structural 
information for an unknown protein, which again can separate intrinsically disordered and 
ordered proteins (Beveridge et al., 2014). 
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2.3.2 Protein and protein complex conformations defined using IMS-
MS 
The combination of MS with IMS has aided the understanding of protein conformation in the 
gas-phase. Since the development of ion mobility devices in commercially available 
instruments, the amount of publications using IMS-MS has increased dramatically (Lanucara 
et al., 2014). Initial studies with IMS-MS showed that a protein’s native conformation was 
believed to be retained upon transition into the gas-phase by measuring CCS values that were 
in agreement with structure predictions, as outlined in Section 1.6.3. In general, the CCS of 
native proteins increases with charge, which has been attributed to Coulombic repulsion 
forces (Wu et al., 1998, Tolmachev et al., 2009). These initial studies propelled further studies 
using IMS-MS to understand protein conformation and complex assembly.  
Using B2m as an example, IMS-MS has been used to show that the species involved in the 
oligomeric states are elongated in nature, rather than globular, defined by their CCS values 
(Smith et al., 2010). This kind of information is vital in understanding how amyloidogenic 
proteins, such as β2m, aggregate which will be pivotal in designing therapeutics which can 
target the oligomeric species responsible for driving aggregate formation. Finally as 
mentioned above, IMS-MS has been crucial in determining protein complex formation. An 
excellent example of this was determining virus capsid assembly using IMS-MS (Figure 2.7) 
(Uetrecht et al., 2011a, Shepherd et al., 2013). IMS-MS and CCS determination was used to 
show that the hexamer was an on-pathway intermediate to whole capsid assembly, formed 
by a nucleus exhibiting a five-fold symmetry. As mentioned with β2m, achieving a greater 
understanding of how the proteins involved in virus capsids assemble will aid the generation 
of future therapeutics that can target these assemblies. 
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Figure 2.7: Figure showing the spectrum of a norovirus capsid under conditions which do not 
permit assembly.  The inset shows the proposed model of the assembly pathway, indicating 
that the experimentally observed hexamer is an on-pathway intermediate. Figure adapted 
from (Uetrecht et al., 2011a). 
 
2.3.3 Mass spectrometry of membrane proteins and their complexes 
While membrane proteins are responsible for a wide range of biological process, as well as 
well as making up 60 % of drug targets (Lappano and Maggiolini, 2011, Dorsam and Gutkind, 
2007, Arinaminpathy et al., 2009), there is significantly less structural information available 
for this class of proteins, only 2.9 % of all protein structures in the PDB. One of the causes for 
this is due to the traditional structural techniques such as X-ray crystallography and NMR 
requiring large amounts of soluble protein, which is often not possible with membrane 
proteins. However, as native MS is a rapid and sensitive technique it can provide critical 
details on membrane protein complexes, as well as documenting and bound lipids and 
molecules. As the analysis of membrane proteins by MS had previously been frustrated by the 
proteins being kept in detergent-containing buffers. Advances in purifications such as 
detergent micelles (Barrera et al., 2009, Barrera and Robinson, 2011, Konijnenberg et al., 
2015), nanodiscs (Marty et al., 2012, Hopper et al., 2013) and amphipols (Leney et al., 2012, 
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Calabrese et al., 2015b, Watkinson et al., 2015) have led to exciting discoveries of membrane 
protein structures and conformations by MS and IMS-MS.  
 
2.3.4 Probing solution conformation with footprinting technologies 
While native MS and IMS-MS yield information that relates to the conformation of proteins 
in the gas-phase, other techniques can be used in conjunction with MS that reveal information 
on protein conformation and dynamics in solution. Protein footprinting technologies are 
capable of examining conformational change and ligand binding in proteins by monitoring 
their response to chemical or enzymatic modifications. Protein footprinting as a 
complimentary technique to MS has evolved rapidly in the last decade (Kaltashov et al., 2013). 
Footprinting technologies include amide hydrogen-deuterium exchange (HDX) (Konermann 
et al., 2011, Pacholarz et al., 2012), hydroxyl-radical based labelling (otherwise known as fast 
photochemical oxidation of proteins (FPOP)) (Sclavi et al., 1998, Calabrese et al., 2015a), 
protein painting (Luchini et al., 2014), chemical labelling (Mendoza and Vachet, 2009, Zhou 
and Vachet, 2012) and chemical cross-linking (XL) (Sinz, 2006, Herzog et al., 2012). 
 
2.3.4.1 Hydrogen-deuterium exchange (HDX) 
HDX involves the exchange of hydrogen with deuterium (or vice versa) by a protein upon 
exposure to a deuterated buffer or solution. Due to the 1 Da mass difference of deuterium 
compared with hydrogen, HDX can be monitored in the resulting mass spectra, as a mass shift 
is observed as more exchange occurs. There are three types of exchangeable hydrogens on a 
protein: the hydrogens on side chain carbons, hydrogens bonded with heteroatoms and 
hydrogens found on backbone amides (Cao et al., 2013). The latter exchange is a reversible 
process and occurs on time-scales measurable using real time experiments using ESI-MS 
(Englander et al., 1996). Combined with liquid chromatography (LC) and MS/MS, region-
specific information can be obtained based on the deuterium uptake of peptides. This can be 
used for the characterisation of protein-protein and protein-ligand interactions (Pirrone et 
al., 2015), epitope mapping (Chen, 2013) or even identifying regions of aggregation (Zhang et 
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al., 2013) by searching for regions of protection from exchange upon oligomerisation. The 
example below shows the use of HDX exchange to define the epitope of factor H binding 
protein (fHbp) (Figure 2.8) which is a key virulence factor and vaccine antigen in Neisseria 
meningitidis. These experiments detected regions involved in binding that were missed using 
other epitope mapping techniques (Malito et al., 2013).  
 
Figure 2.8: The results from epitope mapping of factor H binding protein (fHbp) by HDX-MS.  
The boxes show the deuterium uptake over 30 min in the absence (red) or presence (blue) of 
the binding mAb. The regions of protection are highlighted red on the structure. Figure taken 
from (Malito et al., 2013). 
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One of the major drawbacks to HDX, however, is the problem with back exchange. After 
deuterium exchange has occurred, the protein has to be held at low temperatures and pH to 
minimise any back exchange with hydrogen. While an extremely informative technique, this 
prohibits any further downstream treatment or modification of the protein as proteolysis 
requires that the sample is immediately taken for LC and MS/MS analysis. However, HDX is 
capable of monitoring protein dynamics and identifying rare conformations that may be 
missed by other techniques. Additionally, as mentioned in Section 2.1, while these rare 
conformations may be in a state of flux with native of partially native folds, it can be these 
rare states that are responsible for driving unwanted protein aggregation.  
 
2.3.4.2 Fast photochemical oxidation of proteins (FPOP) 
In this footprinting technology, highly reactive hydroxyl radicals (·OH) are generated from 
hydrogen peroxide, via laser photolysis, which react with amino acid side chains irreversibly 
(Xu and Chance, 2007). This approach generates ·OH in a few nanoseconds, with a laser pulse 
(248 nm) to a flowing solution which contains the protein sample of interest with a small 
amount of hydrogen peroxide present in the sample (typically 10-20 mM) (Zhang et al., 2011). 
The flowing solution ensures that the proteins are only exposed to the laser pulse once in the 
experiment. To control the labelling and limit the lifetime of the ·OH, radical scavengers are 
added into the solution in the form of free amino acids (typically glutamine or histidine). A 
schematic of the experimental set up can be seen below (Figure 2.9). 
 
Figure 2.9: Schematic of the FPOP workflow.  A solution containing the protein of interest, 
hydrogen peroxide (purple ovals) and a hydroxyl radical scavenger (orange spheres) are 
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flowed through a capillary that is pulse by a laser at 248 nm. This creates hydroxyl radicals 
(·OH) which are able to modify the side chains of solvent exposed amino acids.  
 
As well as probing the surface of proteins (Zhang et al., 2010) and epitope mapping (Yan et 
al., 2014b), FPOP has been used to follow protein folding in real time (Chen et al., 2012). By 
initiating protein folding (of a cold denatured protein) with a temperature jump induced by a 
laser pulse, and then labelling at different time points after initiation, the formation of the 
hydrophobic core was monitored before the rest of the protein found its native conformation. 
However, a pitfall of the technique is the amount of accessible sites for modification. The 
reactivity of side chains is not only dictated by their solvent exposure, but also their chemical 
nature. The most reactive residues are the sulfur containing amino acids cysteine and 
methionine, followed by the aromatic side chains: tryptophan, tyrosine and phenylalanine. 
Other potential sides of modification include histidine, leucine, isoleucine, arginine, lysine, 
valine, proline, glutamine and glutamic acid (Takamoto and Chance, 2006, Xu and Chance, 
2007, Konermann et al., 2008). Due to the lack of 100 % amino acid coverage, there is a chance 
interfaces may be missed. 
 
2.3.4.3 Protein painting 
Protein painting is one of the newer footprinting methodologies, being first published in 2014 
(Luchini et al., 2014). This method uses small, organic dyes or ‘paints’ which bind to the 
surface of proteins, presumably by binding to lysine and arginine residues. The power of this 
technique is that the small molecule paints remain bound to the protein’s surface in 
denaturing conditions. Thus, by taking a pair of interacting proteins, such as interleukin 1-
beta (IL1β) and its receptor 1 (IL1), and allowing them to form the complex before adding the 
small molecule paints; the regions of the proteins responsible for the interaction are ‘paint’ 
free. Upon dissociation and denaturation, residues in the interaction interface can be cleaved 
with trypsin while the rest of the protein is protected from the proteolytic enzyme by the 
dyes (Figure 2.10). As only the regions involved in binding are digested by trypsin, upon LC 
and MS/MS analysis of the digested peptides, the regions protected from paint binding can be 
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identified. While a promising technique further studies will be needed to determine its 
generic applicability to identifying and characterising protein-protein interactions and the 
conformations of protein complexes.  
 
 
Figure 2.10: Schematic showing the protein painting workflow.  Protein complexes are coated 
with small molecule ‘paints’. The region of interaction is not accessible to the paints and 
therefore is protected from coating. Upon dissociation and denaturation of the complex only 
the previously protected sites are exposed for digestion by trypsin and will subsequently be 
analysed by MS. Figure adapted from (Luchini et al., 2014). 
 
2.3.4.4 Chemical labelling 
A plethora of chemical reagents are available that can be used to covalently modify the surface 
of a protein at specific amino acid side chains (Mendoza and Vachet, 2009). Examples include 
glycyl ethyl ester which reacts with carboxyl groups on a proteins surface (Liu et al., 2014), 
the use of iodoacetamide or N-ethylmalemides to modify the thiol group of cysteine residues 
(Su et al., 2011) and diethylpyrocarbonate (DEPC) which can be used to modify histidine, 
lysine, tyrosine, serine, threonine and cysteine residues, as well as the N-terminus (Borotto et 
al., 2015). 
This method of labelling proteins is similar to that of FPOP, where solvent exposed amino 
acid side chains are selectively modified depending on the chemical probe being used. The 
advantage of this approach compared with FPOP is that a combination of probes can be used 
to modify a protein to increase coverage and it does not require a laser or expensive 
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experimental set up. However, the disadvantage is that the reactions occur at much slower 
timescales compared with FPOP and therefore any transiently exposed sites may be missed.  
 
2.3.4.5 Chemical cross-linking 
Chemical cross-linking can be used to covalently link two interacting partners; with peptides 
from the interacting partners being sequenced by LC-MS/MS downstream (Sinz, 2006). 
Similar to the chemical labelling approach, the chemical cross-linkers are used to target 
specific surface-exposed residues on the proteins surface, most commonly lysine residues by 
the use of N-hydroxysuccinimide ester chemistry. However, there are cross-linkers which are 
also capable of reacting with carboxyl groups and non-specific cross-linkers which use 
diazirines (free radicals) as the reactive group (Dubinsky et al., 2012) (Figure 2.11) 
As each of the chemical cross-linkers have set distances between their reactive groups, these 
distances can be used as restraints to drive modelling of the interacting proteins. This can be 
beneficial when little is known about a protein complex and its assembly. A paradigm example 
of this was the structure determination of the 1.5 MDa complex, RNA polymerase II 
transcription pre-initiation complex (PIC) by XL-MS and cryo-EM (Murakami et al., 2013). 
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Figure 2.11: Reaction mechanisms for different types of cross-linkers. The reaction 
mechanisms for (a) NHS ester (amine reactive), (b) zero-length carbodiimide (carboxylic acid 
reactive) in conjunction with sulfo-NHS (amine reactive) and (c) diazerine (photoreactive) 
cross-linkers are shown. Figure adapted from (Sinz, 2010). 
 
An advantage of chemical cross-linking is that the restraints achieved from cross-linking 
experiments allow for the validation of generated models. Furthermore, as with some of the 
other techniques, since cross-linking involves a covalent modification, a sample does not need 
to be handled as carefully post cross-linking compared to HDX. A caveat of chemical cross-
linking is that the cross-linkers target specific residues. There is the potential for false-
negatives if there are no cross-linkable residues near the binding site or sites of interaction. 
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The structural MS toolbox has evolved rapidly in the past two decades with the development 
of these various labelling techniques. However, choosing which methodology to use depends 
on the system being studied as each techniques has its own advantages and disadvantages 
(Table 2.1) 
Table 2.1: Summary of the different footprinting techniques. Table adapted from (Dailing et 
al., 2015). 
 Footprinting technique 
 Chemical 
Cross-linking 
Hydrogen- 
deuterium 
exchange 
Fast 
photochemical 
oxidation of 
proteins 
Protein painting 
Experimental 
configuration 
No extra set-up 
required 
Optimised for 
deuterium 
retention 
Optimised for UV 
pulse < 1 µs 
No extra set-up 
required 
pH Neutral-basic Acidic (pH = 2) Neutral- slightly 
basic 
Neutral 
Temperature 4 °C to room 
temperature 
Room 
temperature, 4 °C  
Room 
temperature 
Room 
temperature 
Timescale of 
experiment 
0.5 – 2 h Short (min) < 1 µs Short (min) 
Software 
required 
Specialised 
software 
Specialised 
software 
Standard LC-
MS/MS software 
Standard MS 
software 
Format of results Typically trypsin 
digested 
fragments 
containing 
peptides from 
each protein in 
interaction 
Pepsin digested 
fragments, ~10 
amino acids 
Typically trypsin 
digested 
fragments 
Typically trypsin 
digested 
fragments 
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Protein  
conformation 
Pre-formed 
complexes, 
covalently cross-
linked 
Pre formed 
complexes, 
deuterated 
Pre formed 
complexes, 
oxidised residues 
Pre formed 
complexes, non-
covalent coating 
with dyes 
Identification Binding partners 
are identified 
with low 
specificity for 
interface solvent 
excluded binding 
regions 
Interaction 
regions are 
identified by a 
small 1.0073 Da 
shift in peptic 
fragment peptide 
mass 
Interaction 
regions are 
identified by 
absence of 
oxidization 
Interaction 
regions are 
identified by 
presence of 
tryptic peptides 
exclusive to the 
site of interaction 
Negative 
outputs 
Intra-molecular 
cross-links as 
well as cyclic and 
dead end cross-
links 
Insensitive to 
internal protein 
interactions 
Treatment of the 
protein with a 
laser, may induce 
protein unfolding 
Insensitive to 
internal protein 
interactions 
 
As structural MS has evolved to be a prevalent player in the field of structural biology, the 
technique can be applied to targeting issues of complex formation and aggregation in one 
sector of biology that structural information is paramount: biopharmaceuticals.  
 
2.4 Biopharmaceuticals: monoclonal antibodies 
Monoclonal antibody (mAb) development was introduced in 1975 by Köhler and Milstein, in 
which immortal, mAb secreting, mouse cells are generated through the fusion with myeloma 
cells that secrete a single type of antibody (Köhler and Milstein, 1975); they were later 
presented with the Nobel Prize in medicine and physiology in 1984 for “theories concerning 
the specificity in development and control of the immune system and the discovery of the 
principle for production of monoclonal antibodies”. Their findings swiftly led to the 
generation of the first therapeutic antibody that was approved for human use (Orthoclone 
OKT3, muromonab) by the US Food and Drug Administration (FDA) in 1986, used for the 
treatment of acute rejection in organ transplant patients (Smith, 1996). Now, 30 years after 
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the first approval of Orthoclone OKT3, there has been an explosion in the market for mAbs 
and their fragments (Maggon, 2007, Liu, 2014), with mAbs now ranked as the highest grossing 
class of biopharmaceuticals. MAbs now contribute to 50 % of the top 10 selling drugs, as of 
2014 (in the US), and more than 50 % of the generated revenue. This is a striking difference 
when compared with the top 10 selling drugs from 2000-2011, where only one mAb was 
present in the top 10 selling drugs (Figure 2.12).  
 
Figure 2.12: The top drug sales of the 21st century. (a) (i) Graph showing the top 10 selling 
drugs of from the year 2000-2011 with (ii) the percentage of monoclonal antibody drugs 
shown. (b) (i) Graph showing the top 10 selling drugs of 2014 with (ii) the percentage of 
monoclonal antibody drugs shown. Monoclonal antibody drugs = blue. Figure generated with 
data collated from (Philippidis, 2012, Philippidis, 2015) (www.genengnews.com) . 
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The success of these molecules, aside from the exquisite specificity, can be partly due to the 
advancements in the methodologies used for their generation and production: phage and 
ribosome display (Chames et al., 2009).  
2.4.1 Monoclonal antibodies and their generation 
Intact mAbs, or immunoglobulins (Ig), are 150 kDa plasma glycoproteins that are employed 
by the immune system to detect and neutralise foreign bodies (Van Dijk and Van De Winkel, 
2001). Mab monomers have a characteristic ‘Y’ shape and consist of two pairs of polypeptide 
chains, connected through inter-molecular disulfide bonds: two identical heavy chains (~50 
kDa) and two identical light chains (~25 kDa). There are five different classes of antibodies 
that exist in higher vertebrates: IgM, IgA, IgD, IgG and IgE. The different classes of antibodies 
have unique monomeric structures dictated by their heavy chain (Janeway et al., 1997). Out 
of these classes, the IgG is the most common isotype which has four different subclasses: IgG1, 
IgG2, IgG3 and IgG4 (Janeway et al., 1997); the most common of which is the IgG1 isoform 
(Van Dijk and Van De Winkel, 2001). Each chain consists of sequential immunoglobulin 
domains, structural subunits comprising of two β-sheets arranged in an immunoglobulin fold. 
The higher order structure of the mAb can be broken down into the top half, constituting of 
two antigen binding fragments (Fabs) ‘arms’ (Figure 2.13a,b), and the bottom half of the 
molecule, consisting of the crystallisable fragment (Fc) (Figure 2.13a). The variable regions or 
fragments (Fv) (Figure 2.13a), are the regions of the molecule responsible for recognising their 
cognate antigens through the complementarity-determining regions (CDR) (Figure 2.13a, 
inset). Each variable domain consists of three CDRs that make contacts with the specific 
antigen; the hypervariablity of these CDR loops gives rise to the tremendous diversity in 
antigen-recognition.  
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Figure 2.13: Structure of an IgG1 antibody. (a) Structure of an IgG1 monoclonal antibody with 
the different regions highlighted. Green lines = disulphide bonds. The inset shows an 
individual Ig domain with the CDR loops highlighted (pink). (b) Structure of an isolated 
antigen binding fragment (Fab). (c) Structure of a single chain variable region (scFv) where 
the green line = glycine/serine linker. Figure redrawn from (Saunders, 2014). 
 
As described by Köhler and Milstein in 1975, mAbs were first generated using hybridoma 
technology (Köhler and Milstein, 1975). Briefly, an immortal hybridoma cell line is generated 
by fusing isolated spleen B-cells from immunised mice with an immortal myeloma cell line. 
The myeloma cells lack the HGPRT gene (hypoxanthine-guanine phosphoribosyltransferase), 
which makes them sensitive to aminopterin found in HAT (hypoxanthine-aminopterin-
thymidine) medium. Therefore, only fused cells are able to survive as the myeloma cells 
cannot survive in HAT medium, while the B-cells have a naturally short life time (Nelson et 
al., 2000). However, as mentioned previously, this method of generating mAbs has generally 
been replaced by either phage or ribosome display technologies.  
 
2.4.1.1 Phage display for the generation of mAbs 
The generation of mAbs using phage (Smith, 1985) and ribosome display (Hanes and 
Pluckthun, 1997) methodologies is an attractive approach as it is an in vitro process that 
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generates diverse libraries, 109-1011 and 1012-1014 in size, respectively (Lu et al., Groves et al., 
2014). The phage display technology has been adapted from the work of Georg P. Smith in 
1985, showing that phages can display a peptide of interest, through the fusion of protein III 
of the M13 bacteriophage and the peptide of interest, creating a peptide::pIII protein fusion 
(Smith, 1985).  
This principle was applied to display small mAb fragments, such as scFvs and Fabs, on the 
surface of phage (Carmen and Jermutus, 2002). The scFv or Fab sequence of interest is cloned 
into the phage plasmid between the promoter and phage coat protein to create a ‘phagemid’. 
Phagemid libraries are used to transfect E. coli cultures to express the fusion proteins (Qi et 
al., 2012). Selected hits from the phagemid libraries can then be re-grafted back onto IgG 
scaffolds to generate the fully functioning mAb. A diverse library of phagemids can be used 
to express scFv protein fusions which can be displayed on the surface of phage (Figure 2.14a), 
allowing for ‘panning’ of the fusion proteins to identify sequences that bind the target antigen. 
Any scFvs which do not bind can be removed through wash steps (Figure 2.14b) before 
eluting the scFvs of interest (Figure 2.14c). To increase the affinity of the binding, the binding 
scFvs can be amplified in E. coli, through the introduction of a helper phage to enable correct 
phage assembly (Bazan et al., 2012) (Figure 2.14d). This process is then repeated another 2-3 
times while altering conditions in order to increase the affinity of the scFv for its epitope, 
whereupon the sequence is analysed (Figure 2.14e).  
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Figure 2.14: The process of scFv selection using phage display. (a) Phage containing phagemid 
library are selected and (b) added to the antigen being selected against, which is immobilised 
onto a surface. (c) Binding partners are eluted and (d) re-amplified in E. coli for sequential 
rounds of selection to pan for further antigen affinity. (e) Selected candidates are sequenced 
after 2-3 rounds. Redrawn from (Schirrmann et al., 2011). 
 
Due to the stability of the filamentous phage used in this method, typically f1, fd or M13 
bacteriophages (Bazan et al., 2012), a range of conditions including extreme pH, high and low 
temperatures and a range of ionic strengths can be tested to find the tightest binders (Brigati 
and Petrenko, 2005). The tightest binding sequences can then be transfected into E. coli cells 
to test for binding specificity through ELISA assays (Lee et al., 2007). A paradigm example of 
phage display for the generation of mAbs is the generation of humira (Kempeni, 1999). 
Humira was generated to bind to tumor necrosis factor-alpha (TNFα), inhibiting the 
inflammatory response and aiding the treatment of rheumatoid arthritis, psoriatic arthritis, 
Chron’s disease, and psoriasis.  
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2.4.1.2 Ribosome display for the generation of mAbs 
Ribosome display is another form of in vitro display technology for the generation of mAbs, 
with the advantage of larger library sizes. This methodology uses a similar ‘panning’ 
procedure, cycling through multiple rounds to increase antigen specificity to the mAb 
fragment being displayed. However, here the mAb fragment is displayed from the exit tunnel 
of a free ribosome while still attached to its cognate mRNA sequence (Hanes and Pluckthun, 
1997). Starting with a pool of DNA sequences, each sequence is transcribed and translated in 
vitro to display the different polypeptide chains, typically scFvs. However, a spacer sequence 
is used, which lacks a stop codon, to halt the translation of the sequence while remaining 
attached to the peptidyl tRNA, prohibiting release factors from binding resulting in the 
protein of interest being displayed out of the ribosome exit tunnel, able to bind its target 
antigen. This presentation of the antibody fragment from the ribosome while still attached to 
its corresponding mRNA is called an antibody-ribosome-mRNA (ARM) complex (He and 
Taussig, 1997) (Figure 2.15). 
 
Figure 2.15: Schematic of an antibody-ribosome-mRNA complex. 
 
After non-binding scFv sequences have been removed through a wash step, initial hits can be 
eluted from their antigen and the ARM complex dissociated and the mRNA-scFv complex 
cleaved to release the mRNA. Reverse transcription PCR is then used to generate a pool of 
DNA molecules which can be further mutated and sequential rounds of ‘panning’ carried out.  
The evolution of these in vitro methods of selecting antibody fragments with exceptional 
binding affinity has led to the generation of mAbs unobtainable from conventional 
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immunisation methods (Bradbury et al., 2011). However, one issue that is commonly 
encountered, which these display methods do not address, is the expression levels of selected 
sequences.  
 
2.4.2 Antibody fragments and mimetics 
It was shown some time ago that the full 150 kDa IgG is not required for antigen binding, and 
that binding can be retained upon production of the VH and VL domains connected through 
a peptide linker (Huston et al., 1988). These antibody fragments have since been denoted as 
single chain variable fragments (scFv) (Figure 2.13). The idea of using scFvs as therapeutics 
was an attractive approach as they are smaller in size (~25 kDa) than IgGs and can be 
expressed and purified in E. coli (Guglielmi and Martineau, 2009). This led to the 
interrogation of various antibody fragments, such as Fabs, scFvs and single domain antibodies 
(dAbs) (Ward et al., 1989) (Figure 2.16b), as potential therapeutic candidates. These fragments 
of antibodies can be modified to retain the parent Ig characteristics such as affinity, 
immunogenicity and also effector function (Nelson and Reichert, 2009). Furthermore, 
advancements within the last decade have led to the generation of small polypeptide antibody 
mimetics as therapeutic agents (Figure 2.16a) (Qiu et al., 2007, Tiede et al., 2014). These 
mimetics adopt a similar binding mechanism to that of mAbs, using randomised amino acid 
loop regions to identify the target antigen while being held in place by a scaffold protein.  
However, the use of antibody fragments as therapeutic candidates have their own pros and 
cons. One of the major advantages to antibody fragments and mimetics are their size. Due to 
their relatively low molecular weight, they are able to infiltrate further into tissues and 
tumours compared with their mAb counterparts (Jain, 1990, Yokota et al., 1992). 
Furthermore, it has been hypothesised that due to their smaller size, a larger repertoire of 
epitopes are presented to antibody fragments with the possibility of binding to ‘cryptic’ 
epitopes readily available to fragments that would be un-achievable for full length mAbs. 
Indeed, single domain antibodies were shown to be able to act as potent enzyme 
inhibitors.(Lauwereys et al., 1998). Finally, antibody fragments are ideal as most can be 
produced in microbial systems as these fragments lack the glycosylation sites of full mAbs. 
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This therefore decreases the cost and timescale of their production compared with 
conventional mammalian expression systems. 
The disadvantages of using small antibody fragments arise in their short circulating half-life 
in vivo, due to the lack of an Fc region and therefore antibody fragments are not shielded for 
filtering by the Fc mediated recycling system (Mitragotri et al., 2014). Although it is worth 
mentioning that various Fc fusion proteins (Figure 2.16b) have been developed that bridge 
the gap of utilising small fragment therapeutics, while retaining in vivo Fc derived recycling, 
such as Enbrel, which also treats autoimmune diseases by interfering with TNF and was the 
fifth top selling drug in 2014 (Figure 2.12) (Peppel et al., 1991). It has also been shown that 
the aggregation propensity of mAbs and their different fragments may vary widely (Bird et 
al., 1988) and antibody fragments may be less stable than full length mAbs; this therefore 
requires rigorous analysis of the fragments to ensure their stability as monomers. Finally, as 
full mAbs contain the Fc region they elicit the necessary downstream immune response and 
effector functions, such as complement-dependent cytotoxicity or antibody-dependant cell-
mediated cytotoxicity (Hansel et al., 2010). This is, however, also elicited with the use of Fc 
fusion proteins. Thus, antibody fragments can function by either competing for the binding 
site of a receptor or ligand, simply blocking the action of the molecules, inhibiting a 
downstream response.  
 
Figure 2.16: Examples of antibody mimetics and antibody fragments. (a) Schematic of an 
antibody mimetic with the two variable loops highlighted (pink). (b) Schematic of an 
antibody fragment, dAb-Fc-fusion protein.   
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In summary, both mAbs, antibody fragments and antibody mimetics have advantages and 
disadvantages depending on the antigen being targeted. However mAbs generally have a 
greater stability compared with their fragment counterparts and as mAbs are entirely native 
to the host, they elicit the appropriate downstream responses while having the required in 
vivo half-life, without the need for any further genetic manipulation.  
 
2.4.3 Antibody and biopharmaceutical aggregation 
As mentioned previously, protein aggregation is a problem that affects all fields of protein 
science; from being the nightmare of PhD students, through to contributing to life-
threatening diseases. In biopharmaceutical development, protein aggregation can have 
multiple effects, from the stability of a candidature therapeutic through to jeopardising 
patient safety.   
As outlined in Section 2.1, protein aggregation is a complex problem that can be difficult to 
interrogate due to the mechanisms that drive oligomerisation are often poorly understood. 
Furthermore, added difficulty in characterising protein aggregates can arise due to the 
different classes of protein aggregates which can form: soluble/insoluble, covalent/non-
covalent, reversible/non-reversible and native/denatured (Cromwell et al., 2006, Vasquez-
Rey and Lang, 2011). Due to the stresses impacted on biotherapeutics, aggregate formation 
can occur at any stage of protein development and manufacture (Mahler et al., 2009); from 
pH stress, temperature jumps, changes in ionic strength, storage at high concentration and 
shear/extensional flow forces (Bekard et al., 2011). Finally, while it is ideal that stable 
candidates are chosen during the initial selections, any oligomeric material present in the 
product must be removed at the earliest stage possible. If unnoticed and present in the final 
product, aggregates may invoke an immune response to the active therapeutic agent 
(Rosenberg, 2006). In worst case scenarios, neutralising antibodies can impact the efficacy of 
the therapeutic (Chirmule et al., 2012) or cross-reactivity generates neutralising antibodies to 
endogenous proteins, which can lead to auto-immunity (De Groot and Scott, 2007). Therefore 
two things are clear, that (1) candidate protein therapeutic agents need to be exceptionally 
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stable molecules, and (2) methods need to be in place to rigorously characterise candidate 
sequences to identify the possibility of aggregated material. 
Currently, the main approaches to characterising aggregates in a candidate solution are 
chromatographic methods as well as light scattering, amongst others (Den Engelsman et al., 
2011). However, aside from protein aggregation prediction algorithms, such as Aggrescan 
(Conchillo-Solé et al., 2007) and the spatial aggregation propensity algorithm (Chennamsetty 
et al., 2009b), these techniques are set up to identify protein aggregates once they have 
formed, and then to process their removal. While necessary, these techniques do not yield 
any information into the underlying mechanisms that cause aggregates to form. With a 
greater understanding into the mechanisms that drive these aggregation events, methods 
could be established to minimise or ameliorate these effects earlier in the developmental 
pipeline, increasing the amount of potential candidates entering trials and ultimately, the 
clinic.  
 
2.5 WFL and STT – A model pair of monoclonal antibodies 
The study presented in this thesis focuses on two model antibodies that target nerve growth 
factor (NGF): a highly aggregation-prone mAb, WFL, and a non-aggregation-prone, but 
closely related variant STT that were generated by MedImmune plc. These two samples share 
a sequence identity of 99.6 %, with mutations found in the variable region of the heavy chain 
of the antibodies. STT was engineered from WFL with mutations W30S, F31T and L57T 
(Figure 2.17) which ameliorate the self-association properties of WFL.  
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Figure 2.17: scFv structures of (a) WFL and (b) STT. Residues 30, 31 and 57 are represented 
as sticks in the insets. Homology models were generated from the parent scFv. Structures were 
kindly supplied by MedImmune plc. 
 
WFL is the affinity matured version of its parent mAb that was derived from the parent 
sequence using phage display and has low picomolar (Kd = 1.6-9.8 pM) affinity for its target 
antigen. However, after the affinity maturation process, the poor biophysical characteristics 
that lead to the self-association and aggregation of WFL were realised. Along with poor yields 
in purification (< 30 %), absorption to filter membranes and colloidal instability, WFL eluted 
with a long retention time and asymmetric peak shape upon analysis by high performance 
size exclusion chromatography (HP-SEC), indicative of a high aggregation propensity. By 
contrast, while retaining its affinity for NGF (Kd = 1.8-8.3 pM), STT did not exhibit these poor 
biophysical characteristics (Figure 2.18). The reengineering WFL to STT at these positions 
(30, 31 and 57) were chosen as the parent sequence contained S30, T31 and T57 and did not 
display the poor biophysical characteristics, including aggregation. Thus, it was hypothesized 
that the mutations to hydrophobic residues during the affinity maturation were adding to the 
aggregation propensity of WFL. 
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Figure 2.18: High performance size exclusion chromatography elution profiles of WFL (blue) 
and STT (purple). Grey lines = calibrant proteins: 1, Thyroglobulin (670 kDa); 2, IgG (158 
kDa); 3, Ovalbumin (44 kDa) and 4, Vitamin B12 (1.35 kDa). Data acquired by MedImmune 
plc. 
 
As well as demonstrating difficulties in purification, in vivo data showed that WFL has a 
significantly shorter half-life compared with its parent upon intravenous administration into 
healthy rats and cynomolgus monkeys. By contrast, upon carrying out the same 
pharmacokinetic (PK) studies using WFL and STT, STT exhibited a 2-fold improvement in 
half-life. (Figure 2.19a). Finally, to examine whether the enhanced clearance of WFL was 
driven by non-specific binding to tissues in vivo, binding of both WFL and STT were tested 
against a range of human tissue samples using immunohistochemistry (IHC) (Figure 2.19b). 
The results demonstrated that WFL was indeed binding non-specifically to the range of tissues 
that were tested against. 
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Figure 2.19: Pharmacokinetics and tissue studies of WFL and STT. (a) WFL and STT 
pharmacokinetic profiles showing faster clearance of WFL upon intravenous administration 
(of a 3 mg/kg dose) into healthy rats. (b) Non-specific binding of WFL to various tissue types 
while STT presented no evidence of staining any of the tissue types tested. Data acquired by 
MedImmune plc. 
  
While the generation of STT ameliorates the self-association and aggregation of WFL, the 
underlying mechanism driving the self-association remained elusive. As WFL is one of the 
most extreme cases of antibody self-association experienced by MedImmune plc whilst STT 
differs in only three amino acids (per heavy chain) yet has substantially improved biophysical 
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properties, it was concluded that this pair of mAbs would make an ideal pair to determine 
how subtle changes in sequence can result in catastrophic differences in their aggregation 
properties. 
 
2.6 The aim of this study 
Protein aggregation has sweeping negative effects throughout academia, biopharmaceutical 
production and all of protein science. However, the methods utilised within the 
biopharmaceutical industry are set up to identify and analyse protein aggregates once targets 
have been selected and antibodies generated, which is relatively late in the production 
pipeline. Furthermore, current established methods are able to detect and separate aggregated 
material from a product, but often do not yield site-specific information or insights into the 
mechanism underpinning the oligomerisation events. Therefore, there is a critical 
requirement for the development of techniques that can identify aggregation-prone 
sequences or candidates at the earliest stage possible. Such techniques have to be sensitive to 
small amounts of aggregated material and simple to equip and employ since predictions of 
aggregation-prone regions are only possible once a better understanding of the mechanisms 
are achieved. Thus, the aims of this study are two-fold: (i) to establish techniques that can 
identify the mechanisms responsible for driving the aggregation of a therapeutically relevant 
mAb and (ii) to characterise the regions responsible. Finally, this study aims to establish an in 
vivo method for the rapid detection of aggregation-prone sequences and candidates at early 
stages in candidate selection and biopharmaceutical product development.  
The techniques described should: 
- Be sensitive enough to identify small percentages of oligomeric/aggregated material 
- Require small volumes and concentrations of samples 
- Be amenable to a diverse range of proteins: different size, structures and aggregation 
mechanisms 
- Yield high resolution information into the specific regions responsible for driving 
the oligomerisation/aggregation 
And secondly, be able to: 
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- Accurately measure the extent of aggregation prone-sequences in vivo 
- Have low false discovery rates 
- Be rapid and cost effective in identifying aggregation prone sequences  
- Be applicable to predicting the regions responsible for driving the aggregation events 
All of these requirements are met throughout the studies described in this thesis focusing on 
the two closely related mAbs, WFL and STT, provided by MedImmune plc. Chapter 4 employs 
IMS-MS to identify and characterise small amounts of oligomeric material in terms of their 
mass and shape, via their collision cross-sectional area, to which models were built to evaluate 
potential mechanisms of aggregation. Chapter 5 utilises chemical cross-linking combined 
with mass spectrometry to capture the oligomeric species present in solution and identify 
inter-molecular cross-links, which were then used as restraints to derive high resolution 
models detailing the mechanism of self-association. Finally, Chapter 6 describes the 
development of an in vivo assay to identify aggregation-prone sequences in biotherapeutic 
candidates, which can be applied to the early stages of the biopharmaceutical developmental 
pipeline. Finally, Chapter 7 summarises the new insights gained from the work presented and 
highlights the future developments and impacts of the results presented in this thesis.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
Mass Spectrometers 
LCT Premier time-of-flight mass spectrometer (Waters Corp., Manchester, UK). 
Synapt High Definition Mass Spectrometer (HDMS) quadrupole ion-mobility time-of-flight 
mass spectrometer (Waters Corp., Manchester, UK). 
Synapt G2-Si HDMS quadrupole ion-mobility time-of-flight mass spectrometer (Waters 
Corp., Manchester, UK). 
Xevo G2-XS quadrupole time-of-flight mass spectrometer (Waters Corp., Manchester, UK). 
Centrifuges 
Avanti J-26 XP Centrifuge    Backman Coulter, Brea, CA, USA 
GenFuge 24D Centrifuge    Progen Scientific, London, UK 
Eppendorf 5810R Centrifuge    Fisher Scientific, Loughborough, UK 
Beckman Coulter XL-A Ultracentrifuge   Beckman Coulter Inc., CA, USA 
Incubators, shakers and mixers 
Gallenkamp Economy Incubator Size 1   Sanyo, Watford, UK 
Innova 43 Shaker Incubator    New Brunswick Scientific, USA 
Innova 44 Shaker Incubator    New Brunswick Scientific, USA 
Stuart Oribtal Incubator S1600    Bibby Scientific, Stone, UK 
Protein purification 
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ÄKTAprime Plus     GE Healthcare, Little Chalfont, UK 
ÄKTAmicro      GE Healthcare, Little Chalfont, UK 
HisTrap FF 5 mL Ni Sepharose    GE Healthcare, Little Chalfont, UK 
Superdex Peptide 3.2/30 Column    GE Healthcare, Little Chalfont, UK 
Gel electrophoresis equipment 
Slab Gel Electrophoresis Chamber AE-6200  ATTO, Tokyo, Japan 
Powerpac 3000      Bio-Rad Lab., Hercules, CA, USA 
Powerpac Basic     Bio-Rad Lab., Hercules, CA, USA 
Spectrophotometers 
UltroSpex 2100 Pro UV/Visible Spectrophotometer GE Healthcare, Little Chalfont, UK 
NanoDrop 2000 Spectrophotometer   Thermo Scientific, Surrey, UK 
Electron Microscope 
FEI T12 Transmission Electron Microscope   FEI Inc., Hillsboro, OR, USA 
Other Equipment 
Bio-Rad T1000 Thermocycler    Bio-Rad Lab., Hercules, CA, USA 
Grant JB1 Unstirred Waterbath   Grant Instruments, Shepreth, UK 
Jenway 3020 Bench pH Meter    Bibby Scientific, Stone, UK 
SnakeSkin Pleated Dialysis Tubing – 3,500 MWCO Thermo Scientific, Surrey UK 
Techne Dri-block Heater    Bibby Scientific, Stone, UK 
C18 SepPak Cartridges     Waters corp., Wilmslow, UK 
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3.1.2 Chemicals 
A 
Acetic acid, glacial    Fischer Scientific, Loughborough, UK  
Acetonitrile     Fischer Scientific, Loughborough, UK  
Agar      Melford Laboratories, Suffolk, UK  
Agarose     Melford Laboratories, Suffolk, UK  
Ammonium Acetate, glacial   Fischer Scientific, Loughborough, UK  
Ammonium bicarbonate   Fischer Scientific, Loughborough, UK  
Ampicillin     Formedium, Norfolk, UK  
Arabinose     Sigma Life Sciences, St. Louis, USA  
L-Arginine     Sigma Life Sciences, St. Louis, USA  
B 
Bromphenol Blue    Sigma Life Sciences, St. Louis, USA  
BS3 (bis(sulfosuccinimidyl)suberate)  Thermo Scientific, UK  
C 
Chloramphenicol    Sigma Life Sciences, St. Louis, USA  
Caesium iodide     Sigma Life Sciences, St. Louis, USA  
D 
DTT (1,2-dithioltheritol)   Formedium, Norfolk, UK  
E 
Ethanol     Fischer Scientific, Loughborough, UK  
Ethidium Bromide, EtBr   Sigma Life Sciences, St. Louis, USA  
Ethylenediamine tetra acetic acid, EDTA Sigma Life Sciences, St. Louis, USA  
F 
Formic acid     Fischer Scientific, Loughborough, UK  
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G 
Glycerol      Fischer Scientific, Loughborough, UK 
Glutaraldehyde     Sigma Life Sciences, St. Louis, USA 
H 
Hydrochloric acid     Fischer Scientific, Loughborough, UK 
I 
Instant blue stain     Expedeon, Harston, UK  
Iodoacetamide      Sigma Life Sciences, St. Louis, USA 
L 
LB broth, granulated     Melford Laboratories, Suffolk, UK 
R 
L-Rhamnose      New England Biolabs, Hitchin, UK 
S 
Sodium chloride, NaCl     Fischer Scientific, Loughborough, UK 
Sodium dodecyl sulphate, SDS    Sigma Life Sciences, St. Louis, USA 
Sodium hydroxide, NaOH    Fischer Scientific, Loughborough, UK 
Sodium phosphate monobasic,  NaH2PO4  Sigma Life Sciences, St. Louis, USA 
Sodium phosphate dibasic, Na2HPO4   Sigma Life Sciences, St. Louis, USA 
Sodium succinate     Sigma Life Sciences, St. Louis, USA 
T 
Tetracycline      Formedium, Norfolk, UK  
Tetramethylethylenediamine (TEMED)  Sigma Life Sciences, St. Louis, USA 
Trifluoroacetic acid     Fischer Scientific, Loughborough, UK 
Tris-(hydroxymethyl)-aminomethane, Tris  Melford Laboratories, Suffolk, UK 
Tryptone      Melford Laboratories, Suffolk, UK 
Y 
Yeast extract      Melford Laboratories, Suffolk, UK 
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3.1.3 Enzymes used for molecular biology 
Table 3.1: Enzymes used to carry out the molecular biology in this study. The buffers and 
additives of the corresponding enzymes supplied by the manufacturer were used. 
Enzyme Manufacturer 
XhoI restriction endonuclease (20 U / µL) New England Biolabs, Hitchin, UK 
BamHI restriction endonuclease (20 U / µL) New England Biolabs, Hitchin, UK 
NdeI restriction endonuclease (20 U / µL) New England Biolabs, Hitchin, UK 
T4 DNA ligase (Quick Ligation™ Kit) New England Biolabs, Hitchin, UK 
Taq DNA polymerase (5 U / µL) New England Biolabs, Hitchin, UK 
Vent DNA polymerase (2 U / µL) New England Biolabs, Hitchin, UK 
Antartic phosphatase (5 U / µL) New England Biolabs, Hitchin, UK 
Lysozyme Sigma Aldrich, St. Louis, USA 
Deoxyribonuclease I (DNase I) Sigma Aldrich, St. Louis, USA 
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3.1.4 Antibiotics 
Table 3.2: Antibiotics used in this study. 
Antibiotic Solvent 
dissolved in 
Stock concentration 
(mg/mL) 
Working 
concentration 
(µg/mL) 
Ampicillin H20 100 100 
Chloramphenicol Ethanol 30 25 
Tetracycline Ethanol 5 12.5 
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3.1.5 Media  
Table 3.3: Media used in this study. 
Media Reagents Weight / Volume 
 
 
Luria-Bertani (LB) Media 
Bacto-tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
H2O (18 MΩ) Make up to 1 L 
Autoclave 20 min. at 121⁰C, 15 psi 
 
 
2xTY Media 
Bacto-tryptone 16 g 
Yeast extract 10 g 
NaCl 5 g 
H2O (18 MΩ) Make up to 1 L 
Autoclave 20 min. at 121⁰C, 15 psi 
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3.1.6 Markers and dyes 
Table 3.4: Protein and DNA makers used in this study.  
Marker Manufacturer 
Precision Plus Protein™ Dual Xtra 
Standard 
Bio-Rad, Hemel Hempstead, UK 
100 bp DNA ladder Promega, Southampton, UK 
1 kb DNA ladder Promega, Southampton, UK 
 
Table 3.5: Protein and DNA dyes used in this study 
Dye Manufacturer 
Instant Blue Stain Expedeon Protein Solutions, UK 
Orange G Loading Dye (10x) for DNA Sigma Aldrich, St. Louis, USA 
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3.1.7 Kits 
Table 3.6: Commercially purchase kits used in this study. 
Kit Manufacturer 
QIAquick Gel Extraction QIAGEN, Crawley, UK 
QIAquick PCR Purification QIAGEN, Crawley, UK 
QIAprep spin Miniprep QIAGEN, Crawley, UK 
Q5 Site-Directed Mutagenesis  New England Biolabs, Hitchin, UK 
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3.1.8 LB-agar plates 
Table 3.7: LB-agar plates used in this study. 
Antibiotic resistance required Component 
 
Tetracycline 
2.5 g LB broth 
1.5 g Agar 
10 µg/mL tetracycline 
Make up to 100 mL in H2O 
 
 
Ampicillin-chloramphenicol 
2.5 g LB broth 
1.5 g Agar 
100 µg/mL ampicllin 
30 µg/mL chloramphenicol 
Make up to 100 mL in H2O 
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3.1.9 Buffers 
Table 3.8: Buffers used in this study. 
Buffer Reagent 
 
 
SDS-PAGE 2x loading buffer 
50 mM Tris.HCl, pH 6.8 
100 mM DTT 
2 % (w/v) SDS 
0.1 % (w/v) bromophenol blue 
10 % (v/v) glycerol 
 
Gel electrophoresis cathode buffer 
200 mM Tris.HCl, pH 8.25 
200 mM Tricine 
0.2 % (w/v) SDS 
Gel electrophoresis anode buffer 400 mM Tris.HCl, pH 8.8 
 
Tris-acetate-EDTA (TAE) Buffer 
40 mM Tris.HCl, pH 8 
20 mM acetic acid (glacial) 
1 mM EDTA, pH 7.5 
 25 mM Tris.Hcl, pH 7.4 
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Cell lysis buffer 
50 mg lysozyme 
10 mg DNase I 
300 µM PMSF 
1 mM EDTA 
Make up to 500 mL with H2O 
 
HisTrap™ binding buffer 
50 mM Tris.HCl, pH 7.4 
300 mM NaCl 
40 mM Imidazole 
 
HisTrap™ elution buffer 
50 mM Tris.HCl, pH 7.4 
300 mM NaCl 
400 mM imidazole 
 
Storage buffer 
20 mM sodium succinate 
125 mM arginine, pH 6 
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3.2 Methods 
3.2.1 Mass spectrometry 
All IMS-MS measurements were made using a Synapt G1 high definition mass spectrometer 
(Waters Corp., Wilmslow, UK). Samples were introduced to the mass spectrometer using 
borosilicate capillaries pulled in-house (Sutter Instrument Company, Novato, CA, USA) and 
coated with palladium using a sputter coater (Polaron SC7620, Quorum Technologies Ltd, 
Kent, UK). All samples were analysed in the positive ion mode using nanoelectrospray 
ionisation. The m/z scale was calibrated using 10 mg/mL aqueous caesium iodide (CsI) clusters 
across the acquisition range (typically 500-15,000 m/z). Data were processed and analysed 
with the MassLynx v4.1 and Driftscope software, supplied with the mass spectrometer.  
 
3.2.2 Sample preparation 
Samples were dialysed against 150 mM ammonium acetate, pH 6 using 20 µL dialysis buttons 
(Hampton Research Crop., Aliso Viejo, CA, USA). Calibrant proteins β-lactoglobulin, avidin, 
concanavalin A, alcohol dehydrogenase, pyruvate kinase, glutamate dehydrogenase and 
GroEL were buffer exchanged into 150 mM ammonium acetate, pH 6 using Zeba spin 
desalting columns (3.5 kDa MWCO) (Thermo Scientific, UK) and used for IMS-MS 
calibration. 
 
3.2.3 nESI-MS and IMS-MS of monoclonal antibodies 
MAb samples were dialysed at 1 mg/mL before being infused into the Synapt G1 instrument. 
nESI-MS experiments were conducted under the following settings: capillary voltage, 1.5 kV; 
sample cone, 30 V; extraction cone, 4 V; source temperature, 60-80 ⁰C; backing gas flow, 20 
mL/min, IMS wave height (ramped), 5-30 V and travelling wave speed, 300 ms. For increased 
mass accuracy of mAb samples a trap voltage of 50-80 V was used.  
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3.2.4 TWIMS device calibration 
The calibration of the TWIMS device was carried out using calibrant proteins from the 
Clemmer/Bush (Bush et al., 2010) database appropriate to the mass of the protein of interest. 
Typically used calibrant proteins were: beta-lactoglobulin, B-Lac; concanavalin A, CCA; 
alcohol dehydrogenase, ADH; pyruvate kinase, PyK and glutamate dehydrogenase, GluD. The 
calibrant proteins were acquired using the same conditions to that of the sample in question 
and a calibration curve was constructed using an established method, briefly outlined in 
Section 1.6.2 (Ruotolo et al., 2008). The EDC correction coefficient used in the calibration 
curve construction was 1.57. 
 
3.2.5 Theoretical CCS calculation 
The MOBCAL software was used to calculate the theoretical cross-section for the samples 
studies in this thesis. The MOBCAL projection approximation value (Mesleh et al., 1996) was 
used to generate the projection superposition approximation (PSA) outlined by (Bleiholder et 
al., 2011b). The equation used for this was: 
𝑃𝑆𝐴 = (𝑃𝐴 − 81) 𝑥 1.299 
Equation 3.1 
The MOBCAL software was implemented using a Linux operating system.  
 
3.2.6 LC-MS/MS 
Peptide samples were separated and analysed on a nanoAcquity LC system (Waters Ltd., 
Wilmslow, UK) connected on-line to a Synapt G2-Si mass spectrometer (Waters Corp., 
Wilmslow, UK). 1 µL of sample was injected onto a Acquity M-Class column (C18, 75 µm x 
150 mm) (Waters Ltd., Wilmslow, Manchester, UK) and subsequently separated by a 1-50 % 
gradient elution of solvent B (0.1 % (v/v) formic acid: acetonitrile) in solvent A (0.1 % (v/v) 
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formic acid in water) over a 60 minute time period at a 0.3 µL/min flow rate. The instrument 
was operated in positive ion mode using collision-induced dissociation (CID) for 
fragmentation of selected ions. Data dependant MS/MS experiments were conducted in the 
trap region of the instrument using a 1 second scan with the five most intense ions being 
selected for fragmentation over a 350 – 2000 m/z window. Data were processed and analysed 
with the MassLynx (V4.1) software provided with the instrument, and PEAKS software 
(Zhang et al., 2012). Manually identified and low abundant cross-linked peptides were added 
to an inclusion list to be selected for sequencing.  
 
3.2.7 Cross-linking analysis 
LC-MS/MS spectra were exported from the PEAKS software in .MGF format to be analysed 
with the StavroX software (Götze et al., 2012). The search parameters used were as follows: 
maximum missed cleavages at C-terminal of K and R, 1; static modifications, C to B (alkylated 
cysteine) and variable modifications, M to m (oxidised methionine, max = 2); precursor 
precision, 3.0 ppm; fragment ion precision, 0.8 Da; lower mass limit, 200 Da; upper mass limit, 
8000 Da; false discovery rate cut off, < 5 % with a score cut off of 10 and slow, precise scoring 
applied. 
 
3.2.8 Manual data analysis for cross-linked species 
To identify all candidates as potential inter-molecular cross-links the LC-MS peptide spectra 
were compared. Each spectrum from the dimer sample of 1912 were interrogated to search 
for potential cross-linked candidates. Once a candidate had been identified, the spectrum 
from the cross-linked monomer sample was analysed at the same retention time (± 1 minute) 
to confirm unique inter-molecular cross-links.  
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3.3 Modelling 
3.3.1 MOBCAL modelling of mAbs 
Approximate models for the mAb monomers and their oligomers were modelled using the 
MOBCAL software (Mesleh et al., 1996, Shvartsburg and Jarrold, 1996) by editing the 
MOBCAL code to define the Fab and Fc regions of a mAb as single atoms. Lines 581 and 583 
of the MOBCAL code were changed to the mass of the Fab region of the molecule (47 kDa) 
and line 586 edited for the hydrodynamic radius (30 Å). Lines 591 and 593 were then given 
the mass of the Fc region (53 kDa) and line 596 edited for the Fc hydrodynamic radius (30 Å). 
These values were also implemented on lines beginning 2599 and 2609 of the code. The input 
.mfj file was then modified to manipulate the vector coordinates of the individual regions to 
re-build a monomeric mAb which predicted CCS value was in agreement with experimental 
data. Oligomeric species were then built to the models specified in Chapter 4 (see Section 
4.3.3) and their predicted CCSs calculated.  
 
3.3.2 Generation of spherical models 
To generate spherical models, the Ruotolo method (Ruotolo et al., 2008) and Benesch methods 
(Benesch et al., 2007) were used. An average protein density of 0.44 Da Å-3 was used. 
Ruotolo method: 
𝐶𝐶𝑆 = 𝑀𝑖
2
3  × 2.435 
Equation 3.2 
Where Mi is the mass of the ion 
Benesch method:  
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𝐶𝐶𝑆 =  𝜋((
3𝑀𝑖
4𝜋𝜌
)
1
3 + 𝑅𝑔)
2 
Equation 3.3 
where Mi is the mass of the ion, ρ is the density of the protein (0.44 Da Å-3) and Rg is the radius 
of the buffer gas (nitrogen = 1.55 Å)  
 
3.3.3 Generation of the (127)5 polyprotein structure 
The I27 monomer subunit structure was taken from the PDB (PDB= 1TIT). The four linker 
domains connecting the subunits were then attached to the C-terminus of the previous sub-
unit based upon the linkers used while purifying the proteins; the linker regions added were: 
Table 3.9: Table of amino acid linkers added to the C-terminal of the I27 sub-units 1-4.  
Linker Amino acid composition 
Linker 1 VEAR 
Linker 2 LIEAR 
Linker 3 LSSAR 
Linker 4 LIEARA 
 
The five PDB structures were then aligned manually with one another before the C-terminal 
amino acid from the linker region was connected to the N-terminal leucine of the sequential 
I27 sun-unit. The subunits were connected by Dr Claire Windle (University of Leeds) using 
the Coot software, operated under a Linux operating system.  
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3.3.4 In vacuo molecular dynamics (MD) simulations 
MD simulations were run using the NAMD software (NAMD 2.9) (Phillips et al., 2005), using 
the CHARMM force field (Brooks et al., 1983). Structures were simulated in a solvent free 
system. For the simulation, a constant temperature of 300 K with Langevin thermostat was 
used and a time-step of 2.0 fs with a radial cut-off distance of 12 Å used throughout. Energy 
minimization in vacuo was implemented for a total of 0.5 ns before an equilibration of 10 ns, 
the cut-off distance, force field and time step remained as described above throughout the 
simulation. Visual Molecular Dynamics (VMD) (Humphrey et al., 1996) was then used to 
visualise the simulation and individual frames were saved as PDB coordinates in order to 
compute the CCS using MOBCAL. The VMD software was also used to calculate the root 
mean square deviation (RMSD) and radius of gyration (Rg). The CCS were calculated every 
0.1 ns of the simulation to 1 ns and then every 1 ns thereafter. Analysis of the root-mean-
square deviation (RMSD) revealed whether a protein had equilibrated by the end of the 10 ns 
simulation, any sample that had not finished equilibration was re-submitted for a further 10 
ns until equilibration was reached. The NAMD and VMD software was operated under a 
Linux operating system.  n = 1 for all MD minimisation and equilibration experiments.  
 
3.3.5 Model generation for 1912 scFv dimer 
The 1912 scFv homology model (from parent mAb, kindly provided by MedImmune plc.) was 
submitted to the HADDOCK webserver (van Zundert et al., 2016) with residues W30, F31 
and L57 designated as the active residues to drive the docking procedure. The HADDOCK 
model was then refined in XPLOR-NIH (Schwieters et al., 2003) using a distance restraint set 
by the bis(sulfosuccinimidyl)suberate (BS3) cross-linker (11.4 Å) between residues Q1 of the 
heavy chain and K54 of the light chain with a square well energy potential and residues W30, 
F31 and L57 as sparse, highly ambiguous distance restraints (Clore and Schwieters, 2003). The 
model refinement in XPLOR-NIH was carried out with the help of Dr Theodoros Karamanos 
(University of Leeds).  
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3.4 Biochemical methods 
3.4.1 Analytical ultracentrifugation 
Sedimentation velocity analytical ultracentrifugation (SV-AUC) of antibody samples was 
conducted on a Beckman Coulter XL-A instrument (Beckman Coulter Inc., CA, USA) at 20 
°C. MEDI1912 and MEDI1912_STT were dialysed into 150 mM ammonium acetate, pH 6 or 
analysed in ‘succinate-Arg buffer’ (20 mM sodium succinate, 125 mM arginine, pH 6.0) at the 
same protein concentration (1 mg/mL, determined by A280). A wavelength of 298 nm and 
rotor speed of 28,000 rpm were used. Data were analysed using SEDFIT (Schuck, 2000). AUC 
data were analysed with the help of Dr Clare Pashley (University of Leeds).  
 
3.4.2 Negative stain transmission electron microscopy 
mAb samples at 1 mg/mL, as measured using A280, in storage buffer (Table 3.8). Samples were 
diluted and immediately spotted onto carbon coated electron microscopy grids (400 mesh, 
glow discharged 25 mA for 40 seconds) (Fisher 462 Scientific, Leicestershire, UK) and allowed 
to absorb for 30 seconds. The grids were then washed 463 with milliQ-H2O with blotting on 
Whatman paper between wash steps, Stained with 1 % (w/v) uranyl 464 acetate, air dried 
under a lamp and imaged on a FEI T12 TEM (FEI Inc., Hillsboro, OR, USA) operating 465 at 
120 keV. 
 
3.4.3 Lys-C enzymatic digestion of mAb samples 
Endoproeinase Lys-C from Lysobater enzymogenes (Sigma Aldrich, St. Louis, USA) was used 
to generate Fab and Fc regions from mAb samples. mAb samples were used at 1 mg/mL in 100 
mM sodium phosphate buffer, pH 7.4 and Lys-C added at a 1:50 (protein:enzyme) ratio. The 
protein-enzyme reaction was incubated at 37 ⁰C for 18 hours before the resulting digests being 
taken for dialysis and analysis via MS and IMS-MS.  
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3.4.4 Glutaraldehyde cross-linking 
Protein samples were diluted to 1 mg/mL and buffer exchanged into 100 mM sodium 
phosphate buffer, pH 7.4, using zeba spin columns (Thermo Scientific, UK), for cross-linking 
with glutaraldehyde (Sigma Aldrich, St. Louis, USA). A stock solution of 1 % (w/v) 
glutaraldehyde was used to probe for optimal concentrations across the range of: 0.1 %, 0.05 
%, 0.01 % and 0.001 % (w/v).  
 
3.4.5 BS3 cross-linking  
Protein samples were diluted to 1 mg/mL and buffer exchanged into 100 mM sodium 
phosphate buffer, pH 7.4, using zeba spin columns (Thermo Scientific, UK), for cross-linking 
with a mixture of deuterated (d4) and non-deuterated (d0) BS3 (Thermo Scientific, UK). 1 mg 
of both d0 and d4 BS3 was dissolved in 138.5 µL 20 mM sodium phosphate buffer, pH 7.4. 
Equimolar concentrations of the d0 and d4 cross-linker were added together to yield a 50:50 
mix of d0:d4 as a stock solution. BS3 cross-linker was initially added in increasing ratios for 
optimisation: 1:10, 1:20, 1:50, 1:100, 1:200 and 1:500 (mol/mol) (protein: cross-linker). The 
cross-linking reaction was incubated on ice for 30 minutes before quenching with 50 mM 
Tris.HCl, pH 8 (final concentration). The resulting cross-linked species were then analysed 
using either digestion and peptide size-exclusion chromatography (SEC) or via SDS-PAGE 
analysis and in-gel digestion methods, see Section 2.4.6 and Section 2.4.7/Section 2.4.8, 
respectively.  
 
3.4.6 Enzymatic digestion, peptide purification and concentration 
Prior to digestion, first the samples were denatured with an equal volume of 6 M Gdn.HCl. 
7.5 mM DTT was added to the samples and incubated at 37 °C for 30 min. Samples were then 
cooled back down to room temperature and 15 mM of iodoacetamide added and the reaction 
incubated in the dark at room temperature for 30 min. The samples were then diluted to 
reduce the Gdn.HCl concentration below 1.5 M. The resulting BS3 cross-linked mixture was 
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then digested with a 1:100 (w/w) ratio (enzyme:protein) with gold standard trypsin (Promega, 
UK) for 18 hours at 37 ⁰C. 50 µL Formic acid was then added to quench the reaction, the 
reaction mixture was then made up to 1 mL with ddH20. The digested mixture was purified 
using C18 SepPak cartridges (Waters corp., Wilmslow, UK). The cartridges were equilibrated 
with 1 mL 100 % acetonitrile and washed with 2×1 mL wash buffer (95:5:0.1 (v/v/v), ddH20: 
acetonitrile: formic acid) before the digested mixture was passed through the cartridge. The 
bound mixture was washed with a further 2×1 mL of wash buffer before being eluted with 1 
mL elution buffer (50:50:0.1, ddH20: acetonitrile: formic acid). Eluted peptides were then 
evaporated to completion using a Savant SpeedVac system (Thermo Scientific, UK). The 
peptide mixture was then reconstituted in 40 µL ddH20 and taken for peptide SEC, see Section 
2.4.6. 
 
3.4.7 Peptide size exclusion chromatography (SEC) 
Reconstituted cross-linked peptide mixtures were pipetted into a 96-well plat for injection 
into an ÄKTAmicro (GE Healthcare, Little Chalfont, UK) using an online A-905 auto-
injection system (GE Healthcare, Little Chalfont, UK) with a Superdex Peptide 3.2/30 column 
(GE Healthcare, Little Chalfont, UK) being used for the gel filtration. The column was washed 
and equilibrated with 30 % (v/v) acetonitrile, 0.1 % (v/v) trifluoroacetic acid (Buffer A). 40 
µL of sample was injected using the pick-up injection method and the peptides eluted using a 
constant flow rate of 50 µL/min. 100 µL fractions were collected in a 96-well plate format 
with the elution of peptides being monitored by absorbance at 218, 254 and 280 nm. The 
collected fractions were evaporated to completion using a Savant SpeedVac system (Thermo 
Scientific, UK) before being taken for analysis by LC-MS/MS (see Section 2.2.6). 
 
3.4.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Tris-tricine buffered sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) was used to separate species based upon their molecular weight to analyse the 
formation of cross-linked species. Two glass plates were assembled following the 
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manufacturer’s directions with a 1.5 mm spacer between the plates to ensure a tight seal 
between the plates. The resolving and stacking gels were made up of the components shown 
in Table 3.10. Ammonium persulphate was added to the gel mixtures last before the resolving 
gel was immediately poured into the gel moulds. The stacking gel was poured on top of the 
resolving gel and a 12 well comb was added to create the wells needed once the gels had set. 
The gel cast was left to set for a minimum of 1 hour.  
Table 3.10: Components used to create Tris-tricine SDS-PAGE gels. The volumes stated here 
allow for the casting of two gels (80 mm × 100 mm) using a 1.5 mm spacer. 
Solution component Resolving gel 
(mL) 
Stacking gel 
(mL) 
30 % (w/v) acrylamide: 0.8 % (w/v) bis-acrylamide 7.5 0.83 
3 M Tris.HCl, 0.3 % (w/v) SDS pH 8.45 5.0 1.55 
ddH20 0.44 3.72 
Glycerol 2.0 -- 
10 % (w/v) ammonium persulphate 0.05 0.10 
Tetramethylethylenediamine (TEMED) 0.005 0.005 
 
 
Protein samples for SDS-PAGE were diluted 2-fold with 2x loading buffer (see Table 2.7) and 
boiled for 3 minutes prior to loading onto gels. For identification of molecular weight species, 
the first lane was loaded with 7 µL of Precision Plus Protein™ Dual Xtra Prestained protein 
standard (Bio-Rad,UK). The inner and outer reservoirs were filled with cathode buffer (see 
Table 2.7) and anode buffer (see Table 2.7), respectively, prior to sample loading. 15 µL of 
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samples were loaded into each well before begin electrophoresed. Gels were run with an 
initial current of 30 mA until all samples has entered into the resolving gel, where the current 
was increased to 75 mA until the dye front had reached the bottom of the resolving gel. For 
cross-linked mAb samples, the gels were run until the 25 kDa ladder had reached the bottom 
of the resolving gel in order to separate the oligomeric species. The gels were removed from 
there casts and stained using Instant Blue (Coomassie) stain (Expedeon, UK) and visualised 
using a Syngene InGenius gel documentation system (Syngene, UK) post gel de-staining in 
H2O. 
 
3.4.9 In-gel enzymatic digestion 
A scalpel was used to remove the gel bands of interest and placed into 1.5 mL Eppendorfs. 
The gel pieces were subjected to three repeat rounds of hydration and dehydration with 200 
µL 25 mM ammonium bicarbonate, pH 7.8 and 200 µL 50 % (v/v) acetonitrile/ 25 mM 
ammonium bicarbonate, respectively, to completely de-stain the excised gel pieces. Each 
solution was removed from the Eppendorf tube with a gel loading tip before the subsequent 
solution added Gel pieces were fully submerged in 100 % acetonitrile to shrink the gel piece 
down to completion. The acetonitrile was removed by incubating the open Eppendorfs in a 
laminar flow hood for a minimum of 45 minutes. Gel pieces were re-hydrated with 200 µL 10 
mM DTT for 45 minutes at 37 ⁰C and shaking at 300 RPM in a Thriller shaking incubator 
(WVR Peqlab, Germany) before free cysteines were subsequently alkylated with 200 µL 55 
mM iodoacetamide in the dark at room temperature. A final dehydration step was then 
carried out using 200 µL 50 % (v/v) acetonitrile / 25 mM ammonium bicarbonate. The 
dehydration solution was again removed under a laminar flow hood for a minimum of 45 
minutes. Dry gel pieces were re-hydrated with 0.1 µg/µL gold standard trypsin solution in the 
supplied re-suspension buffer (Promega, UK), ensuring that the trypsin solution was added to 
completely submerge the gel pieces. Gel pieces were incubated for 30 minutes at room 
temperature to allow the trypsin solution to be absorbed before adding 50 µL 25 mM 
ammonium bicarbonate and the reaction incubated at 37 ⁰C for 18 hours, shaking at 300 RPM. 
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20 µL of formic acid was added to quench the reactions and the digested cross-linked peptides 
were purified as described above (see Section 2.4.5). 
 
3.4.10 Polyethylene glycol (PEG) precipitation 
A 40 % (w/v) stock solution of PEG (~8000 average molecular weight) in 20 mM sodium 
succinate, 125 mM arginine, pH 6 buffer was prepared as the titrant. ScFv stock solutions were 
prepared at 150 µM in the same buffer. Samples were prepared in triplicate and loaded into a 
96-well, clear, flat-bottomed plate (Greiner Bio-One, Austria) using a multichannel pipette as 
follows: a) succ-Arg buffer was dispensed into each well with a volume of 100-180 µL. b) 0-
180 µL of the 40 % (w/v) PEG stock was titrated into each well to give a series of PEG 
concentrations from 0-36 % (w/v). c) 20 µL of scFv stocks were dispensed into each well to 
give a final concentration of 15 µM. d) Samples were then mixed by slowly pipetting up and 
down the wells. The plates were examined for any air bubbles and nephelometry 
measurements were taken immediately using a NEPHELOstar Galaxy (BMG Labtech, 
Germany). 
 
3.4.11 In vivo western blot analysis 
A single colony from fresh E. coli BL21 (DE3) cells (transformed with the appropriate plasmid) 
was used to inoculate 100 mL sterile LB containing 10 µgmL tetracycline. Cultures were 
incubated overnight at 37 C with shaking (200 rpm). 1 mL of overnight culture was used to 
inoculate 100 mL sterile LB containing 10 µgmL tetracycline and grown at 37 C (shaking at 
200 rpm) until an OD600 of 0.6 was reached. 10 mL of culture was removed for the uninduced 
sample and centrifuged at 4,000 g for 10 min (4 C). Expression of the β-lactamase fusion 
construct was induced by the addition of filter-sterilized arabinose to a final concentration of 
0.02 % (wv). Cultures were incubated for 1 h (37 C, 200 rpm) and 10 mL was removed from 
each (induced sample). The 10 mL cultures were harvested by centrifugation at 4,000 g for 10 
min (4 C). The cell pellets (uninduced and induced with arabinose) were resuspended in 
phosphate buffered saline (PBS, Dulbecco’s PBS, Sigma) to obtain an OD600 of 5. For whole 
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cell samples, 200 L of the OD600  5 sample was combined with 200 L PBS. 100 µL of 6× 
loading dye (150 mM Tris-HCl, pH 6.8, 300 mM DTT, 6 % (vv) SDS, 0.3 % (wv) 
bromophenol blue) was then added. For soluble samples, 200 L of the OD600  5 sample was 
combined with 200 L bacterial protein extraction reagent (ThermoFisher Scientific) and 
incubated with agitation for 10 min. The sample was then centrifuged at 16,000 g for 30 min 
(4 C) and 100 L of 6× loading dye was added to the supernatant. The mixtures were then 
incubated at 90 C for 10 min.  
Protein samples were separated on a BIORAD Mini-PROTEAN TGX precast protein and were 
transferred to a BIORAD 0.2 µm polyvinylidene fluoride membrane using a Trans-Blot Turbo 
Semi-Dry (Bio-Rad Ltd). Blocking was performed overnight at 4 C using 5 % (wv) milk 
powder in TBST (tris-buffered saline Tween; 20 mM Tris-HCl, 150 mM NaCl, 0.2 % (vv) 
Tween-20). Membranes were incubated overnight with the anti--lactamase antibody (CSB-
PA352353YA0IENL, Cusabio) diluted 1:10,000 in 5 % (wv) milk powder in TBST. The 
membranes were washed for 3× 10 min in TBST. Membranes were then incubated with goat 
anti-rabbit IgG horseradish peroxidase conjugate (7074, New England Biolabs) diluted 
1:10000 in TBST. Membranes were then washed 3× 10 min in TBST before incubation with 
SuperSignalTM western pico chemiluminescent substrate (Thermo Fisher Scientific). The 
emitted signal was detected with Amersham hyperfilm (GE Healthcare).  
 
3.5 Molecular Biology 
3.5.1  E. coli (BL21 (DE3)) transformation 
50 µL of commercially competent BL21 (DE3) cells were transformed with 2 µL of plasmid 
DNA (100 ng/µL). Cells were incubated on ice for 10 minutes to allow the cells to thaw. 2 µL 
of DNA was added to the cells and the mixture incubated on ice for a further 2 minutes. The 
cells were then heat shocked at 42 ⁰C for 10 seconds before being incubated back on ice for 2 
minutes. After the 2 minute incubation on ice, the transformed cells were plated directly onto 
LB-agar plates containing 10 µg/mL tetracylcine. The cells were left to dry in a sterile 
environment for 20 minutes before being incubated overnight at 37 ⁰C. 
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3.5.2 In vivo Assay  
BL21 (DE3) cells (New England Biolabs, Hitchin, UK) were freshly transformed with the 
scFv-β-lactamase construct DNA and plated out onto 10 µg/mL tetracycline plates and 
incubated at 37 ⁰C overnight. 100 mL overnight cultures were prepared in a 250 mL flask with 
2.5 % (w/v) LB media continuing 10 µg/mL tetracycline which were inoculated with a single 
colony and grown for 18 hours at 37 ⁰C, 200 RPM. Two 48 well agar plates containing 10 
µg/mL tetracycline and increasing ampicillin antibiotic are made with the following protocol: 
100 mL 1.5 % (w/v) agar is autoclaved and allowed to cool to < 50 ⁰C before being poured into 
a sterile beaker. 333 µL tetracycline stock and 200 µL arabinose stock were added to give final 
concentrations of 10 µg/mL tetracycline and 0.02 % (w/v) arabinose. A multichannel pipette 
was used to draw up 900 µL and 300 µL agar was pipetted into the first column of each of the 
two plates; the last 300 µL was dispensed back into the beaker. The required volume of 
ampicillin was then added into the agar (see Table 2.10) and mixed thoroughly. 300 µL of agar 
was pipetted into the second column of each plate and the process is repeated until the plates 
were full. The plates were left to set in a sterile environment and then stored upside down 
with their lids on.  
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Table 3.11: Components for to creation of 48-well LB-agar plates used for the MIC assay. The 
volumes stated here allow for the creation of two 48-well LB-agar plates. 
Final (Amp) 
concentration 
(µg/mL) 
Agar vol. 10 mg/mL 
Amp. stock 
required (µL) 
0 100 0 
20 96.4 193 
40 92.8 186 
60 89.2 178 
80 85.6 171 
100 82 164 
120 78.4 157 
140 74.8 150 
 
1 mL of overnight culture was used to inoculate pre-warmed 100 mL sterile LB media 
containing 10 µg/mL tetracycline. The cultures were grown at 37 ⁰C, 200 RPM until an OD600 
= 0.6 is reached. 200 µL arabinose stock (0.02 % (w/v) final concentration) as added to the 100 
mL cultures to induce scFv-β-lactamase protein expression. 400 µL aliquots were moved into 
labelled 1.5 mL Eppendorf tubes and incubated for 1 hour at 37 ⁰C, 200 RPM to allow the 
constructs to be expressed before plating out. Log10 dilutions were carried out by taking 20 µL 
of cell culture and pipetting into subsequent 180 µL 170 mM NaCl, mixing thoroughly and 
Materials and Methods 
98 
repeating. 3 µL of each cell dilution was then plated onto each column of the 48-well 
ampicillin-containing agar plates. The plates were allowed to dry in a sterile environment 
before being incubated upside down at 37 ⁰C for 18 hours.  
 
3.5.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) was carried out to amplify selected DNA sequences in 
vitro. The primer sequences and the purpose of those sequences designed to amplify specific 
genes from the selected plasmids are listed in (Table 2.11). 
Table 3.12: Oligonucleotide primer used in this study. NdeI and XhoI restrictions sites are 
shown in gold and red respectively. The hexa-histag sequence is shown in orange with the 
additional amino acids between the scFv and hexa-histag shown in blue. Start and stop codons 
are underlined.  
Primer Sequence Use 
WFL Forward GGTGGTGACATATGCAGGTTCAGC
TGGTTCAGAGTG 
To clone the scFv gene out of the β-
lactamase construct 
WFL Reverse GCATACTCGAGTTAGTGGTGATGG
TGATGGTGCGCCGCCGCCCCCAGC
ACGGTGAGTTTGGTG 
To clone the scFv gene out of the β-
lactamase construct. Addition of a 
hexahistag at the C-terminus of the 
protein 
STT Forward GGTGGTGACATATGCAGGTTCAGC
TGGTTCAG 
To clone the scFv gene out of the β-
lactamase construct 
STT Reverse GCATACTCGAGTTAGTGGTGATGG
TGATGGTGCGCTGCCGCCAGAACG
GTCAGTTTAGTGC 
To clone the scFv gene out of the β-
lactamase construct. Addition of a 
hexahistag at the C-terminus of the 
protein 
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The typical PCR reaction contained the following components:  
Table 3.13: Table of components used for PCR reactions. 
Component Concentration / volume 
Primers 2 µL (100 ng/µL stock) 
dNTPs 0.25 mM 
DMSO 1 µL 
MgSO4 2, 4 or 6 mM 
Vent DNA polymerase 
(2000 U/mL) 
1 U (0.5 µL) 
Vent DNA polymerase 
buffer 
1× 
Nuclease free deionised 
ddH2O 
To make reactions up to 100 
µL 
DsDNA template 100ng 
A reaction lacking the dsDNA template was used as a negative control to determine if any 
non-specific interactions between primers occurred. 
The theoretical melting temperature (Tm) of the primers was calculate using the following 
equation (Equation 2.2): 
𝑇𝑚 = (𝑛𝐴𝑇  × 2) + (𝑛𝐺𝐶  × 4) 
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Equation 2.2 
Where nAT is the number of AT nucleotide base pairs in the primer sequence and nGC is the 
total number of GC nucleotide base pairs in the primer sequence. The temperature cycle for 
the PCR cycle is shown in (Table 2.12). 
Table 3.14: Temperature cycle for the PCR reactions used in this study.  
Step Temperature (⁰C) Time (s) 
Initial denaturation 95 300 
Denaturation 95 30 
Annealing 55 30 
Elongation 72 45 
Repeat denaturation, annealing and elongation x29 
Final elongation 72 300 
 
The PCR products were then visualised by agarose gel electrophoresis (see Section 2.5.1.2) 
and excised from the gel using a sterilised scalpel. DNA extraction from the gel was performed 
using the QIAquick Gel Extraction Kit (QIAGEN, UK) as described by the instructions 
supplied by the manufacturer.  
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3.5.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out in Tris-acetate-EDTA (TAE) buffer (see Table 3.8). 
Gels were made by dissolving 1.5 % (w/v) agarose (Melford Laboratories Ltd, Ipswich, UK) in 
1x TAE buffer and heating the solution in a microwave until the agarose had dissolved. Once 
cooled to < 50 ⁰C, 0.5 µg/mL ethidium bromide (EtBr) was added. The gels were then poured 
into a 12 x 15 cm cast with a comb in place and allowed to set for a minimum of 20 minutes 
at 25 ⁰C. DNA samples were diluted in 6x orange gel loading buffer (see Table 3.5). 30 µL of 
sample were loaded into the gel lanes, 5 µL of 1 kb and 100 bp DNA ladders (Promega, UK) 
were added to the first two lanes to allow for accurate sample size determination. 
Electrophoresis was carried out in 1x TAE buffer at 100 V until the DNA samples were 
suitably resolved. The results were visualised using ultra violet (UV) transillumination and 
photographed using a Syngene InGenius gel documentation system (Syngene, UK). 
 
3.5.2.3 Restriction digestion of plasmid DNA and plasmid 
dephosphorylation 
Site-specific restriction digestion of plasmid or PCR product DNA was carried out using 
enzymes and buffers acquired from New England Biolabs, USA (NEB). Restriction digestions 
contained the following components: 
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Table 3.15: Table of components used for restriction digests. 
Component Volume 
Plasmid DNA or purified 
PCR product DNA 
30 µL 
10× CutSmart Buffer 4 µL 
NdeI restriction enzyme 
(20 U/µL) 
1 µL 
 
XhoI restriction enzyme 
(20 U/µL) 
1 µL 
 
10× NEB bovine serum 
albumin 
4 µL 
 
 
A control reaction containing no restriction enzymes were carried out in tandem. Reactions 
were incubated for 1 hour at 37 ⁰C. The restriction enzymes were then inactivated by 
incubation at 65 ⁰C for 20 min.  
Restriction enzymes, buffer components and unwanted by-products from the digestion 
protocol were removed through separating the DNA fragments by agarose gel electrophoresis 
(see Section 2.5.2.2). The required DNA fragments were then excised using a sterilised scalpel 
and extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen, UK) as described 
by the instruction supplied by the manufacturer. 
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In order to prevent unwanted pre-ligation of the plasmid DNA, the 5’-ends were 
dephosphorylated with Antarctic Phosphatase (NEB, USA). 1:10 (v/v) of 10x Antarctic 
Phosphatase Reaction Buffer (NEB, USA) and 0.01 U of enzyme per pmol of DNA ends was 
added to the completed digestion reaction. The reaction mixture was incubated for 15 min at 
37 ⁰C. The enzyme was then inactivated through heating at 65 ⁰C for 5 min.  
 
3.5.2.4 Ligation of DNA 
DNA ligation was carried out using the NEB Quick Ligation Kit. A typical ligation reaction 
was set up with the following components: 
Table 3.16: Table of components used for the ligation of DNA inserts into plasmid vector. 
Component Volume / concentration 
Digested and 
dephosporylated DNA vector 
100 ng 
2x NEB Quick Ligation 
Buffer 
10 µL 
NEB T4 DNA Ligase (2000 
U/µL) 
2000 U (1 µL) 
Digested insert DNA up to 20 µL 
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Control reactions were carried out simultaneously using nuclease-free deionised water in 
place of insert DNA. Reactions were incubated for 15 minutes at 25 ⁰C and then incubated on 
ice prior to transformation into pLemo cells (see Section 2.5.2) 
 
3.5.3 Q5 mutagenesis of WFL and STT 
To obtain all possible mutants, the WFL and STT sequences were mutated using a Q5 
mutagenesis kit, following the manufacturer’s protocol.  
Table 3.17: Table of mutants generated with the template DNA and primer sequences listed. 
The mutated residue is highlighted in red. The annealing temperatures are listed. 
Required 
mutant 
Template Primer F Primer R Annealing 
temp (°C) 
W30S β-lactamase-WFL CGGTACGTTTTCCTTTGG
GGCCTTTAC 
CCACTCGCTTTGCAGCT
A 
62 
F31T β-lactamase-WFL TACGTTTTGGACCGGGG
CCTTTACTTGGG 
CCGCCACTCGCTTTGCA
G 
67 
L57T β-lactamase-WFL TATTTTCGGCACGACAA
ACCTGGC 
GGGATAATGCCACCCAT
C 
59 
W30S, 
F31T 
β-lactamase-STT GATTTTTGGGCTGACGA
ACCTGGCC 
GGGATGATACCGCCCAT
C 
63 
W30S, 
L57T 
β-lactamase-STT CACCTTCTCCTTTGGAG
CGTTTACGTGGGTG 
CCGCCGCTCGCTTTGCA
A 
68 
F31T, 
L57T 
β-lactamase-STT GGCACCTTCTGGACCGG
AGCGTTTA 
GCCGCTCGCTTTGCAAG
A 
69 
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The reactions for the Q5 mutagenesis were as follows: 
Table 3.18: Table of components and volumes used for the Q5 mutagenesis. 
Component Volume required (µL) Final concentration 
Q5 Hot start high-fidelity 
2× master mix 
12.5 µL 1x 
10 µM forward primer 1.25 µL 0.5 µM 
10 µM reverse primer 1.25 µL 0.5 µM 
Template DNA (1-25 ng/µL) 1 µL 1-25 ng 
Nuclease-free water 9 µL ----- 
 
The PCR cycling conditions were: 
Table 3.19: Temperature cycle for the PCR reactions for the Q5 mutagenesis. 
Step Temperature time 
Initial denaturation 98 °C  30 s 
 
25 cycles 
98 °C  10 s 
TA of primer 10-30 s 
72 °C  20-30 s/kb 
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Final extension 72 °C  2 min 
hold 4-10 ‘C ----- 
 
 
3.5.4 E. coli (pLemo cells) transformation  
50 µL of commercially competent pLemo cells (New England Biolabs, Hitchin, UK) were 
transformed with 2 µL of plasmid DNA (100 ng/µL). Cells were incubated on ice for 
10 minutes to allow the cells to thaw. 2 µL of DNA was added to the cells and the 
mixture incubated on ice for a further 2 minutes. The cells were then heat shocked at 
42 ⁰C for 10 seconds before being incubated back on ice for 2 minutes. After the 2 
minute incubation on ice, the transformed cells were plated directly onto LB-agar 
plates containing 100 µg/mL ampicillin and 30 µg/mL chloramphenicol. The cells were 
left to dry in a sterile environment for 20 minutes before being incubated overnight 
at 37 ⁰C. 
 
3.5.5 Small scale expression trial 
A small scale expression trial was carried out to identify the optimal amount of L-rhamnose 
concentration required to optimise expression of scFvs in the soluble fraction. Lemo21 (DE3) 
cells were transformed with either the 1912_scFv or STT_scFv plasmid (see Appendix 8.1) as 
described above (see Section 2.5.2). A single colony was taken from a plate of freshly 
transformed bacteria and used to inoculate a 2x1 mL LB overnight cultures containing 100 
µg/mL ampicillin and 25 µg/mL chloramphenicol. 200 µL of overnight culture was used to 
inoculate a 10 mL sterile LB media, in falcon tubes, containing the same antibiotics and 
varying concentrations of L-rhamnose: 0, 100, 250, 500, 750, 1000 and 2000 µM. The cultures 
were grown at 37 ⁰C with shaking at 200 RPM to an OD600 of 0.6. A 2x1 mL sample was taken 
Materials and Methods 
107 
before induction and stored at -20 ⁰C. Protein expression was induced with 40 µL of 100 mM 
filter-sterilised Isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown for a further 4 
hours (37 ⁰C, 200 RPM) before further 2x1 mL samples were taken of the induced samples. 
Whole cell expressions were measured by harvesting the 1 mL samples by centrifugation (10 
minutes, 13,000 RPM) and re-suspending in 2x SDS-PAGE loading buffer, before boiling and 
loaded for SDS-PAGE analysis (see Section 2.4.7).  
 
3.5.6 Separation of the soluble and insoluble fractions 
To gauge the expression levels of the scFvs in the soluble and insoluble fractions of E. coli, the 
cells were lysed and the two fractions separated. 1 mL cultures were sedimented by 
centrifugation (10 minutes, 13,000RPM) to form a pellet. The cell pellet was re-suspended in 
cell lysis buffer (see Table 3.8) and left shaking for 30 minutes at room temperature. The 
reaction was then centrifuged at 13,000 RPM on a benchtop centrifuge to separate the soluble 
and insoluble fractions. The soluble fraction was pelleted using acetone precipitation; ice cold 
acetone was added to the soluble fraction whereupon the mixture was vortexed and left on 
ice for 15 minutes. Following incubation on ice, the mixture was centrifuged at 13,000 RPM 
in a benchtop centrifuge to pellet the soluble protein. The acetone was carefully removed by 
pipette and the remaining pellet was dried in an incubator at 37 ⁰C. Equal amounts of 2x SDS-
PAGE loading buffer was added to both the insoluble and soluble pellets before the samples 
being analysed by SDS-PAGE (see Section 2.4.7). 
 
3.5.7 Large-scale expression of scFv proteins 
The expression of scFvs was scaled up in for in vitro characterisation of the different 
constructs. Lemo21 (DE3) cells were transformed with the relevant plasmid (see Appenix 8.1) 
as described above (see Section 2.5.2). A single colony was picked and used to inoculate at 100 
mL overnight starter culture in a 250 mL flask containing 100 µg/mL ampicillin and 25 µg/mL 
chloramphenicol, incubated at 37 ⁰C and shaking at 200 RPM. 10 mL of starter culture was 
used to inoculate each 1 L of 10× 1 L sterile LB media containing 100 µg/mL ampicillin and 25 
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µg/mL chloramphenicol and either 500 or 1000 µM L-rhamnose (depending on construct) in 
2 L conical flasks. 10× 1 L cultures were incubated at 37 ⁰C, shaking at 200 RPM to and OD600 
of 0.6. ScFv protein expression was induced by the addition of 400 µM IPTG. The cultures 
were grown for another 4 hours before being harvested by centrifugation at 4,000 RPM (JLA 
8.1 rotor) and the soluble and insoluble fractions separated as described by centrifugation at 
15,000 RPM (JLA 16.25 rotor). 
 
3.5.8 Purification of scFvs from the soluble fraction  
The soluble fractions were filtered through a sterile 0.45 µM filter (Millipore Ltd, Watford, 
UK) prior to purification. The soluble fractions were then loaded onto a 5 mL HisTrap™ HP 
column (GE Healthcare, Little Chalfont, UK) using a Pump P-1 peristaltic pump (GE 
Healthcare, Little Chalfont, UK). The column was prepared by passing 5 column volumes of 
filter sterilised water followed by 5 column volumes of filtered binding buffer (see Table 3.8). 
A final 5 column volumes of binding buffer was passed through the column to remove any 
unbound material prior to elution. The column was then attached to an ÄKTAprime plus (GE 
Healthcare, Little Chalfont, UK) with buffer/lines A and B loaded with binding buffer and 
elution buffer, respectively. 2.5 mL fractions were collected at a flow rate of 2 ml/min and a 
maximum pressure of 0.15 MPa. A step-wise elution gradient was used with a 10 % increase 
of buffer B every 20 mL to a final concentration of 100 % B. Protein-containing fractions, 
measured by A280 were pooled together and concentrated to 10 mL, using 20 mL vivaspin 
columns (Sartorius UK Ltd, Epsom, UK), before the final protein concentration was measured 
by A280 and the protein dialysed into storage buffer (see Table 3.8). Using SnakeSkin pleated 
dialysis tubing (Thermo Scientific, UK; 3,500 MWCO), the protein samples were dialysed 
against 5 L of storage buffer (20 mM sodium succinate, 125 mM arginine, pH6). The buffer 
was exchanged three times with a minimum of 3 hours between changes. The protein was 
then divided into 1 mL aliquots in 1.5 mL Eppendorf tubes and snap frozen in liquid nitrogen 
before being stored at -80 ⁰C.  
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4 Characterising monoclonal antibody behaviour in 
the gas-phase 
4.1 Objectives 
The initial ambition of this thesis was to characterise two closely related mAbs, one that is 
highly aggregation prone and its non-aggregation prone counterpart. Using nESI-IMS-MS, 
the aim was to monitor any oligomers formed and their assembly pathway, while 
characterising these species based upon their mass and collision cross-sectional area (CCS) 
values. Once established, modelling methods would be adopted to build models that could 
describe the oligomers that are visualised in the gas-phase. From these models, it was hoped 
to propose a potential mode of oligomer assembly.  
 
4.2 Characterising mAb oligomerisation 
As stated in Section 2.4.3, the aggregation of monoclonal antibodies and biopharmaceuticals 
is a major problem to the industry as a whole (Philo and Arakawa, 2009, Saluja and Kalonia, 
2008, Wang, 2005). Characterising self-association and aggregation is a significant challenge 
since the majority of techniques that can yield high resolution information on binding 
interfaces and sites of aggregation are costly in time; additionally, many of these techniques 
do not lend themselves to heterogeneous samples and therefore struggle to yield atomistic 
detail with some systems, depending on their mode of oligomerisation. Other, more common 
methods of characterising mAb aggregation, such as dynamic light scattering (DLS), size-
exclusion chromatography (SEC) and sedimentation velocity analytical ultra-centrifugation 
(AUC) (Amin et al., 2014, Arthur et al., 2009, Gabrielson et al., 2009) are all excellent methods 
of determining what species are present in the sample, however, yield no information about 
the mode of oligomerisation. It was proposed that that IMS-MS could be utilised to bridge the 
gap between generating higher resolution information while still analysing samples in a fast 
time scale. IMS-MS is also beneficial as a tool for characterising aggregation as most industries 
are equipped with mass spectrometers.  
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4.2.1 Characterising the aggregation propensity of WFL and STT in 
solution 
Before characterising both mAbs in terms of their CCSs in the gas-phase, it was imperative to 
understand the species which were present in solution at the working concentration. AUC 
was carried out on both samples at a concentration of 1 mg/mL (6.74 µM) to establish the 
oligomeric species present in solution (Figure 4.1). The AUC experiment was carried out using 
storage buffer (20 mM sodium succinate, 125 mM arginine, pH 6). 
 
Figure 4.1: Analytical ultracentrifugation of (a) STT and (b) WFL at 1 mg/mL in storage buffer. 
n = 1. 
 
The results of the AUC experiments showed that WFL (blue) adopts different conformations 
from STT (purple) at the working concentration of 1 mg/mL; while predominately dimer, a 
range of oligomers (up to and including a small amount of tetramer) is observed. By contrast, 
only a small proportion of STT forms higher order material. As mentioned before, although 
AUC can indicate which species are present in the sample, no information about the nature 
of the oligomers or how they assemble can be determined and thus an orthogonal technique 
is required.  
Before analysing the two mAbs using nESI-IMS-MS, the AUC experiment was repeated in 
MS compatible buffer (150 mM ammonium acetate, pH 6) (Figure 4.2) that was chosen to 
match the same ionic strength as the storage buffer previously used, while remaining at the 
same pH to directly compare the results.  
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Figure 4.2: Analytical ultracentrifugation of (a) STT and (b) WFL at 1 mg/mL in ammonium 
acetate, pH 6 buffer. n = 1. 
 
The AUC data indicates that the distribution of species present in a 1 mg/mL solution is the 
same in both of the two buffers tested. Since both mAb samples behave in a similar fashion in 
the two respective buffers, as judged by AUC, the samples were taken for further 
characterisation using mass spectrometry. Finally, to obtain insight into the possible 
conformations that WFL and STT might populate, electron microscopy (EM) was employed 
to visualise the oligomeric species present (Figure 4.3). 
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Figure 4.3: Negative stain transmission electron micrographs of samples of WFL and STT at 1 
mg/mL in storage buffer. (a) Class averages obtained of monomeric mAb structures from STT. 
(b) Electron micrographs highlighting the difference in oligomeric species present in WFL 
(blue, right) compared to STT (purple, left). Insets show the class averages obtained for the 
monomeric species in both samples, as well as a dimer species. Red boxes = oligomeric species. 
Black scale bar = 50 nm. n = 2. The data were acquired by Dr Matt Iadanza (University of 
Leeds). 
 
From the EM images, mAb images were obtained with sufficient resolution to observe the 
individual regions (Fab ad Fc) of the antibody (although not which was which) (Figure 4.3a). 
Multiple oligomeric species were observed for the WFL sample from dimeric species up to 
and including oligomeric tangles, with multiple monomers involved. Interestingly, sufficient 
dimeric species were present in the sample to generate a class average, shown in the inset of 
Figure 4.3b (right hand side). This class average suggests that the two WFL monomers may 
be interacting through the binding of two distinct nodes; while it was hypothesized that this 
may be a Fab-Fab interaction due to the location of the mutations from WFL > STT lie, the 
resolution is not adequate enough to conclude this confidently and other methodologies were 
required.  
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4.3 Monoclonal antibodies and their oligomers have a smaller CCS 
value than predicted 
4.3.1 Native MS of mAbs WFL and STT 
Once the buffer conditions had been optimised to reflect the aggregation of WFL and STT 
observed previously, the mAb samples were analysed by native MS. Independent samples of 
WFL and STT were diluted to 1 mg/mL and dialysed against 150 mM ammonium acetate over 
an 18 hours period prior to data acquisition. Spectra were recorded under native-like 
conditions (see Section 3.2.3) in attempt to maintain the oligomeric species present in the 
sample (Figure 4.4). 
 
Figure 4.4: Native mass spectra showing the native-like conformation of (a) STT (purple, top) 
and (b) WFL (blue, bottom). Samples were analysed at a concentration of 1 mg/mL in 150 mM 
ammonium acetate, pH 6. Inset shows increased resolution spectrum, focusing on the 24+ 
charge state ions. Representative spectra of n = 3. 
 
The initial conditions tested show that both WFL and STT exist in a native-like conformation 
with a narrow charge state distribution focused on the base peak of 23+/24+. However, 
analysis of both samples indicates that WFL and STT appear monomeric upon MS acquisition 
with a monomer mass of 148,430.13 ± 6.82 Da (expected = 148,421.96 Da) for WFL and 
148,119.45 ±8.98 Da (expected mass = 148,107.76 Da). As AUC and EM experiments observed 
oligomeric species of WFL, the majority of which is dimer, exist under these buffer conditions 
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in solution (Figure 4.2), it was hypothesized that the process of introducing samples into the 
gas-phase led to an abundance of monomeric species being observed. Alternatively, this may 
have also been predicted since the three mutations between the two proteins is the 
substitution of three hydrophobic residues (W30, F31 and L57T) and it has been reported that 
hydrophobic interactions become weaker in the gas-phase due to the removal of solvent (Loo, 
1997). Since the AUC shows such strikingly different results in solution, we can presume that 
these three residues play a key role in driving the self-association of WFL into dimer and 
oligomeric species. Furthermore, as analysis by MS requires the removal of water from the 
ions, the driving force behind any hydrophobic interactions are removed during the transition 
into the gas-phase. Unless there are other interactions maintaining the interface between the 
oligomeric species, the visualisation of WFL oligomers would be lost without careful 
optimisation of the MS instrument to preserve these interactions.  
To increase the transmission of oligomeric species into the mass spectrometer, the MS 
conditions were optimised accordingly. The backing pressure of the instrument was increased 
(from 3 to 5.5 Mbar) to aid in the transmission of high molecular weight ions while the trap 
voltages and DC bias were optimised in order to maintain the protein-protein interactions of 
WFL. Spectra were acquired for WFL and STT under the new conditions in order to monitor 
the amount of dimer and oligomeric species present in the samples (Figure 4.5).  
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Figure 4.5: Native mass spectra of (a) STT (purple, top) and (b) WFL (blue, bottom). 
Oligomeric species of WFL, up to and including tetramer, can be observed for WFL (shown 
in inset). Representative spectra of n = 4. 
Under these new MS conditions a greater proportion of oligomeric species are present in the 
spectra of WFL (Figure 4.5, bottom). While previously there was only a small amount of dimer 
present in the spectra, the dimeric species present in the spectra (ca. m/z 9000) is now > 10 % 
(of base peak index (BPI)), while higher order species up to and including tetramer are also 
readily observed.  By contrast, only a small percentage of dimer was present in the STT 
sample, which is consistent with the solution-based AUC results obtained (Figure 4.1+Figure 
4.2).  
As conditions were optimised to visualise the oligomeric populations of WFL in the gas-phase, 
the mass spectrometer was set to ion mobility mode in order to identify whether there are 
single or multiple species of oligomers present, and to calculate the CCS of any species 
identified.  
 
4.3.2 IMS-MS of mAbs WFL and STT 
To fully characterise to oligomeric populations identified in the mass spectra, the CCSs were 
determined to enable the development of models to interrogate how WFL self-associates. 
Using the previous MS parameters established, IMS-MS measurements of the two samples 
were acquired along with calibrant proteins in order to estimate CCS values for the two 
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proteins. As oligomeric species up to and including tetramer were identified (~600 kDa), 
calibrant proteins were chosen that encompass the appropriate MW distribution (150 – 600 
kDa); the calibrant proteins used for this study were concanavalin A (CCA), 103 kDa; alcohol 
dehydrogenase (ADH), 148 kDa; pyruvate kinase (PyK), 237 kDa; glutamate dehydrogenase 
(GluD), 336 kDa and GroEL, 801 kDa. 
 
Figure 4.6: Ion mobility driftscope plots indicating the presence of oligomeric species in 
samples under native conditions.   The driftscope plot of (a) WFL highlighting the presence 
of up to and including tetrameric species while only up to dimeric species can be observed for 
(b) STT. ( ) = IgG monomer. Spectra were acquired of WFL and STT in 150 mM ammonium 
acetate, pH6 with a trap voltage of 40 V, IMS gas flow of 1 mL/min and a ramped wave height 
from 5-30 V. Representative date of n = 3. 
 
It is evident from the IMS-MS driftscope data (Figure 4.6) that there is only one conformation 
detected for each oligomeric species observed. Under the conditions used to optimise 
visualisation of the oligomeric species of the mAb samples, tailing is observed behind the main 
peaks in the driftscope plots, indicative of some unfolding of the proteins. To investigate this, 
a trap ramp experiment was used to attempt to fully unfold the protein and monitor any 
unfolding events and at what voltages these occur (Figure 4.7). By extracting all of the arrival 
time distributions (ATDs), and plotting these sequentially versus collision energy, a 
significant shift in the ATD indicative of an unfolding event is observed (Figure 4.7) (Niu and 
Ruotolo, 2015, Tian et al., 2015). 
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Figure 4.7: Contour plots displaying the unfolding profiles of (a) WFL and (b) STT in the gas-
phase over a trap voltage range of 15-100 V. Unfolding events can be identified around 70-80 
V. Representative data of n = 3. 
 
Although tailing begins between 15-20 V, an unfolding event is not observed until around 
70-80 V which is double the voltage employed for the IMS-MS experiments. This gave 
confidence that although there might be some unfolding occurring under the conditions used, 
the arrival time used for the CCS estimation is, presumably, reflective of the native species. 
The CCS values of WFL and STT were calculated for the 21+ charge state and found to be 
being 6820 Å2 and 6843 Å2, respectively. The CCS values of the oligomeric species were also 
calculated and plotted alongside the calibrant proteins used for the study (Figure 4.8). 
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Figure 4.8: Plot of CCS against molecular mass of mAb samples tested and calibrant proteins 
used for CCS measurements. mAb CCS values up to and including tetramer for WFL are 
plotted in either blue (WFL) or purple (STT). Calibrant proteins are plotted in black with 
their respective structures shown. CCA = concanavalin A, ADH = alcohol dehydrogenase 
(PDB – 4W6Z (Raj et al., 2014)), PyK = pyruvate kinase (PDB – 2E28 (Suzuki et al., 2008)), 
GluD = glutamate dehydrogenase (PDB – 1HWZ (Smith et al., 2001)) and GroEl (PDB – 
5DA8). 
 
Interestingly, the CCSs measured for monomeric WFL and STT fall below that of ADH which 
has similar mass (148 kDa). At the beginning of this study, there were no published CCS data 
for IgGs; however, there has since been work from the Cianferani (Debaene et al., 2013, 
Debaene et al., 2014) and Barran (Pacholarz et al., 2014) groups reporting their CCS data for 
IgG proteins. Both report similar values (Figure 4.9c) which gives confidence in the values 
calculated in this study. However, due to the structure of an IgG1, one would expect the cross-
section measured to be significantly larger. Furthermore, it was hypothesized that the CCS 
would have been larger than that of ADH since it has a similar mass (148 kDa), yet a globular 
structure.  
The theoretically predicted CCS values are often reported alongside experimental results as 
an indicative measure of native structure in the gas-phase, with a higher degree of similarity 
between values suggesting a more native-like structure. Due to their multidomain structure, 
IgGs have been shown to populate an ensemble of structures (Clark et al., 2013) due to the 
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inherent flexible hinge region of the molecule which is paramount for their function. 
Therefore, theoretical values were generated for a selection of IgG1 molecules from the PDB 
in order to establish a range of theoretical values for conformers that an IgG might populate. 
Using the MOBCAL software (Shvartsburg and Jarrold, 1996, Mesleh et al., 1996), the CCSs 
of two known IgG1 structures (PDB = 1IGY (Harris et al., 1998) and 1HZH (Saphire et al., 
2001), Figure 4.9a) were calculated to compare with experimental values (Figure 4.9b). The 
CCSs of the two structures were calculated using the PSA scaling factor from the PA output 
of MOBCAL (see Section 3.2.5). 
 
Figure 4.9: Collisional cross-section measurements of mAb samples.   (a) PDB structures of 
two IgG molecules used to calculate theoretical CCS values using the MOBCAL software. (b) 
Plot of CCS of monomeric WFL as a function of increasing charge state. The predicted values 
of the two PDB structures are represented by dotted lines. (c) CCS values from the theoretical 
predictions from references 1 = (Harris et al., 1998) and 2 = (Saphire et al., 2001), as well as 
experimental data from this study and references 3 = (Debaene et al., 2014) and 4 = (Pacholarz 
et al., 2014). 
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It is interesting to note that there is a significant difference in the predicted CCS of the two 
PDB structures which is again a testament to the inherent flexible nature of the molecules 
and their collapse in the gas-phase. The idea was to use multiple PDB structures in order to 
obtain a range of predicted CCS values so that could be compared with the experimental 
results. However, it is clear that the experimental results are far from agreement with the 
range between these two structures. Figure 4.9b+c indicate that there is a 30 % discrepancy 
in the measured cross-sections (Leeds and Cianferani data) compared with the predicted CCS 
of the 1IGY structure. Although there is also a small discrepancy between the experimental 
data (Figure 4.9c), it is important to note that both the Leed’s and Cianferani group’s data 
were measured using Waters instruments (Syanpt G1 and Synapt G2, respectively) with a 
TWIMS device. The Barran group have an in-house modified Water’s instrument that has a 
traditional linear drift cell where the CCS of an ion can calculated directly from its drift time. 
However, the experimental values across the three groups are in agreement with each other 
overall, suggesting that the discrepancy in predicted and observed CCS does not depend on 
the antibody sequence or the mass spectrometer used. 
 
4.3.3 Modelling the mAb oligomeric species 
In an attempt to understand the data, simple models were built using the MOBCAL software 
to interrogate the experimental data (Figure 4.10). Each region of the IgG molecule (2xFab 
and Fc) was represented as a single spherical “atom” with the mass of the individual regions 
(Figure 4.10a) (see Section 3.3.1). These “atoms” were then arranged in 3D space, with the 
same centre on the z-plane and the x- and y-coordinates altered until a theoretical CCS value 
was obtained that was in closer agreement with measured experimental data. Once obtained, 
four different models were constructed that could potentially explain WFL’s mode of self-
assembly into larger oligomers (Figure 4.10). The four different models generated were two 
stacking models (one with the sequential antibodies in opposite orientations), an open “arms” 
model and a closed model (Figure 4.10). The rationale behind these models was that the all 
mutations between WFL and STT are all located in the VH domain and it was hypothesized 
that self-association was likely to be localised to this region of the mAb. 
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Figure 4.10: Modelling of the mAb oligomeric CCS data.   (a) Model of mAb monomer 
showing the Fab and Fc regions of the mAb being represented as single “atoms”. (b) Schematic 
representation of four models hypothesized for mAb aggregation: (i) stacked model, (ii) 
overlapping arms model, (iii) closed model and a (iv) opposite orientation stacked model. (c) 
Plot of CCS vs oligomer number for the different models generated. Stacked model = red, 
opposite orientation stacked model = orange and overlapping arms model = green. Measured 
CCS data are in blue.     
 
Out of the four models generated, the closed model was ruled out since it was presumed that 
higher order oligomerisation would be difficult to achieve if the mechanism proposed was 
correct; a closed state would have to open for any further self-association, which seems 
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unlikely. Upon comparing the data to the generated models, it is clear that none of these 
models explain the data observed adequately, with the stacking models being closest to the 
experimental data. 
Interestingly, it has been reported in the literature that the measured CCS of a mAb monomer 
was in excellent agreement with a spherical model (Debaene et al., 2014), based upon a sphere 
with the given mass of the protein in question. To understand whether a spherical model can 
explain the experimental data generated, spherical models were built based upon the mass of 
WFL and the oligomeric species observed (Figure 4.11). As well using the method used in the 
published report (denoted here as the Ruotolo method (Ruotolo et al., 2008)), a second 
method of generating spherical models was also used (denoted as the Benesch model (Benesch 
et al., 2007)). The Rutolo method generates a spherical model by manipulating the molecular 
mass of a protein of interest using empirically derived factors (see Section 3.3.2, Equation 3.2). 
By contrast, the Benesch model utilises the mathematical basis of calculating the volume of a 
sphere based upon the molecular mass of a protein of interest (see Section 3.3.2, Equation 3.3). 
 
Figure 4.11: Plot of CCS against oligomer number for generated spherical models. Ruotolo 
method (Ruotolo et al., 2008) = green, Benesch model (Benesch et al., 2007) = red and 
measured CCS data =blue.  
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As indicated in the literature (Debaene et al., 2014), the spherical model of the monomer 
using the Ruotolo method is in excellent agreement with the measured data. However, it is 
clear that this does not hold when extrapolated to the oligomeric species, as it deviates further 
from the data with extending oligomer number. Intriguingly, although the Benesch model 
shows less agreement for the monomeric CCS, it agrees well with all of the oligomeric species 
measured. The agreement between the experimental data and the spherical model again 
suggests that there is a significant collapse of the IgGs into more compact structures in the 
gas-phase, resulting in CCS values that fall dramatically below the values expected, based on 
their 3D structure.  
 
4.3.4 IgG collapse in the gas-phase 
To understand the compaction observed in the gas-phase through the experimental CCS data, 
molecular dynamics (MD) was employed in order to probe the behaviour of the molecules in 
the absence of water. By carrying out MD simulation experiments in the absence of buffer or 
water, in vacuo, the conditions that the ions experience in the mass spectrometer can be 
mimicked, with the aim of achieving a glimpse of how the molecules might behave in the 
gas-phase.  
As this methodology was being explored, work was published from the Barran group in 
Manchester using the same approach and showing that mAb structures do appear to collapse 
in the gas-phase (Figure 4.12), consistent with the hypothesis from the experimental data 
presented here. 
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Figure 4.12: Visualisation of IgG collapse in vacuo over a 10 ns simulation.   Figure was taken 
from (Pacholarz et al., 2014). Green and red = heavy chains, blue and yellow = light chains. 
 
The data from the published work reveal that the extent of the collapse can be attributed to 
the flexible hinge region of the mAb structures tested (PDBs = 1IGY, IgG1; IHZH, IgG and 
1IGT, IgG2 (Harris et al., 1997, Harris et al., 1998, Saphire et al., 2001)). It is perhaps 
unsurprising that the collapse observed is focused on the hinge region of the molecules, since 
they are known to be highly flexible regions of the proteins (Sandin et al., 2004, Janeway et 
al., 1997).  
To scrutinize the effect of the hinge region on the observed collapse of the molecules in the 
gas-phase MD simulations, it was hypothesized that if the mAbs were separated into their 
different possible regions (Fab, Fc and F(ab’)2), then the regions still containing the hinge 
would have a preponderant effect on compaction. Before examining the individual regions of 
the structures, it was important to assess whether the same degree of collapse was observed 
in simulations. An IgG1 crystal structure (1IGY) (Harris et al., 1998) was used to carry out a 
10 ns MD equilibration experiment after minimization (Figure 4.13) (see Section 3.3.4).  
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Figure 4.13: In vacuo collapse of mAbs in the gas phase.   (a) Plot of CCS against the measured 
charge states of WFL. The predicted CCSs of the IgG crystal structure (1IGY) and the 
equilibrated structure, after 10 ns, are represented as dotted lines. Measured data are plotted 
as blue squares. (b) Plots of the RMSD and Rg of the 1IGY structure as a function of simulation 
time (in ns). (c) Visual representation of the structure at different time points of the simulation 
showing the collapse around the hinge region.  
 
In the gas-phase MD simulations performed (see Section 3.3.4), the IgG structure collapses to 
a significantly smaller CCS in comparison to the value that is predicted from crystal structure 
(Figure 4.13a). Notably, the CCS at the end of the collapse (84.86 nm2) is in agreement with 
the CCS established from the MD experiments carried out from the Barran group (84.13 nm2) 
(Pacholarz et al., 2014). Furthermore, the RMSD plot (Figure 4.13b) indicates that the 
structure/system has reached equilibrium in the MD simulations (Daggett and Levitt, 1993, 
Walton and Vanvliet, 2006). Finally, the greatest extent of collapse observed from the in 
vacuo simulations involved the hinge region of the molecule, between the CH1 and CH2 
domains (Figure 4.13c), in agreement with the published work. 
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4.4 In vacuo MD simulations of IgG fragments 
To determine the exact role of the hinge region in the collapse of the molecule, the mAb was 
digested into its constituent regions, and the CCSs measured both experimentally and 
computationally. 
Using various proteases, mAbs can be partially digested to yield the individual regions 
that make up the molecule. For example IdeS, which cuts specifically below the 
disulphide bridges in the hinge region, can be used to generate and purify F(ab’)2 
regions of antibodies (Chevreux et al., 2011). By contrast, Lys-C which cuts at the C-
terminal of lysine residues above the hinge region, can be utilised to yield two Fab 
fragments, as well as generate an intact Fc region (Gadgil et al., 2006) (Figure 4.14).  
 
Figure 4.14: Sites of enzymatic digestion by IdeS and lys-C.  Lys-c (grey dotted line) digests 
above the hinge region while IdeS (grey dashed line) cuts below the hinge region. 
By utilising these enzymes, IgG samples can be digested and identical IMS-MS 
measurements carried out in order to gauge the effect the hinge region of the molecule 
has on the overall collapse of the IgG. Lys-C was used to digest WFL into its Fab and 
Fc region before dialysing into 150 mM ammonium acetate, pH 6 and IMS-MS 
measurements made (see Section 3.4.3) (Figure 4.15).  
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Figure 4.15: Enzymatic digestion of mAb WFL using endoproteinase Lys-C.   (a) SDS-PAGE 
showing the specific cleavage of the heavy chain. L= MW ladder, lane 1 = WFL alone, lane 2 
= WFL incubated with Lys-C, lane 3 = mix of digested and undigested mAb and lane 4 = buffer 
blank. (b) Mass spectrum showing the products generated from the lys-C digest. Pink = Fab 
and orange = Fc. Representative spectrum of n = 2.  
 
There is a clear distinction of the two regions of the mAb, indicated in the denaturing SDS-
PAGE (Figure 4.15) and also in the resulting mass spectrum (Fab mass = 47,338.26 ± 3.89 Da, 
Fc mass = 53,382.51 ± 7.57 Da). Interestingly, a Fab dimer is observed in the spectrum (Figure 
4.15b, 4,400-5,300 m/z) indicating that it is the Fab region, where the mutations between 
WFL and STT lie, of the molecule that is responsible in driving the self-association. However, 
some Fab dimer was also observed in a digested sample of STT. As mentioned above, Lys-C 
digests above the hinge region of the molecule and thus the Fc region of the molecule still has 
regions of the flexible linker left intact (~20 residues). Therefore, it was hypothesized that the 
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Fc region of the molecule would experience a greater degree of collapse in the gas-phase in 
comparison to the Fab regions, as the latter regions lack a hinge region (see Figure 4.14). After 
confirming the digestion via MS and SDS-PAGE, the digested sample was analysed via IMS-
MS and the cross-sections for the two regions estimated (Figure 4.16). 
 
Figure 4.16: In vacuo collapse of the Fab and Fc regions of an IgG. (a) (i) Plot of CCS against 
charge state for the Fab region of an IgG. The predicted CCSs of the Fab structure (1IGY) and 
the equilibrated structure, after 10 ns, are represented as dotted lines. Measured data are 
plotted as pink squares. (ii) Visualisation of the collapsed structure is shown (solid mesh) 
against the structure before the equilibration (transparent surface). (b) (i) Plot of CCS against 
charge state for the Fc region of an IgG. The predicted CCSs of the Fab structure (1IGY) and 
the equilibrated structure, after 10 ns, are represented as dotted lines. Measured data are 
plotted as orange squares. (ii) Visualisation of the collapsed structure is shown (solid mesh) 
against the structure before the equilibration (transparent surface). 
 
Similar to the full IgGs, we observe a collapse of both the Fab and Fc regions of the mAbs 
(Figure 4.16). The extent of collapse between the two molecules differs significantly however; 
a larger collapse is observed for the Fc region (crystal structure predicted CCS = 45.08 nm2, 
MD end point predicted CCS = 36.96 nm2) when compared to the collapse of the Fab region 
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(crystal structure predicted CCS = 37.15 nm2, MD end point predicted CCS = 33.03 nm2). Upon 
comparing the experimental data with the predicted values, from both the crystal structure 
and MD end points, it is observed that the Fab CCS data is in closer agreement with the crystal 
structure prediction, while the Fc values are in closer agreement with the MD. This is 
consistent with the previous hypothesis that a greater extent of collapse would occur when 
the hinge remains partially present with the digested region of the molecule.  
To explore this hypothesis further, the F(ab’)2 region, as previously mentioned. By digestion 
below the hinge of the IgG, the two Fab arms remain connected by the inter-heavy chain 
disulphide bridges (see Figure 2.13). This leaves the majority of the hinge region intact 
between the two heavy chains, and so it is likely that a significant collapse would be observed. 
While the experimental CCS for this region of WFL was not calculated, the in vacuo MD 
simulations were carried out on the 1IGY structure to visualise the theoretical extent of 
collapse (Figure 4.17). 
 
Figure 4.17: In vacuo collapse of the F(ab’)2 structure.   (a) Plot of RMSD against simulation 
time. The predicted CCSs of the F(ab’)2 structure (1IGY) and the equilibrated structure, after 
10 ns, are represented as dotted lines. (b) Visualisation of the collapsed structure is shown 
(solid mesh) with the structure before the equilibration shown below (transparent surface). 
 
As predicted, Figure 4.17 shows a wide discrepancy between the crystal structure and MD 
end point predicted CCS values with a difference of 11.25 nm2 (Figure 4.17a, dashed lines). 
Upon visualising the MD results, it is transparent that although the Fab regions themselves 
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collapse (see Figure 4.16), this large collapse can be mainly attributed to the “loss” of the hinge 
region in the molecule by the two Fabs closing together towards the centre of the molecule 
(Figure 4.17).  
The results here, along with the full IgG data, indicate that both the Fab and Fc regions 
collapse to some extent in the gas-phase, but the Fc region collapses to a larger extent. To 
understand whether this was unique to mAbs, other constructs (while maintaining the Ig 
subunit) were examined both experimentally and through in vacuo simulations.  
 
4.5 Characterising gas-phase collapse as a function of linker length and 
composition 
In an attempt to understand the collapse of mAbs in the gas-phase, it was decided to 
characterise other molecules with flexible linkers using the same experimental procedure. For 
these experiments, an I27 concatamer consisting of five I27 subunits connected via small (4-
6 residue) amino acid linker regions was used (denoted hereon as (I27)5). The I27 protein is 
found in titin (Improta et al., 1996), an abundant protein found in striated muscle which aids 
the function of muscle contraction in sarcomeres (Herzog, 2014). (I27)5 is a mechanically 
robust protein and has therefore been used for AFM and mechanical stability studies 
(Oberhauser et al., 1999, Brockwell et al., 2002). Here we use the concatamer to understand 
gas phase collapse as the subunits are connected through small flexible linkers (4-6 amino 
acids) (Figure 4.18). 
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Figure 4.18: Generation of the (I27)5 structure.   (a) The (I27)5 structure was generated by 
adding the required amino acid linkers onto the C-terminus of the monomeric subunit (PDB 
= 1TIT) before stitching the molecules together. Stitching together of the subunits was 
performed in COOT by Dr Claire Windle (University of Leeds). (b) Table of linker 
composition added to the C-terminus of the monomer subunits.  
 
As the individual subunits of (I27)5 are separated by amino acid linkers, it was hypothesized 
that this polymer of Ig domains may behave similarly to the mAb and its fragments; where 
the CCS value of the protein was expected to be lower than that predicted from the modelled 
structure. A sample of (I27)5 (kindly provided by Dr David Brockwell, University of Leeds) 
was dialysed into 150 mM ammonium acetate and its properties in the gas-phase measured 
through nESI-MS and IMS-MS (Figure 4.19). 
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Figure 4.19: Native nESI-MS and IMS-MS spectra of (I27)5 (a) nESI-MS spectrum of (I27)5 
showing monomeric (green) and dimeric (dark green). (b) Driftscope plot of the (I27)5 protein 
indicating the drift time of the different species. Representative spectra of n = 3. 
 
Figure 4.19 shows that a significant amount of (I27)5 forms dimeric species which are also 
observed in the IMS-MS measurements. The measured mass of (I27)5 was 52,076.74 ± 0.41 Da, 
in agreement with previously measured data (52,082 Da). Using the lowest molecular weight 
species present, the CCS was calculated for the (I27)5 monomeric species (Figure 4.20). These 
data were used to test the hypothesis of gas-phase collapse being attributed to the subunits of 
proteins being joined through flexible linkers. Since no crystal or NMR structure exists of the 
(I27)5 concatamer for the CCS prediction, a structure was generated through building the 
linker regions (see Figure 4.20b) and stitching the subunits together to create the full (I27)5 
(see Section 3.3.3). 
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Figure 4.20: In vacuo collapse of the (I27)5 structure.   (a) Plot of CCS against charge state for 
the (I27)5 concatamer. The predicted CCSs of the structure and the equilibrated structure, 
after 10 ns, are represented as dotted lines. Measured data are plotted as green squares. (ii) 
Visualisation of the collapsed structure is shown (solid mesh) against the structure before the 
equilibration (transparent surface). 
 
As observed for the mAb samples and its constituent parts, the CCS of (I27)5 is significantly 
below the value expected based upon the generated structure (Figure 4.20b); suggesting that 
(I27)5 also collapses in the gas-phase. The MD simulations indicate that although the structure 
coils around itself, aiding in the collapse, the individual subunits compact towards the centre 
of the molecule through collapse around the linker regions. This agrees with the hypothesis 
that the collapse observed for biomolecules in the gas-phase is mainly attributed due to the 
flexible hinge regions present in the molecules. (I27)5 has been also been reported as a flexible 
molecule, shown to adopt various conformations via electron microscopy (Li et al., 2001). 
To understand the role that these flexible linker regions play in the observed gas-phase 
collapse, dumbbell-like models were created  of two I27 monomers (PDB = 1TIT (Improta et 
al., 1996)) connected by linkers of varying length and composition; The proteins were 
connected through either glycine-serine (GS) or poly-proline (PP) linkers of varying length. 
The aim was to characterise the effect of linker composition, first through computation, and 
if a significant difference in CCS was observed to express and purify the proteins and measure 
their CCSs experimentally for comparison. Since poly-proline motifs are known to exhibit 
more rigid qualities (Kay et al., 2000, Moradi et al., 2009), it was predicted that the structures 
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linked together through a poly-proline linker would experience less of a collapse. The 
structures were initially linked together with a two amino acid linker: a glycine-serine or 
proline-proline linker to test this hypothesis before moving onto longer linker lengths (Figure 
4.21). 
 
Figure 4.21: In vacuo collapse of two I27 domains connected through two amino acid linkers.   
(a) Plot of RMSD and CCS of the two structures as a function of simulation time. The RMSD 
values are plotted as lines whereas the CCS values are plotted as dotted lines. (b)  Visualisation 
of the two structures after the 10 ns simulation. GS Linker = orange and PP linker = green.  
 
The predicted CCS of the starting structures were 23.80 and 23.77 nm2 for the GS and PP 
linker, respectively. As both predicted CCSs were of similar values, it extrapolates that any 
differences observed in CCS after the MD simulation are due to the linker composition. Figure 
4.21a shows that a small difference in CCS is measured between the two constructs, 19.93 and 
20.64 nm2, suggesting a greater collapse may be possible a GS linker present, compared with 
a PP linker. The extra flexibility of the GS linker allows the two sub-units to form an arc-like 
structure, whereas the PP linker restricts the structure to a more linear orientation (Figure 
4.21b). 
As some difference could be observed when using a two amino acid linker between the I27 
domains, further structures were generated consisting of either a ten or fourteen amino acid 
linker (Figure 4.22) to understand if further differences could be observed. 
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Figure 4.22: Structures of the I27 dimer that were generated to test the extent of gas-phase 
collapse as a function of linker length and composition. (a) Generated structures of the I27 
dimer with GS linkers of different lengths. (i) = 2 amino acid, (ii) = 10 amino acid and (iii) = 
14 amino acid linker. (b) Generated structures of the I27 dimer with PP linkers of different 
lengths. (i) = 2 amino acid, (ii) = 10 amino acid and (iii) = 14 amino acid linker. 
 
In vacuo MD simulations were carried out on the ten and fourteen length structures and the 
CCS differences interrogated to examine if gas-phase collapse is enhanced in constructs 
containing longer linker lengths (Figure 4.23). 
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Figure 4.23: Plots showing the results from the in vacuo simulations of I27 dimer structures 
with 10 and 14 amino acid linkers. (a) (i) CCS plot highlighting the collapse of the two 
molecules with different linker composition. (ii) Plot showing the change in RMSD over the 
10 ns simulation time. GS linker = orange and PP linker = green. (b) (i) CCS plot highlighting 
the collapse of the two molecules with different linker composition. (ii) Plot showing the 
change in RMSD over the 10 ns simulation time. GS linker = orange and PP linker = green. 
 
As found with the two amino acid linker constructs, the initial predicted CCS values of the 
two structures are similar with differences of 0.38 nm2 for the 10 amino acid linker (Figure 
4.23a) and 0.52 nm2 for the 14 amino acid linker (Figure 4.23b). Furthermore, for the 
structures with the 10 amino acid linkers there is an observed difference between the two end 
points, as observed for the initial experiments (Figure 4.22). However, when the linker length 
is increased to fourteen amino acids, similar to the length of the hinge region in IgG1s, both 
structures collapse to almost the same value by the end of the 10 ns simulation (20.64 nm2 for 
GS and 20.62 nm2 for PP). While initial results indicate that different composition of linkers 
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may be able to be distinguished using IMS-MS, this needs further work and constructs made 
for experimental values to be acquired for direct comparison with the predicted results.  
Although there are differences in the estimated CCS values for the constructs with the shorter 
linker lengths, whether these differences would be large enough to detect via direct IMS-MS 
measurements was uncertain. Therefore, instead of cloning and purifying these constructs it 
was decided to look for other protein structures that have flexible linker regions (such as 
mAbs and (I27)5) to characterise, experimentally, how they behave in the gas-phase of a mass 
spectrometer.  
 
4.6 Exploring the conformations of elongated structures in the gas-
phase 
As mentioned previously, native IMS-MS experiments have been well-used to characterise a 
plethora of globular proteins and protein complexes (Scarff et al., 2008, Leary et al., 2009, van 
Duijn et al., 2009, Hilton et al., 2010, Zhou et al., 2014). However, the technique has not been 
as implemented as often to characterise longer, elongated proteins. Two other proteins, with 
elongated structures, were chosen to study via IMS-MS: the surface protein G (SasG) and the 
POTRA domains of Bam A (Figure 4.24).  
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Figure 4.24: Structures of the BamA barrel with POTRA domains and SasG. (a) BamA from E. 
coli (PDB = 5D0O (Gu et al., 2016)) showing the five POTRA domains (cyan) from BamA 
(blue) and (b) SasG used to investigate the gas-phase collapse properties of elongated 
molecules. Inset shows the two repeat domains of SasG.  
The POTRA domains were chosen for analysis since, similar to the (I27)5, the protein consists 
of five POTRA subunits (POTRAS 1-5) that are connected through small linker regions (4-5 
residues) between the domains (Knowles et al., 2008, Gatzeva-Topalova et al., 2010). While 
their function is not fully known, it is believed that the POTRA domains serve as loading 
machinery of client proteins into the BamA barrel and Bam complex for folding into the outer 
membrane (Fleming et al., 2016). SasG is responsible for the adherence and the biofilm 
formation of its host Staphylococcus aureus (S. aureus) (Corrigan et al., 2007). This protein 
was of particular interest as it consists of repeats of two domains (G5 and E), in which the C-
terminus of the previous subunit is directly connected to the N-terminus of the subsequent 
G5/E subunit. Furthermore, SasG is responsible for biofilm formation the protein has been 
shown to form long, elongated fibrillar structures that maintain a highly extended 
conformation in solution (Gruszka et al., 2015). How the molecule behaves in the gas-phase 
was of interest since it elongated, yet does not have a ‘beads on a string’ architecture. The 
POTRA domains are constituents of the Bam complex that lie N-terminal to the BamA barrel 
(Gu et al., 2016).  
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The POTRA domains and SasG (kindly supplied by Robert Schiffrin, University of Leeds and 
Prof. Jennifer Potts, University of York, respectively) were dialysed against 150 mM 
ammonium acetate and characterised using nESI-MS (Figure 4.25). 
 
Figure 4.25: Native mass spectra of the POTRA domains (top) and SasG (bottom).   A small 
proportion of dimeric species can be observed for SasG as well as a highly charged species at 
low m/z. Representative spectra of n =2.  
 
The results showed that the POTRA domains and SasG predominantly exist as monomers, 
with measured masses of 45,480.61 ± 3.49 Da and 95,513.49 ± 8.08 Da, respectively. 
Interestingly, SasG exists in two monomeric conformations: a native-like charge state 
conformation (centred on 20+/21+) and a highly charged conformation (centred on 48+). As 
mentioned in the introduction to this study, this highly charged conformation is usually 
indicative of an unfolded state (see Section 2.3.1).  
IMS-MS measurements were then taken for the two samples and their CCSs determined. As 
carried out before, these CCS values were compared directly to the predicted values from both 
the initial structures and the gas-phase equilibrated structures (Figure 4.26). It is important to 
note that the structure used for the SasG predictions and simulations was generated from 
SAXS data (Gruszka et al., 2015), which was kindly supplied by Prof. Jennifer Potts group 
(University of York, UK).  
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Figure 4.26: In vacuo collapse of the POTRA domains and SasG.   (a) Plot of CCS against 
charge state for the POTRA domains. The predicted CCSs of the POTRA domains (5D0O) and 
the equilibrated structure, after 10 ns, are represented as dotted lines. Measured data are 
plotted as blue squares. (b) Plot of CCS against charge state for SasG. The predicted CCSs of 
the SasG structure and the equilibrated structure, after 10 ns, are represented as dotted lines. 
Measured data are plotted as red (native species) and dark red (highly charged species) squares.  
 
Consistent with the previous structures examined, both the POTRA domains and SasG 
collapse in the gas-phase, with the experimental data in closer agreement with the in vacuo 
equilibrated structures. Interestingly, the native-like conformation measured by IMS-MS of 
SasG is significantly smaller than the predicted CCS of both the initial structure and the 
simulated structure (Figure 4.26b). Upon analysis of the SasG simulation, it appeared that the 
structure still had further potential for collapse since the RMSD of the simulation was not 
equilibrated after 10 ns (Figure 4.27). 
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Figure 4.27: In vacuo collapse of SasG after 10 ns.(a) Visual representation of the SasG 
structure after a 10 ns equilibration experiment. (b) Plot of RMSD against simulation time 
indicating that the simulation has not reached equilibrium.  
 
Unlike all of the other systems tested, the RMSD of SasG (Figure 4.27) indicates that the 
simulation had not yet reached equilibration after 10 ns as the values had not plateaued. 
Visualisation of the structure also made it clear to see that there was further potential space 
for the structure to collapse as only the N-terminus had altered significantly. Since the protein 
is made up of repeating subunits, there was no clear reason that only one region of the 
molecule should undergo collapse. To obtain further information of how the molecule might 
adapt in the gas-phase, the simulation of SasG was extended until the structure had reached 
equilibration (around 35 ns) so that the experimental results can be compared to the final 
equilibrated conformation (Figure 4.28).  
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Figure 4.28: In vacuo collapse of SasG after 40 ns.   (a) Plot of RMSD against simulation time 
showing that the simulation reaches equilibrium around 35 ns. A visual representation of the 
structure, at 40 ns, is also presented. (b) Plot of CCS against charge state for SasG. The 
predicted CCSs of the SasG and the equilibrated structure, after 10 and 40 ns, are represented 
as dotted lines. Measured data are plotted as red (native species) and dark red (highly charged 
species) squares. 
 
After a 40 ns simulation, the molecule has appeared to reach equilibration and a larger 
compaction can be observed across the molecule (Figure 4.28). Unlike Figure 4.27, the C-
terminal region of the molecule has also altered significantly whereas after 10 ns only changes 
significant changes around the N-terminus were observed. Intriguingly, comparison of the 
CCS from the 40 ns simulation with the experimental values (Figure 4.28) revealed that the 
experimental CCS is still lower than that predicted from the simulations. This was observed 
across multiple of the systems tested, most noticeably the IgG and SasG data, and it is still 
currently unknown what factors might attribute to this final collapse observed in the IMS-
MS measurements. 
  
4.6.1 The potential of gas-phase collapse across other biomolecules 
Gas-phase collapse has been observed across a range of proteins in this thesis. However, gas-
phase collapse is not limited to proteins. Data acquired by a previous student in the Ashcroft 
lab (Dr Henry Fisher), using model RNA molecules as the test system (Fisher, 2014), presented 
similar data. 
Characterising Monoclonal Antibody Behaviour in the Gas-Phase 
144 
Two candidate RNA structures were selected in this previous work, 2PCV (Jin et al., 2007) 
and 2DRB (Tomita et al., 2006). While both RNA molecules contain 35 nucleotides in length 
and have similar mass, 11, 217 Da for 2PCV and 11, 219 Da for 2DRB, the two molecules had 
distinct MOBCAL predicted CCS from their known crystal, using the PA method, of 1445 Å 
and 1146 Å f structures, respectively. These RNAs have also been analysed (by Dr. Henry 
Fisher) using IMS-MS in order to measure their CCSs experimentally (Figure 4.29). 
 
Figure 4.29: Observed collapse for the two RNA PDB structures. (a) Visual representation of 
the two RNA molecules showing that RNA 2PCV (orange) has a more extended conformation 
compared to RNA 2DRB (blue). (b) Plot of CCS against charge state showing that all measured 
CCSs fall below either of the expected CCS MOBCAL predictions. Measured CCS data were 
acquired by Dr Henry Fisher.  
 
In contrast with the differences in their predicted CCS values, the measured CCSs of the two 
RNA molecules are indistinguishable from one another. Of particular interest, both RNA 
molecules collapse in the gas-phase IMS-MS experiments to values smaller than those 
predicted by their crystal structures. 
This suggests that the phenomenon of gas-phase collapse is not unique to proteins alone and 
that it is plausible for other biomolecules with an expected elongated structure to be 
susceptible to this compaction within a mass spectrometer.  
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4.7 Discussion 
Native IMS-MS as a technique has been widely used in the area of structural biology. IMS-
MS has been used to characterise intermediates in virus particle assembly (Shepherd et al., 
2013, Knapman et al., 2010, Uetrecht et al., 2011a), amyloid oligomeric intermediates 
(Bleiholder et al., 2011a, Bleiholder et al., 2013, Woods et al., 2013, Young et al., 2014b) and 
has been pivotal in the structural analysis of membrane proteins, which can be difficult to 
analyse using other structural techniques (Wang et al., 2010, Lanucara et al., 2014, Calabrese 
et al., 2015b, Watkinson et al., 2015). Interestingly, it is worth noting that native 
characterisation of WFL showed a decrease in the amount of dimer present in comparison to 
the results obtained from the AUC experiments (Figure 4.2+4.5); whilst a small amount of 
dimer was generated for STT under these conditions (Figure 4.5a). For STT, this suggests that 
there is a degree of non-specific interactions being formed, which may be attributed to 
concentration of the analyte or an artefact of the ionisation process (Robinson et al., 1996, 
Veenstra, 1999, Davidson et al., 2016). As mentioned previously, the observed decrease in the 
amount of dimer of WFL, in the native mass spectra, is consistent with the weakening of 
hydrophobic interactions upon transition into the gas phase (Loo, 1997, Breuker and 
McLafferty, 2008), which may explain the discrepancies observed between the AUC and 
native MS data. Therefore, the AUC data is a more likely representation of the degree of self-
association in solution.  
While IMS-MS can be useful to compare experimental results to theoretical values, the 
majority of work in the literature has focused on characterising globular proteins; whereas 
the structural study of elongated and linear proteins through IMS-MS is less well developed. 
In this Chapter, the results presented demonstrate that native IMS-MS measurements may be 
less applicable to such elongated structures. By firstly characterising mAb samples and moving 
on to other elongated systems, there appears to be a general trend where the molecules 
undergo collapse/compaction upon the transition to the gas-phase.  
The notion of proteins undergoing collapse upon transition to the gas-phase is not a new 
concept. While not many, there have been reports of the gas-phase collapse of various protein 
structures including membrane proteins (Mehmood et al., 2014), molecular chaperones 
(Hogan et al., 2011), RNA binding proteins (Ruotolo et al., 2005), and of course, antibodies 
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(Pacholarz et al., 2014). The factors that underpin the causation of gas-phase compaction and 
collapse, however, are still unknown. Work in this Chapter attempts to address these factors 
through the characterisation of different proteins with elongated structures.  
Pacholarz et al. showed that full mAbs undergo significant compaction in the gas-phase and 
suggested that the flexible nature of the hinge region may be responsible. By characterising 
the digested regions of an IgG (Fab, Fc and F(ab’)2), significant collapse was observed 
predominantly in regions that contain or partially retain the hinge region. While it is clear 
that regions that have this flexible hinge region undergo the largest extent of collapse, it is 
unclear what drives this linker to compact. While this result occurs in the gas-phase, it is 
important to note that mAbs have been shown to adopt an ensemble of structures, both 
extended and collapsed, in solution. SAXS data have highlighted the flexibility in the hinge 
region of an IgG2 molecule, presenting an ensemble of structures that populate an Rg as small 
as 15.94 Å (Clark et al., 2013). While the data presented on IgGs in this Chapter indicate a 
compaction around the hinge region with the Fab arms and the Fc still existing on the same 
plane, SAXS data suggest that it is possible for an IgG2 to fold over its hinge region. This could 
explain the discrepancy that is observed in the IgG collapse data, both presented here (see 
Figure 4.13) and in the literature; although both agree that a collapsed is observed as 
evidenced by the in vacuo simulations, the experimental CCS values still fall below the 
predicted values. If the molecules were to fold around their hinge region, as well as 
compacting, one would expect a significantly smaller CCS that may be in closer agreement 
with the experimental values, which could also be the case for the F(ab’)2 modelling (see 
Figure 4.17). Therefore, although it is still unknown what causes the significant collapse of 
mAbs in the gas phase, it can be concluded that the flexible hinge region is playing a critical 
role.  
As the hinge region proves critical, it was decided that further clarity surrounding this 
collapse could be achieved by investigating molecules with similar flexible linker regions 
between domains. (I27)5 was chosen as the molecule retains the Ig fold while orientating the 
subunits in a different global architecture. As observed with the IgG data, (I27)5 undergoes 
compaction in the gas-phase which also involves the hinge regions of the protein (see Figure 
4.20). While the study into linker length and composition remained inconclusive, the focus 
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of altering linker composition for either increased distance or flexibility/rigidity is an 
approach that is of interest (Klein et al., 2014). Therefore, a focus on linker length and 
composition in the gas-phase is an area that needs to be explored further.  
The correlation between proteins containing flexible linker regions and gas-phase collapse 
was striking and thus was further probed. IMS-MS has been used, in the vast majority of 
studies, to characterise globular proteins; while elongated and extended proteins been left on 
the side-lines. To understand how elongated structures behave in the gas phase, two other 
proteins were adopted for study using IMS-MS: SasG and the POTRA domains of BamA. Alike 
the other systems analysed in this study, both SasG and the POTRA domains collapse to 
significantly compact structures in the gas-phase (Figure 4.26-4.29). It was hypothesized that 
the POTRA domains would undergo gas-phase collapse due to the small linkers connecting 
the individual domains. However, SasG was an interesting discovery as the protein lacks any 
obvious linker regions; with the C-terminus of one subunit immediately connected to the N-
terminus of the sequential subunit (Figure 4.24). Although being stable and extended in 
solution (Gruszka, 2012, Gruszka et al., 2015), the IMS-MS data show that the protein adopts 
a surprisingly compact structure in the gas-phase (~60 % smaller CCS than predicted). While 
an extended conformation is observed in solution, this result suggests that elongated 
structures struggle to retain their solution conformations in the transition to the gas-phase.  
Finally, the study was extended to the analysis of other biomolecules.  The latter results in 
this Chapter highlight that RNA undergoes similar gas-phase compaction (see Figure 4.29), as 
observed for various proteins. This was presented through the IMS-MS analysis of the two 
RNA molecules with PDB structures, 2PCV and 2DRB. The result showing that these two 
molecules both collapse to a state with a smaller CCS than predicted reveals that it is not only 
proteins that undergo collapse upon transition to the gas-phase; that this phenomenon is 
observed across various biomolecules.  
In summary, the data presented here in Chapter 4 demonstrate the potential for biomolecules 
to collapse upon the transition from solution to the gas-phase. While the correlation between 
expected CCS of a protein and the measured value are in excellent agreement for many 
globular proteins, as evidenced throughout the literature (Clemmer et al., 1995, Jarrold, 1999, 
Benesch and Ruotolo, 2011, Illes-toth et al., 2015, Loo et al., 2005, Scarff et al., 2008, 
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Wyttenbach and Bowers, 2011) as well as small molecules (Campuzano et al., 2011),this does 
not necessarily hold true for elongated structures. Chapter 4 demonstrates a potential and 
critical caveat of IMS-MS, which highlights for caution to be taken when measuring the CCS 
values for proteins or biomolecules with no known 3D structure.
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5 Defining the site of self-association using chemical 
cross-linking 
5.1 Objectives 
Chapter 4 provided evidence of the oligomeric species of WFL present in solution. Chapter 5 
now sets out to characterise these oligomers and identify the region responsible for the self-
association. Chemical cross-linking was employed to capture the oligomeric species and their 
conformations which were then interrogated using liquid chromatography coupled with 
tandem mass spectrometry.  
 
5.2 Introduction 
5.2.1 Chemical cross-linking 
As described in Section 2.2, the structural characterisation of proteins and protein complexes 
has been dominated by techniques such as X-ray crystallography and NMR with cryo-EM 
now being raised to the same pedestal due to recent technical advancements (Bai et al., 2015, 
Nogales, 2016). However there are many systems which are not amenable to these techniques 
due to either protein size or a high degree of flexibility/dynamics in a system (Leitner, 2016). 
Mass spectrometry has been instrumental in bridging this structural gap (Rappsilber, 2011). 
There has been a surge of publications in recent years utilising mass spectrometry, coupled 
with structural proteomic techniques such as hydrogen-deuterium exchange (HDX), photo-
oxidative labelling of proteins (FPOP) (Baud et al., 2016, Heinkel and Gsponer, 2016) and 
chemical cross-linking (XL) to achieve high resolution structural information of protein 
complexes (Navare et al., 2015, Walzthoeni et al., 2015, Liu et al., 2015, Nguyen‐Huynh et al., 
2015, Belsom et al., 2016, Politis et al., 2015, Packiam et al., 2015, Chen et al., 2016c, Chen et 
al., 2016b). One excellent example of this was the solution of a 3 MDa complex, the RNA 
polymerase II transcription pre-initiation complex (Murakami et al., 2013), using XL-MS in 
combination with cryo-EM.  
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XL-MS is an ideal technique for characterising aggregation-prone systems as it is able to 
“capture” any oligomeric species present in solution, insensitive of conformation, which can 
be analysed downstream. Furthermore, due to the covalent nature of the cross-links, unlike 
techniques such as HDX which involve careful sample handling after labelling, cross-linked 
samples can be taken for further reactions before analysis. With sophisticated chemistry, it is 
possible to target any residue on a protein’s surface via photo activatable cross-linkers, such 
as diazirines, or target specific residues using N-hydroxysuccinimide (NHS) ester chemistry 
(amine group on lysine residues) or conjugation with carbodiimides (carboxyl groups) (Sinz 
et al., 2015, Liu and Heck, 2015, Chen et al., 2016a, Arlt et al., 2016, Tran et al., 2016, Faini et 
al., 2016). 
Here we utilise a routinely used amine-specific cross-linker, BS3 
(bis(sulfosuccinimidyl)suberate) (Figure 5.1) (d'Souza et al., 1988, Andrews et al., 1989, 
Palecanda et al., 1992, Nürnberger et al., 1995, Huang et al., 2004, Fischer et al., 2013), in 
order to cross-link solvent exposed lysine residues presented on the surface of WFL oligomers.  
 
Figure 5.1: Structure of the chemical cross-linker used in this study. (a) Structure of BS3 and 
(b) its mechanism of action. The amine group of lysine residues attacks the ester group of BS3 
and an amide bond is formed between the lysine residue and the cross-linker.  
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Unlike HDX experiments, which typically use pepsin to digest labelled proteins due to the 
low temperature and low pH requirements of the technique, any protease can be used to 
generate peptide fragments from a cross-linked sample. However, trypsin is most commonly 
used due to its valuable sequence coverage, specificity and its compatibility with mass 
spectrometry analyses (Olsen et al., 2004). 
 
5.3 Analysing chemical cross-linking data 
To analyse the results of the chemical cross-linking using MS, after digestion, it is imperative 
to purify the cross-linked peptides in order minimise the background noise arising from non-
cross-linked peptides, the latter of which are in the majority. There are currently two methods 
that are used to purify cross-linked material: peptide size exclusion chromatography (SEC) 
(Leitner et al., 2014) and in-gel digestion (Shevchenko et al., 1996). The peptide SEC method 
was established by Prof. Reudi Aebersold’s group at ETH Zurich (Switzerland). When 
carrying out SEC on a protein digest, a range of overlapping peaks are observed in the elution 
profile (Figure 5.2a). However, due to cross-linked peptides being heavier in mass on average, 
compared with their non-cross-linked counterparts, they elute earlier in the elution from a 
peptide SEC column (Figure 5.2b); thereby enriching the amount of cross-linked material in 
the earlier eluting fractions (Leitner et al., 2014) . 
 
Figure 5.2: Example elution profiles for non-cross-linked and cross-linked samples. Example 
elution profile for a (a) non-cross-linked peptic digest and (b) cross-linked peptic digest. A 
shift in elution can be observed (blue (ii) to orange (i)) for cross-linked peptides.  
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Chemical cross-linking followed by in-gel digestion is routinely used to identify cross-linked 
fragments in the field (Morgner et al., 2015). This method has the advantage of isolating 
individual species from an SDS-PAGE gel where the user knows that inter-molecular cross-
links are present in the sample due to the corresponding molecular weight on the gel (Figure 
5.3). 
 
Figure 5.3: Schematic of the in-gel digestion workflow. (a) Protein samples with and without 
varying amounts of cross-links are analysed via SDS-PAGE. (b) Bands of interest are carefully 
excised from the gel and (c) taken forward for in-gel trypsin digestion, followed by LC-
MS/MS. L = protein marker. 
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5.4 WFL oligomers can be captured using chemical cross-linking 
5.4.1 Chemical cross-linking with glutaraldehyde 
To probe the accessibility of WFL and STT to chemical cross-linking, solvent exposed lysines 
were first interrogated by reacting the protein with glutaraldehyde, targeting amine groups 
(Migneault et al., 2004). While glutaraldehyde polymerises in solution to form various linker 
lengths (Aso and Aito, 1962a, Aso and Aito, 1962b), this experiment established whether it 
was possible to capture the oligomeric species of WFL while specifically targeting lysine 
residues.  
Briefly, WFL was cross-linked at 1, 2 and 4 mg/mL in 100 mM sodium phosphate, pH 7.4 with 
varying amounts of glutaraldehyde (0.1 – 0.005 % (w/v), 25 % (w/v) stock solution) (see 
Section 3.4.4). Cross-linking reactions were incubated on ice for 20 minutes before quenching 
with Tris. HCl, pH 8, at a final concentration of 50 mM.  The resulting cross-linked species 
were then analysed via SDS-PAGE (see Section 3.4.8) (Figure 5.4). 
 
Figure 5.4: SDS-PAGE gel of WFL samples cross-linked with glutaraldehyde. WFL was cross-
linked at protein concentrations of 4 (blue), 2 (green) and 1 (orange) mg/mL with decreasing 
amounts of glutaraldehyde, from 0.1 – 0.005 (w/v) %. L = protein marker. Stained with Instant 
Blue Coomassie stain.  
 
Cross-linking with glutaraldehyde resulted in a significant proportion of WFL precipitating 
out of solution, from 0.1 – 0.05 % (w/v) glutaraldehyde. However, the laddering effect 
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observed reveals that it was possible to cross-link WFL oligomers by exclusively targeting 
solvent exposed lysine residues.  
While effectively cross-linking the IgG sample, glutaraldehyde is not an ideal chemical cross-
linker for the follow-on sequencing in the mass spectrometer due to the heterogeneous 
lengths that glutaraldehyde forms. Therefore, as it had been concluded that targeting the 
lysine residue was a viable method, a cross-linker with equivalent specificity but 
homogeneous linker length was chosen for further cross-linking studies.  
 
5.4.2 Chemical cross-linking with BS3 
To ensure specificity in the cross-linking experiments and to allow for downstream mass 
spectrometry analysis, the amine specific cross-linker BS3 was chosen as it had an appropriate 
cross-linker length of 11.4 Å and has been historically and widely, but not exclusively, used 
in the field (Back et al., 2003). There was a concern that any longer length cross-linkers would 
increase the probability of forming uninformative intra-molecular cross-links due to the 
increased length. Furthermore, BS3 is commercially available in deuterated (d4) and non-
deuterated (d0) forms, making downstream analysis easier for the user (Seebacher et al., 2006, 
Fischer et al., 2013). By using a 50:50 mix of deuterated and non-deuterated cross-linker, any 
site that is modified by BS3 has a 50 %  probabilistic chance to be modified by either the 
deuterated or non-deuterated form (Schmidt and Robinson, 2014). This is reflected in the 
resulting mass spectra by the appearance of a fingerprint doublet peak that differs 4 Da in 
mass (Figure 5.5). 
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Figure 5.5: Schematic showing the MS-identification of cross-linked peptides. (a) No peaks 
are observed in this region of the mass spectrum, in the absence of cross-linker while (b) new 
peaks appear showing typical isotope distribution for a tryptic peptide upon addition of BS3. 
(c) A signature doublet set of peak is formed when cross-linking with a 50:50 mix of 
deuterated and non-deuterated BS3 cross-linker. The 4 Da difference indicating the d0/d4 
mass difference in BS3 for the tryptic peptide is shown.  
 
The mixture of deuterated and non-deuterated cross-links allows the unequivocal detection 
of cross-linked peptides when analysed using MS. Therefore, a comparative approach can be 
taken by searching for cross-links that are unique to the oligomeric species present in the 
sample. 
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Samples of WFL and STT were cross-linked with increasing (molar excess) amounts of 
deuterated and non-deuterated BS3 (d0/d4) (see Section 3.4.5). The IgGs were cross-linked at 
a constant antibody concentration of 1 mg/mL since WFL has been shown to be 
predominantly dimeric at this concentration, whilst STT is predominantly monomeric (see 
Figure 4.1). The reactions were performed on ice for 30 min before quenching with Tris.HCl, 
pH 8, at a final concentration of 50 mM. The resulting cross-linked mixtures were then 
analysed via SDS-PAGE (see Section 3.4.8) (Figure 5.6). 
 
Figure 5.6: Non-reducing SDS-PAGE gel of WFL and STT samples cross-linked with BS3. 
Protein samples were cross-linked at 1 mg/mL with increasing amounts of BS3, from 50× to 
500× molar excess. L = protein marker. * = corresponds to monomer with the loss of a single 
light chain. Representative gel of n = 5. Stained with Instant Blue Coomassie stain. 
 
Similar to the cross-linking experiments with glutaraldehyde (Figure 5.4), WFL forms a range 
of oligomeric species in the presence of cross-linker while STT only forms a small amount of 
dimeric species. At cross-linker concentrations higher than 100× molar excess, WFL begins 
to precipitate out of solution and such high cross-linker concentrations were subsequently 
avoided. Importantly, the difference in cross-linking efficiencies observed reflect the 
behaviour of WFL and STT in solution (see Figure 4.1), with the majority of STT being 
monomeric.  
As stated above, the cross-linked peptides required purification and enhancement to minimise 
the background noise arising from non-cross-linked peptides before sequencing in the mass 
Defining the Site of Self-Association Using Chemical Cross-Linking 
158 
spectrometer. Both the peptide SEC method and in-gel digestion method were applied to 
analyse which approach yields a larger number of cross-linked peptides, at greater purity.  
 
5.4.2.1 Purifying cross-linked peptides via peptide SEC 
For the peptide SEC, samples of WFL and STT were cross-linked with 100× molar excess of 
d0/d4 BS3 as described above and in Section 3.4.5. After cross-linking and quenching, mAb 
samples were denatured in 6 M guanidine hydrochloride (Gdn.HCl) for 30 min. Cross-linked 
samples were then treated with 10 mM DTT for 30 min at 37 °C and subsequently treated 
with 25 mM iodoacetamide for 20 min at 25 °C in the dark. 100 mM sodium phosphate, pH 
7.4 was added to the reduced and alkylated samples to dilute the GdnHCl below 1.5 M. 
Trypsin was then added to the samples at a ratio of 1:50 (w/w) (enzyme:protein) and incubated 
at 37 °C for 18 h. The resulting cross-linked and non-cross-linked peptide mixtures were then 
purified using C18 SepPak cartridges (see Section 3.4.6) before being evaporated to 
completion in a SpeedVac system. Peptides were then re-suspended in 40 µL H2O before being 
loaded onto a Superdex 3.2/30 peptide column (see Section 3.4.7) equilibrated in 30 % (v/v) 
acetonitrile and 0.1 % (v/v) trifluoroacetic acid (TFA), as described in (Leitner et al., 2014) 
and Section 3.4.7. Cross-linked and non-cross-linked samples were then analysed via peptide 
SEC for comparison (Figure 5.7). 
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Figure 5.7: Peptide SEC elution profiles for non-cross-linked and cross-linked samples of WFL 
and STT. (a) Peptide SEC elution chromatograms of (i) non-cross-linked and (ii) cross-linked 
WFL. (b) Peptide SEC elution chromatograms of (i) non-cross-linked and (ii) cross-linked 
STT. Fractions from 1 mL (-2) to 1.5 mL (+2) are highlighted. Representative data of n = 3. 
 
Peptide SEC reveals a shift in the chromatograms of the cross-linked samples (Figure 5.7a.ii. 
and b.ii.), indicative of cross-linked peptides being present. The fractions were collected and 
concentrated by evaporation in a SpeedVac system before being taken forward for MS/MS 
sequencing (see Section 3.4.7). The fractions were reconstituted in 0.1 % (v/v) formic acid 
then separated and infused into the G2Si mass spectrometer using an ACQUITY LC system 
(see Section 3.2.6). 
Unfortunately, no intermolecular cross-linked peptides were identified in the samples 
sequenced when analysed with the StavroX software (Götze et al., 2012, Götze et al., 2015). 
It was a concern that while cross-linked peptides elute in earlier fractions, two small peptides 
connected through a cross-link may elute in later fractions; amongst the non-cross-linked 
material. Furthermore, as the sample contained monomer to tetrameric species the 
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concentration of each cross-linked species would potentially be low in this complex mixture, 
which will include both intra- and inter-molecular cross-links. Finally, due to the amount of 
remaining monomeric species present in the cross-linked samples (see Figure 5.6) it was 
hypothesised that the inter-molecular cross-linked species would be low in abundance and 
ultimately, difficult to visualise. Therefore, it was decided to use the in-gel digestion method 
as this may minimise the background noise by only analysing peptides forming from the 
oligomeric species of interest. 
 
5.4.2.2 Purifying cross-linked peptides via SDS-PAGE and in-gel 
digestion 
The advantage of the in-gel digestion method was that as bands were excised from a non-
reducing SDS-PAGE gel, the band corresponding to the dimer of WFL can be preferentially 
selected for digestion and subsequent sequencing. By only excising the dimer band this aids 
in two ways: by (1) minimising the background noise from intra-molecular cross-links from 
all other species that were in the sample and (2) as this species presents itself as a dimer, it 
was confidently concluded that inter-molecular cross-links had to have been formed.  
Samples of WFL and STT were cross-linked with a 100× molar excess of d0/d4 BS3 as 
described in Section 3.4.5 and separated on a non-reducing SDS-PAGE gel, with a non-cross-
linked sample in tandem. Bands corresponding to the non-cross-linked monomer, cross-
linked monomer and cross-linked dimer of both WFL and STT were excised from the SDS-
PAGE gel, cut into small cubes (around 1 mm3) and subjected to in-gel digestion with trypsin 
(see Section 3.4.9). Briefly, the gel pieces were dehydrated with 50 % (v/v) acetonitrile in 25 
mM ammonium bicarbonate, pH 7.8 to remove the gel stain. The IgGs were then reduced by 
incubating the gel pieces with 10 mM DTT for 45 min at 37 °C. The DTT solution was removed 
and the gel pieces were subsequently incubated with 50 mM iodoacetamide to alkylate the 
free cysteine residues. A final dehydration step was carried out with 100 % acetonitrile before 
the solution removed and the gel pieces dried to completion in a SpeedVac system. The gel 
pieces were then re-solvated in a 0.1 µg/mL trypsin solution and incubated at 25 °C for 15 min 
to allow the trypsin solution to absorb into the gel pieces. Excess trypsin was removed from 
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the samples and replaced with 50 µL (enough to cover the gel pieces) 25 mM ammonium 
bicarbonate, pH 7.8. The trypsin digest reactions were then incubated at 37 °C for 18 h. The 
tryptic peptides were recovered by 4 repeat rounds of de-hydrating the gel-pieces with 50 µL 
of 60 % (v/v) acetonitrile, 5 % (v/v) formic acid. The recovered peptides were concentrated 
by evaporating the solutions to completion, before re-suspending the peptides in 0.1 % (v/v) 
formic acid and loading them onto the ACQUITY LC system for peptide separation and 
infusion into the G2Si mass spectrometer. 
Upon data analysis with the both the StavroX  and MassMatrix (Xu and Freitas, 2007, Xu et 
al., 2010) software, while many intra-molecular cross-links were identified in both the cross-
linked monomer samples of WFL and STT and the cross-linked dimer sample of WFL, only 
one, tenuous, inter-molecular cross-link was identified automatically (see Appendix 8.37-
8.39). The only cross-link that was identified, unique to the dimeric species, was a cross-link 
at the bottom of the mAb in the CH3 domains (LTVDKSR-LTVDKSR). However, this was 
only identified in one repeat and not others, potentially suggesting that this may be a non-
specific interaction. This raised a concern about using the automated data analysis software as 
there had to be inter-molecular cross-links present in the samples as evidenced by SDS-PAGE. 
It was subsequently hypothesised that due to the manner of how cross-linking programs 
function, by looking for corresponding peptides at the intact peptide level first, was where 
problems were being encountered. If the cross-linked species were low in abundance, which 
was highly likely, then the peptides may have not been being selected for sequencing and 
therefore the programs unable to identify them.  
Therefore, to identify any inter-molecular cross-linked peptides the mass spectra were 
analysed manually.  
 
5.5 Sequencing of WFL cross-links indicates Fab-Fab interactions 
The mass spectra from the LC runs were analysed manually and in a comparative manner; 
looking for cross-linked peptides (doublet peaks in the spectra) that were unique to the WFL 
dimer species and only present in that sample (Figure 5.8).  
Defining the Site of Self-Association Using Chemical Cross-Linking 
162 
  
F
ig
u
re
 5
.8
: M
as
s 
sp
ec
tr
a 
sh
ow
in
g 
th
e 
id
en
ti
fi
ca
ti
on
 o
f 
cr
os
s-
li
n
k
 p
ep
ti
d
es
 u
n
iq
u
e 
to
 W
F
L
. M
as
s 
sp
ec
tr
a 
of
 t
h
e 
W
F
L
 (
a)
 m
on
om
er
 b
an
d
 a
n
d
 
(b
) 
d
im
er
 b
an
d
 a
t 
th
e 
sa
m
e 
re
te
n
ti
on
 t
im
e 
sh
ow
in
g 
a 
u
n
iq
u
e 
cr
os
s-
li
n
k
ed
 p
ep
ti
d
e.
 M
as
s 
sp
ec
tr
a 
of
 t
h
e 
ST
T
 (
c)
 m
on
om
er
 b
an
d
 a
n
d
 (
d
) 
d
im
er
 
b
an
d
 a
t 
th
e 
sa
m
e 
re
te
n
ti
on
 t
im
e 
sh
ow
in
g 
n
o 
cr
os
s-
li
n
k
ed
 p
ep
ti
d
e 
p
re
se
n
t 
in
 e
it
h
er
 s
p
ec
tr
u
m
. 
Sh
ad
ed
 a
re
a 
= 
cr
os
s-
li
n
k
ed
 p
ep
ti
d
e.
 
R
ep
re
se
n
ta
ti
ve
 s
p
ec
tr
a 
of
 n
 =
 3
. 
 
Defining the Site of Self-Association Using Chemical Cross-Linking 
163 
Manual analysis of the different spectra revealed a cross-link unique to the WFL dimer sample 
(Figure 5.8b, m/z 824-830). As previously mentioned, this peptide was, presumably, not 
identified by the cross-linking programs as this peptide was never selected for sequencing due 
to its low ion intensity, potentially arising from low abundance in solution (see Appendix 
8.40). 
The mass spectrometer was tuned manually so that the quadrupole would only allow 
transmission of ions of 824.2 m/z. The cross-linked dimer sample of WFL was once again 
infused into the mass spectrometer in order for the identified cross-linked peptide to be 
sequenced by tandem mass spectrometry (Figure 5.9). 
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Sequencing of the cross-linked peptide at 824.2 m/z revealed a cross-link between the N-
terminus of the heavy chain to a lysine residue (K54) in the variable region of the light chain. 
While the collision voltages could be optimised further as the base peak in the spectrum 
remains as the precursor ion (824.2 m/z), the cross-linked peptide was fragmented sufficiently 
so that two partial peptides could be identified from their y-ion series. The two identified 
sequences were searched for in the full IgG sequence and were found to be unique peptide 
sequences, where the first was the N-terminal peptide from the heavy chain 
(QVQLVQSGAEVK) and the second was the peptide from the variable region of the light 
chain (LLIYDNNKRPSGIPDR).  
Furthermore, due to the collision energies used for the sequencing, a series of doubly charged 
peptides could be identified at higher m/z in the spectrum (~1070 m/z). It was clear from the 
mass spectrum that these doubly charged species still correspond to two cross-linked peptides, 
as evidenced by the doublet peak from using the d0/d4 BS3 cross-linker (Figure 5.9). It was 
hypothesised that the doubly charged species would contain fragments of the two peptides 
that were being cross-linked, and would serve as further evidence for the cross-link existing 
across the two peptides shown above. As it appears sequencing of cross-linked peptides 
preferentially fragments one peptide before the other, with preferential fragmentation of 
specific sequences known (Qin and Chait, 1995), it was assumed that the first doubly charged 
peak at 1069 m/z would correspond to one intact peptide cross-linked to a fragment of the 
other. Therefore, the observed masses of the doubly charged species were compared with the 
expected masses of different cross-linked combinations (Figure 5.10). 
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As predicted, Figure 5.10 reveals that the doubly charged species observed in the MS/MS 
spectrum correspond to peptides from the variable region of the light chain, cross-linked to 
fragments of the N-terminal heavy chain. This confirms that the cross-link is occurring at the 
N-terminus of the heavy chain to the lysine residue (K54) on the other peptide.  
Strikingly, only one cross-link was identified from the 300 kDa complex of the WFL dimer. 
Although unexpected, this result can be explained as one of the cross-linked sites is at the N-
terminus of the heavy chain, at a glutamine residue. An N-terminal glutamine or glutamic 
acid residue has been shown to be able to cyclise spontaneously to a pyroglutamate (Liu et al., 
2011) (Figure 5.11). 
 
Figure 5.11: Cyclisation of glutamine to pyroglutamate.  
  
Figure 5.11 shows that the amine group at the N-terminus is lost upon cyclisation to a 
pyroglutamate and therefore so is the cross-linkable site. It was suggested by MedImmune 
that around 95 % of the molecule is believed to form the pyroglutamate and would explain 
the difficulty in identifying the cross-linked peptides.  
However, the identification of this cross-linked site suggests that the self-association of the 
WFL dimer is driven by a Fab-Fab interaction.  
 
5.6 Visualising the cross-link in a structural model 
In order to investigate the site responsible for the self-association of WFL and visualise the 
identified cross-link, two simplistic models were proposed (Figure 5.12). These models are 
similar to those explored in Chapter 4 (see Section 4.3.3). 
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Figure 5.12: Hypothesised models of WFL self-association based on the chemical cross-linking 
data.   
 
Both models are consistent with the cross-linking data and furthermore, would place residues 
W30, F31 and L57 at the heart of the binding interface, which was predicted, as mutating 
these residues ameliorates the self-association. Finally, these models are attractive as both 
leave a Fab arm free on each mAb either side of the binding interface, which would allow for 
further oligomer extension. However, to achieve higher resolution models a docking 
approach was employed to utilise the restraints that had been established from the chemical 
cross-linking data.  
As the mutations from WFL to STT lie in the variable regions of the IgG, the scFv homology 
models (supplied by MedImmune plc.) of each mAb were used for docking and to generate 
high resolution models. The HADDOCK software was used to generate the docked structures 
(van Zundert et al., 2016). Firstly, models were generated by driving the docking procedure 
using residues W30, F31 and L57 of each molecule as the active residues (see Section 3.3.5) 
(Figure 5.13). Additionally, while these residues were specified as the active residues since 
they are mutated in STT, hydrogen-deuterium exchange (HDX) mass spectrometry data, 
obtained by Dr J.J. Phillips at MedImmune plc, shows protection at these residues, amongst 
others, upon dimer formation (see Figure 5.17). It was of interest to observe if the models 
generated were in agreement with the cross-linking data without further refinement. 
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Figure 5.13: HADDOCK docked dimer structures of WFL from the top two clusters. (a) WFL 
dimer from the first cluster showing the two monomeric subunits coming together with a 
~180 ° rotation from each other. (b) WFL dimer from the second cluster showing the two 
monomeric sub units coming together with the heavy and light chains parallel. Inset shows 
the distance between the identified cross-linked residues. Identified cross-linked residues are 
represented as orange sticks. As the cross-linked residues are 22 Å apart, this model needs 
refined. 
 
As only three solvent exposed residues were set as the active residues to drive the docking 
procedure, models with different orientations were generated, centred on residues W30, F31 
and L57 (Figure 5.13). The two top clusters show models with one scFv (pink) rotated around 
the other. The cross-linked residues, Q1 and K54, are indicated as orange sticks and the first 
structure (Figure 5.13a) shows that these two residues are at opposite sides of the dimer 
interface and therefore a cross-link would not be possible. Interestingly however, the second 
model (Figure 5.13b) has the two structures orientated in such a manner that the cross-linked 
residues are on the same side of the interface. However, the inset shows that the distance 
between these two residues is 22 Å. The distance restraint set by BS3 is 11.4 Å and therefore 
the model does not satisfy the cross-linking data.  
In order to incorporate the cross-linking data a second docking procedure was carried out, 
this time adding a distance restraint of 11.4 Å between the identified cross-linked residues 
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(see Section 3.3.5), Q1 (Cδ) and K54 (Nζ); while maintaining the dimer interface set by 
residues W30, F31 and L57 (Figure 5.14). 
 
Figure 5.14: Proposed model for the self-association of WFL. (a) Atomistic model showing the 
refined docked dimer of WFL with (i) no disruption to the dimer interface upon refinement 
and (ii) the cross-linked residues within 11.4 Å of one another. (b) Proposed model for the 
oligomerisation of WFL, driven through Fab-Fab interactions with the potential binding sites 
for further oligomer extension.  
 
The refined model reveals that it is possible to have the cross-linked residues within 11.4 Å 
(Figure 5.14a.ii.) while not perturbing the hydrophobic dimer interface formed by residues 
W30, F31 and L57 (Figure 5.14a.i.). With these data, a model was proposed which involves 
the monomeric IgGs of WFL self-associating via a hydrophobically driven, Fab-Fab 
interaction. This model also explains how larger oligomers can be formed at higher 
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concentrations by the addition of further monomers onto the free Fab arm of each WFL mAb 
involved, leading to runaway polymerisation (Figure 5.14b). Furthermore, this model also 
facilitates the other cross-link that was identified by the StavroX software that was unique to 
the dimer (see Section 5.4.2.2). Due to the flexibility found within the hinge region, it would 
be possible for the two Fc domains to come into close contact and for the cross-link between 
the two CH3 regions to exist. This may be further suggested as the cross-link was not 
identified in all repeats, as stated before. Interestingly, this model reflects the structures that 
were earlier observed in the electron micrograph images (Figure 4.3). 
 
5.7 Discussion 
Mass spectrometry has seen a surge in the field of structural biology with the advances in 
labelling techniques, especially with systems that are too large or dynamic to be studied 
through conventional structural techniques (Konermann et al., 2014, Vandermarliere et al., 
2015). While a structural proteomics approach will never achieve structures with resolution 
procurable to techniques such as X-ray crystallography, NMR or cryo-EM, it is the 
combination of MS with these techniques that proves invaluable. In Chapter 5 it was 
demonstrated that chemical cross-linking, coupled with MS, led to the determination and 
characterisation of the site responsible for the self-association and oligomerisation of a 
therapeutically relevant mAb.  
An interesting question that arose from this study was why such few inter-molecular cross-
link were identified? Cross-linking experiments typically yield multiple inter-molecular cross 
links that can be used as restraints to build models (Kosinski et al., 2015, Hofmann et al., 
2015). Programs have been designed to aid in the visualisation of multiple cross-links across 
multi-sub-unit complexes (Combe et al., 2015), so why were only two cross-links identified 
here? Two possible explanations for this are that (1) there were no other cross-linkable sites 
due to the mechanism of self-association, and (2) that due to the complexity of working with 
a homologous system, inter-molecular cross-links were being masked by co-existing intra-
molecular cross-links. The docked model was interrogated for any other cross-linkable sites, 
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that were within the 11.4 Å (Nζ to Nζ) distance restraint set by BS3, that should have been 
identified by sequencing (Figure 5.15).  
 
Figure 5.15: Structure showing all possible cross-linkable residues on the proteins surface. (a) 
Front and (b) back view of the dimer structure with all cross-linkable residues represented as 
purple sticks. Identified cross-linked residues are represented as orange sticks with the 
residues 30, 31 and 57 involved in the dimer interface are shown as blue sticks.  
 
Analysis of other possible cross-links revealed only one other site around the dimer interface 
that lies slightly out of the distance restraint set (12.9 Å). However, the two residues that 
would be involved in this cross-link are the same as the identified cross-link, Q1 and K54, but 
from the other sub-units. Therefore, while it is possible this cross-link may have existed in 
solution, its impact would have been to add to the abundance of the cross-link previously 
identified. However, the conversion of glutamine to pyroglutamate lowers the cross-linking 
efficiency at this site and therefore some cross-links may be being missed. Subsequently as 
mentioned above, the other possible explanation would have been the masking of inter-
molecular cross-links by the same intra-molecular cross-links (Figure 5.16). 
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Figure 5.16: Schematic showing the potential for false negative cross-links. (a) Schematic 
showing that an intra-molecular cross-link may exist between residues x and y that also (b) 
exists inter-molecularly upon oligomerisation 
 
If an inter-molecular cross-link is formed upon oligomer formation, but the same cross-link 
can be made intra-molecularly, there would be no way to differentiate these in the resulting 
mass spectra. To navigate this possibility, cross-linking oligomers formed by mixing labelled 
protein (15N) with non-labelled protein, inter-molecular cross-links could be differentiated 
from their intra-molecular counter parts by their mass.  
Although working with a complex homologous system, the approach described here was able 
to successfully identify an inter-molecular cross-link from which a model could be generated. 
This model (Figure 5.14) was also in agreement with HDX-MS and aggregation prediction 
data that were acquired by MedImmune (Figure 5.17).  
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Figure 5.17: Sites of protection observed upon dimer formation and predicted areas for 
aggregation.  (a) Localised sites of protection upon dimer formation for the (i) heavy chain 
and (ii) light chain variable regions of WFL. 99 % confidence limits for significant protection 
upon dimer formation are shown (grey shaded area, dashed lines). Residues of significant 
protection are underlined with residues mutated from parent sequence are highlighted in red. 
(b) Spatial aggregation propensity algorithm prediction of WFL for aggregation prone sites 
(exposed hydrophobic regions) are highlighted in red. (c) Spatial aggregation propensity 
algorithm prediction of STT for aggregation prone sites (exposed hydrophobic regions) are 
highlighted in red. Residues 30, 31 and 57 are highlighted in both structures. Data was 
acquired and analysed by Dr J.J. Phillps (MedImmune plc.). 
 
Furthermore, the model presented in this thesis proposes that the WFL monomers are 
interacting through Fab-Fab interactions; it is hypothesised that these are the interactions 
that were being observed in class averages of the dimer in the EM micrographs shown in 
Chapter 4 (Figure 4.3). While the individual regions of the structures could not be classified 
due to the resolution of the images, the data here suggest that the micrographs were 
presenting the Fab-Fab interactions characterised in this Chapter.  
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Chemical cross-linking has aided in the characterisation of many protein complexes (Dyche 
Mullins and Pollard, 1999, Schraven et al., 1990, Brunner, 1993, Singh et al., 2010, Hall et al., 
2016, Greenberg et al., 2016, Zheng et al., 2016, Yu et al., 2015). However, one area where 
cross-linking is less frequently applied is in biopharmaceutical characterisation, particularly 
in aggregation-prone candidates. This may be because such an approach often required 
computational workflows to aid data analysis and other structural data in order to yield 
reliable models. However, with the plethora of structures now available in the protein data 
bank (PDB), and the more recent EM data bank (EMDB), it is predicted that cross-linking 
combined with mass spectrometry will continue to be a useful technique in the study of the 
structure and topology of large dynamic protein systems (Leitner et al., 2016, Sinz et al., 2015). 
Therefore, it is proposed that the method utilised in this study, in combination with other 
structural MS techniques such as HDX-MS or hydroxyl radical foot printing (FPOP), could be 
used as a generic approach to characterise such systems. The promising advantages of utilising 
structural MS methodologies are their ability to characterise large, dynamic systems that 
otherwise cannot be studied through conventional approaches and finally, removing the 
requirement for large volumes of protein at high concentrations to undertake such studies. 
The combination of structural MS techniques could therefore aid in the re-engineering of 
aggregation-prone biologics, and assist in the improvement of their biophysical properties.  
In summary, the site responsible for the self-association of a therapeutically relevant IgG was 
characterised here using XL-MS. However, one interesting question that arose from this study 
was whether all mutations of WFL to STT are needed to remove the propensity of the IgG to 
self-associate? Positions 30, 31 and 57 were selected for mutation due to these sites being 
altered from the parent sequence during the affinity maturation process, which unfortunately 
resulted in the poor biophysical characteristics and self-association; while not perturbing 
antigen binding. Furthermore, these residues were also highlighted upon analysing the 
sequence with an aggregation propensity algorithm (Figure 5.17) (spatial aggregation 
propensity, SAP (Voynov et al., 2009). However, it was unclear whether mutations at all three 
sites were needed, or if one residue was key into disrupting the propensity to aggregate. This 
was next interrogated using scFvs of different sequences and is described in Chapter 6. 
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6 Developing an in vivo screen to identify aggregation-
prone sequences in biopharmaceuticals 
6.1 Objectives 
The work presented in Chapter 5 characterised the region responsible for the self-association 
of the IgG WFL, with the three positions (W30, F31 and L57) mutated to STT playing 
prominent roles in driving the self-association. However, it was unclear whether all three 
residue substitutions are needed to mitigate the self-association propensity of WFL. The final 
objective of this study was to investigate the residues involved individually, and in 
combination, to understand if all three mutations are critical to ameliorate the self-
association. An in vivo system was employed to carry out the investigation which involved 
moving from full IgGs to scFv format.   
 
6.2 Introduction 
6.2.1 In vivo system for monitoring aggregation 
Chapter 6 utilises a published in vivo method to monitor the aggregation of client proteins 
(Saunders et al., 2016). The assay exploits the natural antibiotic defence system of E. coli and 
uses β-lactamase as a reporter. In a split enzyme assay, the protein of interest is cloned into a 
glycine-serine (G/S) linker separating the two domains of β-lactamase (Figure 6.1a+b). This 
system was first utilised to characterise protein stability in vivo (Foit et al., 2009, Hailu et al., 
2013). As the assay is rapid to perform and the analysis simple, it was postulated that this 
would be a convenient technique to use to examine the effects of multiple combinations of 
mutations on the aggregation propensity of scFv molecules.  
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Figure 6.1: Schematic of the tri-partite β-lactamase construct.  (a) The protein of interest 
(green) is inserted in between the two domains of β-lactamase (purple and pink) connected 
via glycine-serine (G/S) linkers (blue). (b) Structural schematic showing where the protein of 
interest lies in respect to the two β-lactamase domains. (c) Fully folded tri-partite construct 
can fold to form the functional enzyme and cleave β-lactam antibiotics. Figure taken and 
adapted from (Saunders et al., 2016). 
 
Upon expression of the construct, the two halves of the β-lactamase can fold to form the fully 
functioning enzyme, which cleaves β-lactam antibiotics in the surrounding periplasm (Figure 
6.1). The insertion of an aggregation prone protein into the construct causes the functioning 
enzyme to be pulled into the aggregate or degraded, resulting in a loss of β-lactam antibiotic 
resistance. The assay is performed in a 48-well agar plate, whereby the ability of the bacteria 
to grow at increasing concentrations of antibiotic is recorded. The assay is quantified by 
measuring the maximal dilution at which the cells grow across increasing ampicillin 
concentrations (Figure 6.2). 
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Figure 6.2: Schematic showing the in vivo assay work flow.  (a) Cell dilutions are plated across 
a 48-well agar plate containing increasing ampicillin concentrations. Maximal cell growth at 
a given dilution is scored at each antibiotic concentration. (b) Data plotted in graph format 
for comparison between constructs.  
 
The data, plotted as a graph of the maximal cell dilution the cells grow at against the increasing 
ampicillin concentration (Figure 6.2a), enabled comparison of the aggregation propensity of 
different test proteins. Furthermore, the results of multiple in vivo assays can be compared to 
one another by calculating the area under the plotted curves (Figure 6.2b) and represented as 
bar charts; making the comparison of multiple constructs easier for the analyst. 
While the in vivo assay has been successfully applied to the characterisation of amyloidogenic 
proteins and identifying inhibitors for these systems (Saunders et al., 2016), this study aimed 
to extend the application of the in vivo assay to characterising proteins relevant to the 
biopharmaceutical sector.  
 
6.2.2 Characterising biopharmaceuticals using the in vivo assay 
The β-lactamase tripartite system has been shown to maintain function after incorporation of 
proteins up to 40 kDa in size (Foit et al., 2009). As for the characterisation of 
biopharmaceuticals, while this system is unable to characterise full IgGs, it is ideal for the 
analysis of the scFvs. This is desirable since it has been found that the aggregation of mAbs 
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can often be due to the sequences found in the variable regions of the Fab arms (Wang et al., 
2009, Wu et al., 2014). Furthermore, many industries have standard scaffolds onto which 
candidate IgG fragments are grafted for the formation of the functional mAb molecule 
(Renaut et al., 2012, Stewart et al., 2012). Therefore, it was hypothesised that β-lactam 
antibiotic resistance would be lost upon the insertion of an aggregation prone scFv into the 
β-lactamase tripartite system (Figure 6.3a), similar to the results published for the 
amyloidogenic proteins (Saunders et al., 2016).  
As with the amyloid systems studied previously, it was hypothesised that upon expression in 
the periplasm β-lactamase function would persist when a stable scFv was inserted into the 
construct (Figure 6.3b). However, the insertion of an aggregation prone scFv, such as WFL, 
would cause self-association and pull the β-lactamase into the aggregate which would be 
reported through the loss of antibiotic resistance and, ultimately, cell death (Figure 6.3c).  
 
 
Figure 6.3: scFv-β-lactamase tri-partite system. (a) ScFv of interest is cloned into the linker 
region of β-lactamase. (b) β-lactamase remains monomeric and functional with a stable scFv 
insert and can cleave β-lactam antibiotics. (c) Aggregation prone sequences pull β-lactamase 
into the aggregate and host β-lactam antibiotic resistance is lost. Orange spheres = antibiotic. 
 
To test the potential of the in vivo assay as a platform for identifying aggregation prone scFvs, 
the model pair at the focus of this study, WFL and STT, were used. The question of whether 
all three mutations were needed to ameliorate the self-association of WFL was of particular 
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interest, in addition to the possibility of being able to identify differences between the 
different point mutations.  
 
6.3 In vivo assay identifies differences of aggregation prone scFvs  
6.3.1 In vivo analysis of candidate scFvs 
For proof of concept it was important to analyse the effects that WFL and STT, in single-chain 
format, have on the tripartite β-lactamase system. Fortunately, the WFL_scFv and STT_scFv 
sequences had previously been cloned into the β-lactamase construct (creating βla-WFL and 
βla-STT) and screened in the in vivo assay (Figure 6.4). 
 
Figure 6.4: Comparison of in vivo assay data for WFL and STT sequences. The maximal 
dilution (MCD) at which cells still grow is monitored. Data obtained by Dr Janet Saunders 
(University of Leeds). 
 
A striking difference was observed between the two constructs, with bacteria expressing the 
βla-STT outperforming βla-WFL significantly. Since a significant difference could be 
observed between the two constructs, it was decided to screen the individual point 
mutations between WFL and STT to understand the effect of these mutations on in vivo 
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aggregation. Using either the WFL or STT plasmid DNA, Q5 mutagenesis was carried out to 
mutate the residues of interest (Table 6.1) (see Section 3.5.3).  
Table 6.1: Table of constucts and mutated residues, from WFL, made to compare the 
aggregation of the scFvs in the MIC assay. 
Construct  Mutations from WFL 
WFL ----- 
SFL W30S 
WTL F31T 
WFT L57T 
STL W30S, F31T 
SFT W30S, L57T 
WTT F31T, L57T 
STT W30S, F31T, L57T 
 
After confirmation of the correct sequences, the effects of the individual mutations were 
screened in the in vivo assay to analyse their effect on aggregation of the scFv-β-lactamase 
constructs (Figure 6.5, plates for WFL, SFL and STT can be seen in Appendix 8.41).  
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Figure 6.5: Comparison of in vivo assay results across all generated constructs. (a) Assay results 
for all single point mutations from WFL to STT. The parent WFL and STT results are plotted 
for comparison. (b) Assay results for single point mutations from STT to WFL. WFL and STT 
results are plotted for comparison. (c) Assay results for all constructs tested. (d) Bar chart 
showing the area under the curves (A.U.) for all constructs. Error bars show the standard error 
of the mean, n = 4 across all experiments, data collected with Dr Janet Saunders. 
 
Strikingly, the in vivo assay was able to distinguish the aggregation propensity of the different 
constructs. Furthermore, this demonstrates the use of the in vivo assay for the characterisation 
of biopharmaceutical candidates which share an incredible sequence homology, yet have 
significantly different aggregation profiles. 
The results of the assay show that tryptophan 30 has the largest effect on in vivo growth. 
Figure 6.5a highlights this with a significant increase in cell growth being observed only upon 
mutating W30 to S30. This result is reflected in Figure 6.5b where a significant decrease in 
cell growth is observed in mutants only containing tryptophan at position 30 (orange and 
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blue). This result was confirmed upon analysis of the full data, where mutations of WFL at 
positions 31 (F31T, WTL – purple) and 57 (L57T, WFT – green) have no significant effect on 
cell growth (Figure 6.5d). While position 30 plays the most significant role in self-association, 
the double mutations indicate that F31 also plays a role in the self-association to a larger 
degree than L57 (Figure 6.5b+d). However, it is clear that all three mutations are needed to 
fully ameliorate the self-association of WFL.  
In order to confirm that the results obtained in the MIC assay were due to protein self-
association and aggregation, western blots were carried out on all of the constructs to ensure 
that the expression levels of the proteins were the same (Figure 6.6).  
 
Figure 6.6: In vivo results are a result of protein aggregation and not a difference in expression 
levels. (a) Bar chart showing the area under the curves for all constructs. n = 4 (b) Western 
blots for the un-induced (UI) and induced (I) constructs. The whole (W) and soluble (S) 
fractions are shown for each construct. The arrows indicate the full βla-scFv constructs. An 
anti-β-lactamase antibody (CSB-PA352353YA0IENL) was used for blotting. Western blots 
were carried out by Dr Janet Saunders and Dr Matthew Jackson (University of Leeds).  
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Western blot analysis revealed that the total expression levels of the proteins was similar and 
therefore the results observed are due to the self-association and aggregation of the different 
constructs; rather than differences in expression levels. Furthermore, it can be observed that 
the amount of protein found in the soluble fraction of the cells correlates well with the in 
vivo growth observed, hence the less aggregation prone the sequence, the more protein is 
found in the soluble fraction of the cells.  
 
6.3.2 Analysing the structural effects of the different point mutations 
Homology models were built from the WFL_scFv structure (supplied by MedImmune plc) to 
analyse the effects of the different mutations on the surface properties of the scFv.  The 
hydrophobic surfaces of the different mutants were analysed to interrogate how these patches 
may aid in the self-association (Figure 6.7).  
 
Figure 6.7: ScFv Homology models of the (a) WFL, (b) WTL, (c) WFT, (d) WTT, (e) SFL, (f) 
SFT, (g) STL and (h) STT.  Residues 30, 31 and 57 are shown as sticks. Pink surface = 
hydrophobic areas, blue surface = rest of protein. 
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The mutations from WFL > STT reduce the area of the exposed hydrophobic patch and once 
again reveal how W30, F31 and L57 are aiding the self-association that was mapped in Chapter 
5. Interestingly, the results from the MIC assay show that there is a substantial effect on cell 
growth upon mutation of W30S. However, a large proportion of the hydrophobic patch 
remains present in this construct. The structure of the SFL (W30S) mutant was investigated 
in further detail to observe the effects this mutation had on the proteins surface (Figure 6.8). 
 
Figure 6.8: Structural differences between (a) WFL and (b) SFL as a result of mutation at 
position 30 (W30S). Circle = mutated tryptophan at position 30 between the two constructs. 
 
Closer analysis of the SFL mutant revealed the removal of an important surface-exposed 
tryptophan residue that plays a strong role in the self-association of WFL, as also shown in 
Chapter 5. The results from the in vivo assay highlight how important this residue is in 
mediating the interaction between WFL monomers, with around 50 % of cell growth being 
recovered by this mutation alone (when compared with STT (Figure 6.5)).  
While it is clear that individual mutations have a significant effect on restoring cell growth 
in vivo, it was important to test whether aggregation in the tripartite β-lactamase system 
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results from the same mechanism of self-association as observed for the full IgGs in vitro. 
Therefore it was decided to sub-clone the scFvs out of the β-lactamase construct, so that the 
individual scFvs could be purified and their aggregation propensities characterises in vitro. As 
WFL and STT had been fully characterised as mAbs, these two sequences along with SFL 
(W30S) were selected for characterisation, since SFL has significant effects on cell growth in 
vivo this construct was of particular interest to analyse whether it aggregates in a similar 
manner to that of WFL.  
 
6.4 In vitro characterisation reveals WFL_scFv self-associate through 
the same mechanism as IgG 
6.4.1 Purification of WFL_scFv and STT_scFv 
As WFL performed the poorest in the in vivo assay, protein preparation and purification 
procedures were established and optimised on this construct along with STT_scFv. It was 
anticipated that all other constructs could be expressed and purified using the same procedure 
that was optimised on WFL_scFv.  
 
6.4.1.1 Cloning and protein expression trials 
The results presented thus far indicate WFL aggregates both in vitro as an IgG and in vivo as 
a scFv. One key question regarding the observed aggregation was whether the mechanism of 
self-association and aggregation the same for the IgG and the equivalent scFv. To explore this, 
both WFL_scFv and STT_scFv were expressed and purified to enable characterisation of their 
self-association in vitro. Restriction digests of WFL_scFv and STT_scFv were used to sub-
clone the scFvs out of the β-lactamase construct and a hexa-histag was added to the C-
terminus of the scFvs to aid in purification (Figure 6.9) (see Section 3.5.2.1). 
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Figure 6.9: Results from PCR amplification. (a) Agarose gel showing the amplification of WFL 
and STT scFv sequences from the scFv-β-lactamase containing plasmid. C = control with no 
Mg2+ (b) Agarose gel showing the results of the double cut vector and the purified DNA 
sequences from PCR amplification. UC = uncut plasmid, DC = double cut. i = 1 kbp DNA 
ladder and ii = 100 bp DNA ladder. 
 
WFL_scFv and STT_scFv DNA was amplified and ligated into a pET23a vector to be 
transformed into E. coli cells for expression and purification. As WFL has a strong propensity 
to aggregate, the pLemo cell line was chosen to express the two single-chain proteins. As less 
expression can often yield higher protein yields of difficult to express proteins (Rosano and 
Ceccarelli, 2014), the expression of the scFv containing plasmid can be controlled through the 
expression of lysozyme; under a separate and tuneable promoter, using L-rhamnose. This also 
aids the amount of protein found in the soluble fraction of the cells and is therefore attractive 
for purification.  
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The pET23a plasmids encoding WFL_scFv and STT_scFv (pET23a-WFL and pET23a-STT, see 
Appendix 8.1+8.22) were transformed into pLemo E. coli cells and plated out onto agar plates 
containing 100 µg/mL ampicillin and 30 µg/mL chloramphenicol (see Section 3.5.4). Single 
colonies from the plates were used to inoculate separate 10 mL of LB media containing 100 
µg/mL ampicillin and 30 µg/mL chloramphenicol and grown for 18 h overnight, after which 
200 µL of each were used to inoculate 7×10 mL LB media containing 0-2000 µM L-rhamnose 
containing 100 µg/mL ampicillin and 30 µg/mL chloramphenicol. Cultures were grown at 37 
°C, 200 rpm until an OD600 of 0.6 was reached, where 2×1 mL aliquots were taken for the 
analysis of expression levels in the un-induced samples. Protein expression was induced with 
a final concentration of 400 µM IPTG and the bacteria grown for a further 4 h where a further 
2×1 mL aliquots were taken for analysis of expression levels in the induced samples. All 
samples were corrected to the OD600 of the uninduced samples prior to the samples being 
pelleted by centrifugation. One set of the aliquots were then re-solubilised in 2× SDS-loading 
buffer (see Section 3.5.5) and then analysed via SDS-PAGE (see Section 3.4.8) to monitor 
whole cell protein expression (Figure 6.10). 
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Figure 6.10: SDS-PAGE gel showing the tuneable expression of scFv constructs. (a) SDS-PAGE 
results of WFL_scFv whole cell expression across an increasing L-rhamnose concentration. 
(b) SDS-PAGE results of STT_scFv whole cell expression across an increasing L-rhamnose 
concentration. UI = uninduced samples, L = protein marker. Coomassie staining. 
 
As the scFvs were to be purified from the soluble fractions, it was important to identify the 
L-rhamnose concentration at which the largest proportion of the scFvs remained soluble. The 
pelleted aliquots were used to analyse the amount of protein in the soluble fractions. The 
pellets were lysed to separate the soluble and insoluble fractions (see Section 3.5.6) and 
separated by centrifugation. The soluble fraction was collected and the protein concentrated 
by acetone precipitation (see Section 3.5.6) and centrifugation. The insoluble and soluble 
Developing an in vivo Screen to Identify Aggregation Prone Sequences in Biopharmaceuticals 
191 
fractions were then re-solubilised in equivalent volumes of 2× SDS-loading buffer and 
analysed via SDS-PAGE (Figure 6.11). 
 
Figure 6.11: SDS-PAGE results showing the amount of protein found in the soluble and 
insoluble fractions. (a) SDS-PAGE showing the amount of STT_scFv found in the soluble (top) 
and insoluble (bottom) fractions of lysed cells across increasing L-rhamnose concentrations. 
(b) SDS-PAGE showing the amount of WFL_scFv found in the soluble (top) and insoluble 
(bottom) fractions of lysed cells across increasing L-rhamnose concentrations. UI= uninduced 
sample, L = protein marker. Coomassie staining.  
 
As suggested from the western blot analysis of the constructs expression (Figure 6.6), more of 
the STT_scFv protein is found in the soluble fraction compared with WFL_scFv. Analysis of 
the soluble and insoluble fractions revealed that the greatest amount of soluble WFL_scFv 
was found at an L-rhamnose concentration of ≥ 750 µM, while the 100-500 µM L-rhamnose 
concentration yielded the largest amount of soluble STT_scFv. L-rhamnose concentrations of 
1000 µM and 500 µM for WFL_scFv and STT_scFv were therefore used for subsequent protein 
preparations.   
Once growth conditions had been optimised for maximal protein yields in the soluble 
fraction, the preparations were scaled up to produce enough scFv proteins for in vitro 
characterisation. 
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6.4.1.2 scFv purification 
The WFL, STT and SFL scFvs were expressed as described in Section 6.4.1.1 and purified by 
nickel affinity chromatography. Briefly, single colonies of pLemo competent cells 
transformed with either pET23a-WFL, pET23a-STT or pET23a-SFL plasmids were used to 
inoculate 200 mL of LB containing 100 µg/mL ampicillin and 30 µg/mL chloramphenicol in 
500 mL flasks. These cultures were incubated for 18 h at 37 °C before 10 mL was used to 
inoculate each of ten 1 L of 2×TY media (see Table 3.3, Section 3.5.7) in 2 L flasks, containing 
100 µg/mL ampicillin, 30 µg/mL chloramphenicol and either 1000 µM, 500 µM or 750 µM L-
rhamnose for the respective constructs (WFL, STT and SFL). The cultures were incubated at 
37 °C until the cells reached an OD600 of 0.6 (typically 4 h). ScFv protein expression was then 
induced by the addition of 400 µM IPTG. The cultures were grown for a further 4 h before 
harvesting. The cells were lysed, as described in Section 3.5.8, and the soluble and insoluble 
fractions separated. The soluble fractions from each of the cultures was taken forward for 
purification.  
To purify the scFv proteins from the other solubly expressed host proteins, the whole fraction 
was loaded onto a HisTrap column for purification via nickel affinity chromatography. The 
column was washed with binding buffer (see Table 3.8, Section 3.5.8) and the soluble fraction 
was loaded onto the column before elution with a stepwise gradient of elution buffer (see 
Table 3.8, Section 3.5.8) (Figure 6.12-6.13). 2.5 mL fractions were collected throughout the 
elution and those containing the scFv proteins were identified via SDS-PAGE. The fractions 
corresponding to the scFv protein of interest were pooled together before being concentrated 
and subsequently dialysed against storage buffer (see Table 3.8, Section 3.5.8). The dialysed 
protein aliquoted into 1 mL samples, snap-frozen in liquid nitrogen and stored at -80 °C. 
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Figure 6.12: Purification of WFL_scFv. (a) Elution profile of WFL_scFv from the nickel 
affinity column. Blue = elution trace recorded at 280 nm, green = trace showing the increasing 
increments of buffer B. (b) SDS-PAGE gel of selected fractions from WFL_scFv elution. L = 
protein marker. Coomassie staining. 
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Figure 6.13: Purification of STT_scFv. (a) Elution profile of STT_scFv from the nickel affinity 
column. Blue = elution trace recorded at 280 nm, green = trace showing the increasing 
increments of buffer B. (b) SDS-PAGE gel of selected fractions from STT_scFv elution. L = 
protein marker. Coomassie staining.  
 
The purified proteins were examined by mass spectrometry to confirm the purity of the 
samples. Samples of WFL_scFv and STT_scFv were dialysed against 150 mM ammonium 
acetate, pH 6 before being infused directly into the mass spectrometer for ESI-MS analysis 
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(Figure 6.14).
 
Figure 6.14: Mass spectra of the purified scFvs (a) WFL_scFv and (b) STT_scFv. Representative 
spectra of n = 2. 
 
Mass spectrometry analysis confirmed the protein identity with measured mass of the 
WFL_scFv (27,755.93 Da) and STT_scFv (27671.58 Da) proteins agreeing well with the 
expected masses (27,754.8 Da and 27,670.6 Da, respectively).   
As methods had been established for the large scale expression and purification of scFv 
constructs, the SFL_scFv (W30S) protein was expressed and purified so that a comparative 
analysis could be carried out across the scFv construct (Appendix 8.4). As expected from the 
in vivo results, STT_scFv yielded the most protein while WFL_scFv yielded the least (Table 
6.2). 
Table 6.2: Table of scFv constructs expressed and purified 
Construct Yield (mg/L) 
WFL_scFv ~ 0.3  
SFL_scFv ~ 0.5 
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STT_scFv ~ 2 
6.4.2 In vitro analysis of scFv constructs 
6.4.2.1 Polyethylene glycol precipitation 
To assess the aggregation potential of the different scFvs in vitro, a polyethylene glycol (PEG) 
precipitation experiment was set up. PEG has been shown to cause proteins to precipitate 
from solution by acting as a water scavenger and increasing the apparent concentration of 
protein in the sample (Atha and Ingham, 1981, Vasquez-Rey and Lang, 2011, Hammerschmidt 
et al., 2015, Gagnon, 2008). The experiment was also chosen as MedImmune had acquired 
PEG precipitation data on the full length IgGs of WFL and STT (Figure 6.15a). Samples of 
WFL_scFv, SFL_scFv and STT_scFv were added to buffer with increasing amounts of PEG-
8000 (average molecular weight = 8000) and the amount of protein aggregation was 
determined using nephelometry (see Section 3.4.10) (Figure 6.15).  
 
Figure 6.15: PEG precipitation assay showing WFL precipitates out of solution earlier than 
STT as both IgG and scFvs. (a) PEG precipitation results of WFL (blue) and STT (Purple) as 
full IgGs. Data collected by MedImmune. (b) PEG precipitation assay results of WFL (blue), 
SFL (orange) and STT (purple) as scFvs. IgG data = 6.74 µM, scFv data = 15 µM. n = 3. 
 
The trend between the two precipitation experiments correlates well. It is not unexpected 
that the IgG samples require a lower percentage of PEG to precipitate since it has been 
demonstrated that larger proteins experience a greater effect from the PEG in this assay 
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(Ingham, 1977, Atha and Ingham, 1981). However, in all cases, proteins with the WFL 
sequence precipitate out of solution at significantly lower PEG concentrations than STT. 
Importantly, SFL_scFv requires a concentration of PEG-8000 intermediate to that required 
for WFL and STT (~13 % (w/v)) to precipitate out of solution; consistent with the in vivo 
assay results. 
 
6.4.2.2 Chemical cross-linking of scFvs 
As chemical cross-linking of the full length IgGs of WFL and STT resulted in identification 
of the site responsible for self-association, the technique was once again employed to 
characterise the self-association of the scFv proteins.  
The three scFvs (WFL, SFL and STT) were dialysed into 100 mM sodium phosphate buffer, 
pH 7.4. As cross-linking of the IgGs was carried out at 6.74 µM and there are two scFvs per 
full IgG, the scFv samples were diluted to a concentration of 15 µM for the chemical cross-
linking experiments (see Section 3.4.5). WFL_scFv, SFL_scFv and STT_scFv were cross-linked 
with increasing amounts of the 50:50 mixture of the non-deuterated (d0) and deuterated (d4) 
BS3 cross-linker and the reaction performed on ice for 30 min. The reactions were quenched 
with Tris.HCl, pH 8 at a final concentration of 50 mM and the results analysed via SDS-PAGE 
(see Section 3.4.8) (Figure 6.16) 
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Figure 6.16: SDS-PAGE gel showing scFvs cross-link in a similar manner as full length IgGs 
across increasing cross-linker concentrations. L = Protein marker and dotted line = merging 
point of two separate gels. Coomassie staining. Representative gel of n = 3. 
 
As observed for the full IgGs (See Figure 5.6), WFL_scFv forms oligomeric species, when 
cross-linked with BS3, while STT_scFv only forms a small amount of dimer across all cross-
linker concentrations tested. Consistent with the PEG precipitation results, the data here are 
once again in accord with the in vivo assay results, where the extent of SFL_scFv self-
association is intermediate between that of WFL and STT in that a significantly larger amount 
of dimer is present, compared with STT_scFv. The monomer and dimer bands, at 50× and 
200× cross-linker, were excised from the gel and an in-gel digestion of the samples carried out 
(see Section 3.4.9). 
The digested cross-linked material was purified and injected into the Waters G2Si mass 
spectrometer for LC-MS/MS analysis. As low abundance peptides were once again being 
searched for, the threshold for peptide to be selected for sequencing was lowered and the 
number of peptides sequenced in any one scan was increased to six. Comparative analysis of 
the resulting mass spectra revealed that the same cross-link which was found in the IgG data 
(Figure 6.17-6.18) was identified in WFL_scFv. Furthermore, a new cross-link between the 
N-termini of the two heavy chains was identified in the WFL and SFL samples (Figure 6.19-
6.20). 
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The results from the chemical cross-linking experiment show that the same cross-linked 
peptide that was identified in the full IgGs was also identified in the scFv construct of WFL 
(Figure 6.17-6.18). This peptide was unique to WFL_scFv and indicates that the mechanism 
of self-association is the same irrespective of the format: either IgG or scFv. However, it is 
clear from the cross-linking gel (Figure 6.16) that SFL (W30S) forms a dimeric species that 
should be observed in the cross-linking analysis. A separate set of cross-linked peptides was 
identified for both WFL and SFL (W30S) that was only present in the spectra corresponding 
to the digested dimer bands and was also absent in either the STT monomer or dimer spectra 
(Figure 6.19-6.20).  
An interesting question that this raised was why was this cross-link not identified in the full 
IgG data? While it could be possible that the mechanism of self-association had changed, 
which would explain why it was not observed, it was hypothesized that it was more likely 
due to the differences in the amino acid sequences of the two constructs. As these proteins 
had been expressed in E. coli, there was an additional methionine residue on the N-terminal 
of the scFv and therefore this cross-link may have been identified as the two N-termini were 
brought into closer proximity. However, as mentioned previously, the N-terminal glutamine 
residue in the full IgG undergoes conversion to a pyroglutamate residue (see Section 5.5); 
which is not possible in the scFvs as the N-terminal glutamine has been replaced with 
methionine. Therefore, another possible explanation as to why this cross-link was not 
identified in the IgGs is because it requires two Fab regions to dimerise that both have the 
non-pyroglutamate at position one, which has a low probabilistic chance.  
In summary, while the unique cross-link identified for WFL_scFv was in agreement with the 
full length IgG data and suggests that the mechanism of aggregation of the IgG and the scFv 
is the same, it was essential to understand whether the second cross-link, between the two N-
termini, agrees with the previous model generated in Chapter 5 or whether a new interface 
was being identified.  
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6.4.3 Modelling the self-association of scFvs 
To understand the mechanism of self-association between the scFvs, the same docking 
procedure (see Section 3.3.5 and Section 5.6) was utilised.  
Residues W30, F31 and L57 were used to drive the docking procedure while setting 11.4 Å 
distance restraints between the same cross-linked atoms as previously established from the 
IgG data i.e. the N-terminal glutamine of the heavy chain to lysine 54 (K54) of the light chain, 
as well as the newly identified cross-link; N-terminal methionine to N-terminal methionine. 
The structure with the lowest energy across the entire molecule is shown in Figure 6.21. 
 
Figure 6.21: Structure of the WFL_scFv docked dimer.  (a) Front view showing that all 
identified cross-linkable sites are within 11.4 Å and (b) back view showing the dimer 
interface. Inset = residues 30, 31 and 57 used to drive the docking procedure. Residues W30, 
F31 and L57 are shown as red sticks.  
 
The modelled structure showed that it is possible for either cross-link to exist while 
maintaining a hydrophobic dimer interface. This structure has altered from the original model 
with the two leucine residues involved in the dimer interface (Figure 6.21b, red sticks) being 
located further away from the interaction site. However, this agrees with the in vivo data 
where the mutation of this leucine to threonine (L57 > T57) does not have any effect on E. coli 
cell growth (Figure 6.5). 
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One question that needed to be addressed was why were higher order oligomers (up to and 
including tetramer) observed for the scFv, when the previous model based on full IgGs would 
suggest only dimers would be possible? While there was a second available binding site on 
the IgG’s Fab arm for oligomer extension, this model suggests that it would be difficult for 
higher order oligomers to form from scFvs. To investigate this, the hydrophobic surface of the 
dimer model was analysed to interrogate if there were any hydrophobic patches where other 
scFvs may potentially bind (Figure 6.22). 
 
Figure 6.22: Surface representation of the docked dimer structure. The dimer interactions 
exposes a large hydrophobic region (pink) on the side of the docked structure. Labelled 
residues (orange) represent identified cross-linked residues. The two WFL monomers are 
represented as the teal and blue surfaces. 
 
The interaction that leads to dimer formation results in a large hydrophobic patch being 
exposed near the dimer interface. This yields insight into how larger oligomeric species may 
arise and result in the loss of functional β-lactamase in the in vivo assay. 
 
6.5 Comparing the aggregation of scFvs and IgGs 
Finally, while the mechanism of aggregation between scFv and IgG has been shown to be the 
same across the two formats, it was of interest to understand how the in vivo data compared 
with aggregation of the mutated constructs as IgGs in vitro. For this, the results obtained from 
the β-lactamase in vivo assay were compared with retention time data from size-exclusion 
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chromatography (SEC), acquired by MedImmune plc, for the eight mutants as IgGs (Figure 
6.23). 
 
Figure 6.23: Comparison of in vivo scFv data and in vitro IgG data. The in vivo growth data = 
box plots, IgG retention times = circles.  
 
A remarkable correlation can immediately be seen between the in vivo and in vitro data. 
Therefore, as well as the mechanism of self-association being conserved across scFv and IgG 
constructs analysed here, the data highlights that the β-lactamase in vivo assay can identify 
exactly the same aggregation prone sequences identified for the full IgGs in vitro.  
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6.6 Discussion 
Early identification of aggregation-prone hotspots on the surface of proteins is required either 
in order to engineer these out in the context of potential therapeutics (Ratanji et al., 2014, 
Agrawal et al., 2011, Kayser et al., 2012), or to develop inhibitors of aggregation in the case of 
disease-relevant proteins (Weiss et al., 2008, Dickey et al., 2005, Ross and Poirier, 2004, David 
and Tayebi, 2014). This identification can often be difficult due to aggregation-prone 
sequences being buried or partially buried in a proteins structure and hence local or global 
unfolding may be required for aggregation to ensue. Furthermore, in terms of biotherapeutic 
development, significant economic cost may be spent during the development of a project 
before the aggregation propensity of a system is recognised, and any aggregates that do form 
may evoke an immunogenic response (Zurdo et al., 2011, Zurdo, 2013, Obrezanova et al., 
2015). Therefore, there is a requirement for assays and screens that are able to identify 
aggregation prone sequences/regions as early as possible in the production pipeline. 
Rational design has been favoured historically to remove unwanted self-association (Courtois 
et al., 2016, Camilloni et al., 2016, Geoghegan et al., 2016). However, introducing a stretch of 
mutations, or even a single point mutation, can have significant detrimental effects on a 
protein’s stability, as well as having potential adverse effects on its ability to fold. The β-
lactamase assay described in this Chapter was focused on addressing this question at the scFv 
level. As this is an in vivo, cell survivability assay, accurate protein folding as well as the 
ability to remain soluble is required for full β-lactamase function. Therefore, any adverse 
effects brought on by mutation would potentially be identifiable.  
As the β-lactamase assay had been successfully applied previously to both amyloidogenic 
proteins as well as single-domain antibodies (dAbs) (Saunders et al., 2016), it was 
hypothesized that the assay would also readily identify aggregation-prone sequences in scFvs 
and hence could be used as a screen for proteins with robust bioprocess capability. However, 
concerns were raised about relating the aggregation of scFvs to the aggregation of full length 
IgGs, as they lack the stability of IgGs and hydrophobic hydrophobic surfaces between the 
two variable regions can be exposed, often leading to engineering being required to form 
stable scFv fragments (Glockshuber et al., 1990, Worn and Pluckthun, 2001, Miller et al., 
2010). However, the results presented in this Chapter from the in vivo β-lactamase system 
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beautifully follow the aggregation properties observed from the PEG precipitation and cross-
linking results in vitro; as well correlating incredibly well with the full IgG data obtained by 
MedImmune plc. Finally, investigation of the self-association via chemical cross-linking 
analysis confirms that the mechanism of aggregation is conserved across the two formats, IgG 
and scFv, with only small changes being made to the original model upon the identification 
of an additional cross-link site.  
The data presented here open up the exciting avenue for the β-lactamase assay to be used to 
pan for aggregation prone sequences early during biotherapeutic development. As candidate 
sequences are often screened against the target antigen using antibody fragments, such as 
scFvs or Fabs, the aggregation propensity of lead sequences could be evaluated before 
converting to full IgG format (Figure 6.24). 
 
Figure 6.24: Schematic of therapeutic candidate selection, isolation and optimisation. The 
point in the developmental process at which the β-lactamase in vivo assay could be 
incorporated is shown. 
 
Whereas screening IgGs for self-association requires in vitro analysis, typically SEC post 
expression and purification (Hong et al., 2012, Paul and Schwab, 2014, Steve and Chakrabarti, 
2013), the β-lactamase in vivo screen allows for the same characterisation in a two-day assay 
that can be performed prior to IgG expression and purification. In summary, whilst reducing 
the need to screen for self-association and aggregation at the IgG level, the β-lactamase assay 
developed here allows for rapid identification of aggregation-prone sequences that can be 
removed from the industrial pipeline before creation of IgGs for further development.   
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Successful integration and accurate characterisation of scFvs by the β-lactamase assay could 
be used in other ways to facilitate biopharmaceutical development. Candidate sequences 
could be evolved and improved through random mutagenesis and screened at increasing 
ampicillin concentrations in order to select the least aggregation prone sequences. The model 
system presented in this work, WFL and STT, would be ideal for such a study. By performing 
random mutagenesis on the WFL sequence and carrying out an in vivo assay at antibiotic 
concentrations where the STT-β-lactamase construct permits cell growth but WFL does not, 
aggregation hotspots could be evolved out of the sequence. Ultimately, this would save time 
by removing the requirement for structural characterisation and analysis in order to 
determine the residues responsible for self-association and their removal through rational 
design. However, while selecting for monomer stability via random mutagenesis, there is 
potential for affinity to be lost by mutations affecting the binding site for the antigen. 
Therefore, careful sequencing analysis would be required in order to retain affinity while 
driving the propensity of a sequence to self-associate to a minimum. 
To conclude, the in vivo β-lactamase system applied here was able to successfully disentangle 
aggregation prone mutants in therapeutically relevant scFvs sequences. This opens an exciting 
new avenue for the in vivo assay to be used in assessing the aggregation propensity of 
candidate sequences upstream in the developmental pipeline; thus eliminating the 
requirement for large scale IgG expression and purification of multiple variants. 
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7 Concluding remarks and future directions 
7.1 Successes and limitations 
Uncontrolled protein self-association and aggregation has implications in more than 50 
known human diseases (Sipe et al., 2012), including Alzheimer’s, Parkinson’s and type II 
diabetes; with an ageing population in today’s world, this has enormous social and economic 
burdens (Boyle et al., 2010). Furthermore, the underlying potential for any protein to self-
associate is a major issue that negatively impacts the biopharmaceutical sector and its ability 
to develop new products to target disease (Frokjaer and Otzen, 2005, Gómez de la Cuesta et 
al., 2014, Zurdo et al., 2011). The capacity for oligomeric species to form various structures 
and morphologies, which can be large or small and soluble in nature (Fink, 1998), make their 
identification and furthermore, their characterisation, challenging. Hence, to alleviate even a 
fraction of these burdens, there is a critical need for the development of techniques that can 
not only characterise oligomeric species upon their formation, but to identify these species as 
early as possible in the design and development of proteins as biologics.  
In the search for techniques that can identify and characterise oligomeric forms of a candidate 
protein, the demand is for a technique that has high sensitivity, requires low sample volumes 
and concentrations and finally, can shed light on the structure or morphology of any 
oligomeric species present in a complex mixture of species. Native mass spectrometry is 
equipped to answer all of these issues. With incredible sensitivity, mass spectrometry can 
detect small amounts of oligomeric material in heterogeneous mixtures, while requiring only 
microlitre volumes at micromolar concentrations. Additionally, with the coupling of IMS and 
MS, insights into the shape and conformation of each individual species can be established 
(Pinkse et al., 2003, Uetrecht et al., 2011b, Illes-toth et al., 2015), revealing insights into the 
mode of self-association. These approaches been applied successfully in various studies 
monitoring the assembly of protein complexes (Uetrecht et al., 2010, Zhong et al., 2012, 
Lanucara et al., 2014). While a logical approach to prevent aggregation is to target the protein 
at the monomer level, by either stabilising the monomeric form or eliminating aggregation-
prone sequences, this is often not possible for multiple reasons. The first of these is the 
difficulty in identifying aggregation-prone sequences in a candidate protein. Prediction 
algorithms have been developed with some success (Wang et al., 2009, Chennamsetty et al., 
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2009a, Chennamsetty et al., 2009b). However, these algorithms are often not robust enough 
to rule out aggregation due to the complex nature of aberrant protein self-assembly. 
Orthogonal techniques are thus required to validate the predictions. Secondly, in order to 
predict the regions responsible for aggregation, information about the protein’s structure in 
the aggregation-prone state is required. This is not always possible, especially when working 
with intrinsically disordered proteins or where the aggregation-prone species is rare or in 
dynamic equilibrium with multiple species 
In the attempt to aid the biopharmaceutical industry and product development, the work in 
this thesis set out to identify and characterise a therapeutic mAb (WFL), with a strong 
tendency to self-associate, which was raised against nerve growth factor. A combination of 
mass spectrometric techniques were used to identify of the oligomeric species formed, and to 
determine the underlying mechanism self-association of WFL. Finally, an in vivo screen was 
developed and used to identify aggregation-prone sequences. In Chapter 4, native MS and 
IMS-MS were employed to visualise the oligomeric species of WFL, using their estimated 
CCSs to postulate models of its potential mode of self-association. Experimentally derived CCS 
values are commonly used to validate theoretical models, by comparison of measured and 
predicted CCS values and their agreement with one another. Strikingly, upon comparing the 
monomeric CCS of WFL to a predicted value from the crystal structure (1IGY), a 32 % 
decrease from the predicted value was observed. Taking the accepted error (3-5 %) of the 
IMS-MS measurements (Ruotolo et al., 2008, Smith et al., 2009), the measured value was 
clearly inconsistent with the crystal structure. However, this value was in agreement with 
previously published data of the CCSs of other IgGs (Debaene et al., 2014, Pacholarz et al., 
2014), suggesting that the structure compacts, or collapses, upon transition to the gas phase. 
To explore this observation, in vacuo molecular dynamics simulations were carried out to 
visualise this compaction. At a similar time, the Barran group published their findings on 
other mAbs also showing this gas-phase collapse of IgGs (Pacholarz et al., 2014), and 
concluded that the hinge region appears to be the major player in this collapse. As there are 
relatively few studies reporting the gas-phase collapse of proteins, the gas-phase behaviour of 
three other proteins, two which share flexible hinge-like regions, were examined.  
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So how are proteins behaving in the gas-phase? The results presented in this thesis reveal that 
a number of proteins do collapse in the gas-phase, whether there are flexible linker regions 
between the domains or not, as exemplified in the case of SasG. Yet what drives this collapse? 
The structural re-arrangement of proteins in the gas-phase has been discussed, with a mention 
of side chain collapse within a picosecond timescale upon transition into the gas-phase 
(Counterman and Clemmer, 1999, Breuker and McLafferty, 2008). So perhaps the extent of 
collapse observed for IgGs and SasG is an extrapolation of these same effects. While it is 
unclear which forces that are causing this collapse in the gas-phase, the absence of water leads 
to the loss of hydrophobic interactions and an increase in electrostatic interactions. Therefore, 
it is possible that there are weak underlying interactions that become dominant in the gas-
phase, leading to the observed collapse. Furthermore, the proteins selected for study in 
Chapter 4 were chosen based on their unusual structures: the majority of IMS-MS and CCS 
work in the literature has been carried out globular proteins, for which the majority of these 
globular proteins yield CCS values in agreement with the predicted values. So why is collapse 
observed for only a small set of proteins? Perhaps all proteins collapse in the gas-phase to 
some extent, as shown for the side chain collapse of the globular protein cytochrome c 
(Steinberg et al., 2008). However, with globular proteins already being compact structures, 
there is little room for further collapse of the tertiary and quaternary structure. By contrast, 
elongated structures with flexible hinge regions have the additional space for collapse to 
occur, as highlighted with the work this thesis. It is clear that the structure of proteins and 
their behaviour in the gas-phase has become an area of interest within the field in recent years 
(Ruotolo et al., 2005, Hogan et al., 2011, Mehmood et al., 2014, Pacholarz et al., 2014). The 
discovery that many proteins may collapse to some extent, whether that be a local or global 
collapse, leads to the particular interest in the pursuit of measuring the CCSs of various other 
elongated structures, in an attempt to obtain a greater understanding of the conformations 
that proteins can adopt upon the transition from solution to the gas-phase. 
The discovery that mAbs collapse in the gas-phase ruled out the use of IMS-MS to identify 
the mode of self-association of WFL. Therefore, chemical cross-linking was employed in 
Chapter 5 as an alternative technique to identify the mechanism of WFL’s aggregation. By 
cross-linking the WFL oligomers and identification of the interacting regions using LC-
MS/MS, a model explaining the mechanism of self-association was generated. As mentioned 
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in Chapter 1, the use of structural technique prior to MS, such as FPOP (Yan et al., 2014b), 
HDX (both solution and gas-phase (Pirrone et al., 2015, Beeston et al., 2015)), protein painting 
(Luchini et al., 2014), chemical labelling (Borotto et al., 2015) and chemical cross-linking 
(Chen et al., 2010) can be used in the search for high resolution structural data, especially 
when techniques such as NMR and X-ray crystallography are not possible. For general protein 
analysis as well as protein therapeutics, it is essential to have techniques at the researcher’s 
disposal to enable identification of self-association interfaces as well as the mechanisms that 
drive aggregation. With a greater understanding of the mechanisms and forces that cause 
uncontrolled self-association, therapeutic candidates will be able to be developed with 
enhanced protection against aggregation, ultimately aiding their potential to enter clinical 
trials and hopefully the therapeutic market, where these candidate drugs are urgently needed.  
The ability to characterise protein aggregates in high resolution is of primary importance once 
they are detected. One of the most logical approaches would be to establish a technique which 
can identify aggregation-prone sequences before they are selected for protein expression and 
production. Chapter 6 set out to address this by the development of an in vivo β-lactamase 
tripartite system that has previously been used to identify inhibitors of the aggregation of 
amyloid systems (Saunders et al., 2016). The ability of the assay to identify aggregation prone 
sequences in scFvs was examined, with the in vivo results obtained correlating remarkably 
with previous in vitro data obtained on the full length IgG variants. Prior to expression and 
purification of the intact, evolved IgG, the aggregation propensity of the WFL sequence 
previously remained hidden. Furthermore, there is still unexplored potential for the in vivo 
β-lactamase system and its use within the pharmaceutical sector. The assay could be used for 
the directed evolution of candidate sequences and the identification or removal of 
aggregation-prone hot-spots. Thus, the results presented in Chapter 6 have enormous 
implications in industry for screening for soluble biopharmaceutical sequences. This would 
impact both the time and cost that are currently invested into minimising aggregation-prone 
sequences for the development of promising biologics. 
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7.2 The protein aggregation predicament 
As mentioned previously, protein aggregation is responsible for a plethora of life-threatening 
diseases, many of which are closely correlated with old age. With our life expectancy 
increasing year by year (Reynaud, 2010), protein aggregation is set to become an increasing 
problem. This therefore begs the question: 
How can unwanted and uncontrolled protein self-association and aggregation be 
circumvented? 
This intellectual question plagues all protein scientists. From a PhD project level, the aim will 
be to understand the mechanisms of aggregation, all the way through to protein therapeutic 
development and manufacturing, targeting the diseases that these aggregation events cause. 
The great challenge in controlling aggregation lies ultimately in obtaining a better 
understanding of the mechanisms that underpin aberrant protein self-assembly. With such 
knowledge, therapies targeting aggregation based protein diseases could be developed, as well 
as the design of aggregation resistant biotherapeutics, aiding the path to market. 
The work detailed within this thesis presents the mechanism in which a therapeutic mAb, 
targeting NGF, self-associates. However, is this enough to understand protein aggregation as 
a whole? No, probably not. Nevertheless, to aid in the identification of aggregation-prone 
sequences and the development of future algorithms which can accurately identify such 
sequences, information on self-associating and aggregation-prone systems, like WFL, is 
required. Without it, the tremendous leaps forward that current aggregation prediction 
software have made in the past two decades would not have been possible (Buck et al., 2012). 
Furthermore, what can be achieved in the struggle against protein aggregation is the 
development of techniques for the rapid identification of aggregation-prone sequences, as 
well as techniques which can characterise them. The in vivo β-lactamase assay described 
herein may aid in this quest, whether that is through identifying aggregation-prone sequences 
that can be studied to understand the protein aggregation problem, or through its ability to 
aid in the development of next generation biopharmaceuticals. Overall therefore, MS, and MS 
based methods, are sure to see an increased use in the development of new understandings of 
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protein aggregation and how to avoid aggregation in the development of new proteins as 
biologics. 
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8 Appendices 
8.1 DNA protein sequences of β-lactamase (βla) fusion proteins used in 
the in vivo assay and their plasmid maps 
8.1.1 βla-WFL 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTTGTGCAGA GCGGTGCGGA GGTCAAAAAA 
CCCGGCAGCT CTGTAAAAGT TAGCTGCAAA GCGAGTGGCG GTACGTTTTG GTTTGGGGCC 
TTTACTTGGG TTCGTCAAGC GCCGGGCCAG GGCTTGGAAT GGATGGGTGG CATTATCCCT 
ATTTTCGGCC TCACAAACCT GGCGCAAAAC TTTCAAGGTC GCGTTACCAT TACGGCGGAC 
GAAAGCACCA GTACCGTCTA TATGGAGCTG TCAAGCCTGC GCTCAGAAGA CACCGCAGTT 
TACTACTGTG CGCGTAGCAG CCGCATTTAC GACTTGAATC CTAGCCTCAC AGCGTACTAC 
GACATGGATG TGTGGGGGCA GGGCACCATG GTTACGGTGT CGAGTGGTGG TGGGAGCAGT 
GGTGGAGGTG GGTCCGGGGG CGGCGGCGGC GCGCAAAGCG TATTAACTCA GCCGCCGAGC 
GTGAGCGCAG CCCCTGGGCA GAAAGTCACC ATTTCATGCA GCGGCTCCTC CAGCGATATC 
GGCAACAATT ACGTGTCCTG GTATCAGCAG CTGCCTGGCA CTGCGCCGAA GCTGTTGATT 
TATGACAACA ATAAGCGTCC CTCGGGTATT CCAGATCGTT TTTCTGGCTC TAAAAGCGGG 
ACATCAGCGA CACTGGGCAT CACCGGGCTG CAGACGGGGG ATGAAGCCGA TTATTACTGC 
GGGACCTGGG ATAGTTCCCT GAGCGCGTGG GTGTTTGGCG GGGGCACCAA ACTCACCGTG 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
 
Appendix 8.1: DNA sequence of the β-lactamase WFL fusion construct. The periplasmic signal 
sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFWFGAFTW VRQAPGQGLE WMGGIIPIFG LTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.2: Protein sequence of the β-lactamase WFL fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.3: Plasmid map of pBR322-βla-WFL. Generated and kindly provided by Dr Janet 
Saunders (University of Leeds) 
  
Appendices 
220 
8.1.2 βla-SFL 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTTGTGCAGA GCGGTGCGGA GGTCAAAAAA 
CCCGGCAGCT CTGTAAAAGT TAGCTGCAAA GCGAGTGGCG GTACGTTTTC CTTTGGGGCC 
TTTACTTGGG TTCGTCAAGC GCCGGGCCAG GGCTTGGAAT GGATGGGTGG CATTATCCCT 
ATTTTCGGCC TCACAAACCT GGCGCAAAAC TTTCAAGGTC GCGTTACCAT TACGGCGGAC 
GAAAGCACCA GTACCGTCTA TATGGAGCTG TCAAGCCTGC GCTCAGAAGA CACCGCAGTT 
TACTACTGTG CGCGTAGCAG CCGCATTTAC GACTTGAATC CTAGCCTCAC AGCGTACTAC 
GACATGGATG TGTGGGGGCA GGGCACCATG GTTACGGTGT CGAGTGGTGG TGGGAGCAGT 
GGTGGAGGTG GGTCCGGGGG CGGCGGCGGC GCGCAAAGCG TATTAACTCA GCCGCCGAGC 
GTGAGCGCAG CCCCTGGGCA GAAAGTCACC ATTTCATGCA GCGGCTCCTC CAGCGATATC 
GGCAACAATT ACGTGTCCTG GTATCAGCAG CTGCCTGGCA CTGCGCCGAA GCTGTTGATT 
TATGACAACA ATAAGCGTCC CTCGGGTATT CCAGATCGTT TTTCTGGCTC TAAAAGCGGG 
ACATCAGCGA CACTGGGCAT CACCGGGCTG CAGACGGGGG ATGAAGCCGA TTATTACTGC 
GGGACCTGGG ATAGTTCCCT GAGCGCGTGG GTGTTTGGCG GGGGCACCAA ACTCACCGTG 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.4: DNA sequence of the β-lactamase SFL fusion construct. The periplasmic signal 
sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFSFGAFTW VRQAPGQGLE WMGGIIPIFG LTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.5: Protein sequence of the β-lactamase SFL fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.6: Plasmid map of pBR322-βla-SFL. 
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8.1.3 βla-WTL 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTTGTGCAGA GCGGTGCGGA GGTCAAAAAA 
CCCGGCAGCT CTGTAAAAGT TAGCTGCAAA GCGAGTGGCG GTACGTTTTG GACCGGGGCC 
TTTACTTGGG TTCGTCAAGC GCCGGGCCAG GGCTTGGAAT GGATGGGTGG CATTATCCCT 
ATTTTCGGCC TCACAAACCT GGCGCAAAAC TTTCAAGGTC GCGTTACCAT TACGGCGGAC 
GAAAGCACCA GTACCGTCTA TATGGAGCTG TCAAGCCTGC GCTCAGAAGA CACCGCAGTT 
TACTACTGTG CGCGTAGCAG CCGCATTTAC GACTTGAATC CTAGCCTCAC AGCGTACTAC 
GACATGGATG TGTGGGGGCA GGGCACCATG GTTACGGTGT CGAGTGGTGG TGGGAGCAGT 
GGTGGAGGTG GGTCCGGGGG CGGCGGCGGC GCGCAAAGCG TATTAACTCA GCCGCCGAGC 
GTGAGCGCAG CCCCTGGGCA GAAAGTCACC ATTTCATGCA GCGGCTCCTC CAGCGATATC 
GGCAACAATT ACGTGTCCTG GTATCAGCAG CTGCCTGGCA CTGCGCCGAA GCTGTTGATT 
TATGACAACA ATAAGCGTCC CTCGGGTATT CCAGATCGTT TTTCTGGCTC TAAAAGCGGG 
ACATCAGCGA CACTGGGCAT CACCGGGCTG CAGACGGGGG ATGAAGCCGA TTATTACTGC 
GGGACCTGGG ATAGTTCCCT GAGCGCGTGG GTGTTTGGCG GGGGCACCAA ACTCACCGTG 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.7: DNA sequence of the β-lactamase WTL fusion construct. The periplasmic 
signal sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFWTGAFTW VRQAPGQGLE WMGGIIPIFG LTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.8: Protein sequence of the β-lactamase WTL fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.9: Plasmid map of pBR322-βla-WTL. 
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8.1.4 βla-WFT 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTTGTGCAGA GCGGTGCGGA GGTCAAAAAA 
CCCGGCAGCT CTGTAAAAGT TAGCTGCAAA GCGAGTGGCG GTACGTTTTG GTTTGGGGCC 
TTTACTTGGG TTCGTCAAGC GCCGGGCCAG GGCTTGGAAT GGATGGGTGG CATTATCCCT 
ATTTTCGGCA CGACAAACCT GGCGCAAAAC TTTCAAGGTC GCGTTACCAT TACGGCGGAC 
GAAAGCACCA GTACCGTCTA TATGGAGCTG TCAAGCCTGC GCTCAGAAGA CACCGCAGTT 
TACTACTGTG CGCGTAGCAG CCGCATTTAC GACTTGAATC CTAGCCTCAC AGCGTACTAC 
GACATGGATG TGTGGGGGCA GGGCACCATG GTTACGGTGT CGAGTGGTGG TGGGAGCAGT 
GGTGGAGGTG GGTCCGGGGG CGGCGGCGGC GCGCAAAGCG TATTAACTCA GCCGCCGAGC 
GTGAGCGCAG CCCCTGGGCA GAAAGTCACC ATTTCATGCA GCGGCTCCTC CAGCGATATC 
GGCAACAATT ACGTGTCCTG GTATCAGCAG CTGCCTGGCA CTGCGCCGAA GCTGTTGATT 
TATGACAACA ATAAGCGTCC CTCGGGTATT CCAGATCGTT TTTCTGGCTC TAAAAGCGGG 
ACATCAGCGA CACTGGGCAT CACCGGGCTG CAGACGGGGG ATGAAGCCGA TTATTACTGC 
GGGACCTGGG ATAGTTCCCT GAGCGCGTGG GTGTTTGGCG GGGGCACCAA ACTCACCGTG 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.10: DNA sequence of the β-lactamase WFT fusion construct. The periplasmic 
signal sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFWFGAFTW VRQAPGQGLE WMGGIIPIFG TTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.11: Protein sequence of the β-lactamase WFT fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.12: Plasmid map of pBR322-βla-WTL. 
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8.1.5 βla-STL 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTGGTTCAGA GTGGCGCGGA GGTTAAGAAA 
CCGGGGTCAA GTGTTAAGGT GTCTTGCAAA GCGAGCGGCG GCACCTTCTC CACCGGAGCG 
TTTACGTGGG TGCGTCAGGC GCCGGGCCAG GGTTTGGAAT GGATGGGCGG TATCATCCCG 
ATTTTTGGGC TCACGAACCT GGCCCAAAAT TTCCAGGGGC GGGTGACGAT CACGGCAGAT 
GAGAGTACAT CGACTGTGTA TATGGAACTG TCCAGCTTGC GCAGTGAAGA CACGGCGGTG 
TATTACTGCG CCCGCTCCAG CCGGATCTAC GACTTGAACC CATCCCTGAC CGCCTATTAT 
GATATGGATG TATGGGGCCA AGGCACGATG GTGACGGTGA GCTCTGGCGG CGGGTCAAGT 
GGGGGAGGGG GTTCGGGGGG TGGTGGAGGC GCACAGTCTG TTTTAACCCA GCCCCCGAGT 
GTGAGCGCCG CACCCGGGCA GAAAGTGACA ATCTCGTGTT CGGGTAGCTC TAGCGACATC 
GGCAATAATT ATGTCAGCTG GTACCAACAG CTGCCGGGAA CTGCGCCTAA ATTGCTGATC 
TACGATAATA ACAAACGTCC GAGTGGAATC CCTGACCGCT TCTCCGGGTC AAAAAGCGGC 
ACCAGCGCCA CGTTAGGGAT TACTGGCCTG CAAACGGGGG ATGAAGCAGA CTATTATTGT 
GGCACGTGGG ATAGCAGTTT AAGTGCCTGG GTTTTTGGGG GCGGCACTAA ACTGACCGTT 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.13: DNA sequence of the β-lactamase STL fusion construct. The periplasmic signal 
sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFSTGAFTW VRQAPGQGLE WMGGIIPIFG LTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.14: Protein sequence of the β-lactamase STL fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.15: Plasmid map of pBR322-βla-STL. 
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8.1.6 βla-SFT 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTGGTTCAGA GTGGCGCGGA GGTTAAGAAA 
CCGGGGTCAA GTGTTAAGGT GTCTTGCAAA GCGAGCGGCG GCACCTTCTC CTTTGGAGCG 
TTTACGTGGG TGCGTCAGGC GCCGGGCCAG GGTTTGGAAT GGATGGGCGG TATCATCCCG 
ATTTTTGGGA CGACGAACCT GGCCCAAAAT TTCCAGGGGC GGGTGACGAT CACGGCAGAT 
GAGAGTACAT CGACTGTGTA TATGGAACTG TCCAGCTTGC GCAGTGAAGA CACGGCGGTG 
TATTACTGCG CCCGCTCCAG CCGGATCTAC GACTTGAACC CATCCCTGAC CGCCTATTAT 
GATATGGATG TATGGGGCCA AGGCACGATG GTGACGGTGA GCTCTGGCGG CGGGTCAAGT 
GGGGGAGGGG GTTCGGGGGG TGGTGGAGGC GCACAGTCTG TTTTAACCCA GCCCCCGAGT 
GTGAGCGCCG CACCCGGGCA GAAAGTGACA ATCTCGTGTT CGGGTAGCTC TAGCGACATC 
GGCAATAATT ATGTCAGCTG GTACCAACAG CTGCCGGGAA CTGCGCCTAA ATTGCTGATC 
TACGATAATA ACAAACGTCC GAGTGGAATC CCTGACCGCT TCTCCGGGTC AAAAAGCGGC 
ACCAGCGCCA CGTTAGGGAT TACTGGCCTG CAAACGGGGG ATGAAGCAGA CTATTATTGT 
GGCACGTGGG ATAGCAGTTT AAGTGCCTGG GTTTTTGGGG GCGGCACTAA ACTGACCGTT 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.16: DNA sequence of the β-lactamase SFT fusion construct. The periplasmic signal 
sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFSFGAFTW VRQAPGQGLE WMGGIIPIFG TTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.17: Protein sequence of the β-lactamase SFT fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.18: Plasmid map of pBR322-βla-SFT. 
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8.1.7 βla-WTT 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTGGTTCAGA GTGGCGCGGA GGTTAAGAAA 
CCGGGGTCAA GTGTTAAGGT GTCTTGCAAA GCGAGCGGCG GCACCTTCTG GACCGGAGCG 
TTTACGTGGG TGCGTCAGGC GCCGGGCCAG GGTTTGGAAT GGATGGGCGG TATCATCCCG 
ATTTTTGGGA CGACGAACCT GGCCCAAAAT TTCCAGGGGC GGGTGACGAT CACGGCAGAT 
GAGAGTACAT CGACTGTGTA TATGGAACTG TCCAGCTTGC GCAGTGAAGA CACGGCGGTG 
TATTACTGCG CCCGCTCCAG CCGGATCTAC GACTTGAACC CATCCCTGAC CGCCTATTAT 
GATATGGATG TATGGGGCCA AGGCACGATG GTGACGGTGA GCTCTGGCGG CGGGTCAAGT 
GGGGGAGGGG GTTCGGGGGG TGGTGGAGGC GCACAGTCTG TTTTAACCCA GCCCCCGAGT 
GTGAGCGCCG CACCCGGGCA GAAAGTGACA ATCTCGTGTT CGGGTAGCTC TAGCGACATC 
GGCAATAATT ATGTCAGCTG GTACCAACAG CTGCCGGGAA CTGCGCCTAA ATTGCTGATC 
TACGATAATA ACAAACGTCC GAGTGGAATC CCTGACCGCT TCTCCGGGTC AAAAAGCGGC 
ACCAGCGCCA CGTTAGGGAT TACTGGCCTG CAAACGGGGG ATGAAGCAGA CTATTATTGT 
GGCACGTGGG ATAGCAGTTT AAGTGCCTGG GTTTTTGGGG GCGGCACTAA ACTGACCGTT 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.19: DNA sequence of the β-lactamase WTT fusion construct. The periplasmic 
signal sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFWTGAFTW VRQAPGQGLE WMGGIIPIFG TTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.20: Protein sequence of the β-lactamase WTT fusion construct. The glycine-
serine linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The 
heavy and light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.21: Plasmid map of pBR322-βla-WTT. 
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8.1.8 βla-STT 
ATGAGTATTC AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT 
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA 
CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC GGTATTATCC 
CGTGTTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG 
GTTGAGTACT CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA 
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC 
GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT 
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG 
CCTGCAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTAGG TGGTGGTGGT 
TCTGGTGGTG GTGGCTCGAG CCAGGTTCAG CTGGTTCAGA GTGGCGCGGA GGTTAAGAAA 
CCGGGGTCAA GTGTTAAGGT GTCTTGCAAA GCGAGCGGCG GCACCTTCTC CACCGGAGCG 
TTTACGTGGG TGCGTCAGGC GCCGGGCCAG GGTTTGGAAT GGATGGGCGG TATCATCCCG 
ATTTTTGGGA CGACGAACCT GGCCCAAAAT TTCCAGGGGC GGGTGACGAT CACGGCAGAT 
GAGAGTACAT CGACTGTGTA TATGGAACTG TCCAGCTTGC GCAGTGAAGA CACGGCGGTG 
TATTACTGCG CCCGCTCCAG CCGGATCTAC GACTTGAACC CATCCCTGAC CGCCTATTAT 
GATATGGATG TATGGGGCCA AGGCACGATG GTGACGGTGA GCTCTGGCGG CGGGTCAAGT 
GGGGGAGGGG GTTCGGGGGG TGGTGGAGGC GCACAGTCTG TTTTAACCCA GCCCCCGAGT 
GTGAGCGCCG CACCCGGGCA GAAAGTGACA ATCTCGTGTT CGGGTAGCTC TAGCGACATC 
GGCAATAATT ATGTCAGCTG GTACCAACAG CTGCCGGGAA CTGCGCCTAA ATTGCTGATC 
TACGATAATA ACAAACGTCC GAGTGGAATC CCTGACCGCT TCTCCGGGTC AAAAAGCGGC 
ACCAGCGCCA CGTTAGGGAT TACTGGCCTG CAAACGGGGG ATGAAGCAGA CTATTATTGT 
GGCACGTGGG ATAGCAGTTT AAGTGCCTGG GTTTTTGGGG GCGGCACTAA ACTGACCGTT 
CTGGGATCCG GGAGCGGTTC CGGAAGCGGA GGAGGTGGTT CAGGCGGAGG TGGAAGCTTG 
ACTCTAGCTA GCCGGCAGCA GCTCATAGAC TGGATGGAGG CGGATAAAGT TGCAGGACCA 
CTTCTGCGCT CGGCCCTTCC GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG 
CGTGGGTCTC GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA GATCGCTGAG 
ATAGGTGCCT CACTGATTAA GCATTGGTAA 
Appendix 8.22: DNA sequence of the β-lactamase STT fusion construct. The periplasmic signal 
sequence is in purple. The WFL sequence is shown in blue with the XhoI and BamHI 
restriction sites shown in orange and red, respectively. The glycine-serine linker is 
highlighted in bold. Codons for positions 30, 31 and 57 are highlighted in yellow. Start and 
stop codons are underlined. 
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MSIQHFRVALIPFFAAFCLPVFA – signal sequence 
HPETLVKVKD AEDQLGARVG YIELDLNSGK ILESFRPEER FPMMSTFKVL 
LCGAVLSRVD AGQEQLGRRI HYSQNDLVEY SPVTEKHLTD GMTVRELCSA 
AITMSDNTAA NLLLTTIGGP KELTAFLHNM GDHVTRLDRW EPELNEAIPN 
DERDTTMPAA MATTLRKLLT GELGGGGSGG GGSSQVQLVQ SGAEVKKPGS 
SVKVSCKASG GTFSTGAFTW VRQAPGQGLE WMGGIIPIFG TTNLAQNFQG 
RVTITADEST STVYMELSSL RSEDTAVYYC ARSSRIYDLN PSLTAYYDMD 
VWGQGTMVTV SSGGGSSGGG GSGGGGGAQS VLTQPPSVSA APGQKVTISC 
SGSSSDIGNN YVSWYQQLPG TAPKLLIYDN NKRPSGIPDR FSGSKSGTSA 
TLGITGLQTG DEADYYCGTW DSSLSAWVFG GGTKLTVLGS GSGSGSGGGG 
SGGGGSLTLA SRQQLIDWME ADKVAGPLLR SALPAGWFIA DKSGAGERGS 
RGIIAALGPD GKPSRIVVIY TTGSQATMDE RNRQIAEIGA SLIKHW 
Appendix 8.23: Protein sequence of the β-lactamase STT fusion construct. The glycine-serine 
linker is highlighted in bold. Residues 30, 31 and 57 are highlighted in yellow. The heavy and 
light chains are shown in blue and purple, respectively. 
 
 
Appendix 8.24: Plasmid map of pBR322-βla-STT. Generated and kindly provided by Dr Janet 
Saunders (University of Leeds). 
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8.2 DNA and protein sequences of scFv constructs used for in vitro 
characterisation and their plasmid maps 
8.2.1 WFL_scFv 
CATATGCAGG TTCAGCTGGT TCAGAGTGGT GCGGAGGTCA AAAAACCCGG 
CAGCTCTGTA AAAGTTAGCT GCAAAGCGAG TGGCGGTACG TTTTGGTTTG 
GGGCCTTTAC TTGGGTTCGT CAAGCGCCGG GCCAGGGCTT GGAATGGATG 
GGTGGCATTA TCCCTATTTT CGGCCTCACA AACCTGGCGC AAAACTTTCA 
AGGTCGCGTT ACCATTACGG CGGACGAAAG CACCAGTACC GTCTATATGG 
AGCTGTCAAG CCTGCGCTCA GAAGACACCG CAGTTTACTA CTGTGCGCGT 
AGCAGCCGCA TTTACGACTT GAATCCTAGC CTCACAGCGT ACTACGACAT 
GGATGTGTGG GGGCAGGGCA CCATGGTTAC GGTGTCGAGT GGTGGTGGGA 
GCAGTGGTGG AGGTGGGTCC GGGGGCGGCG GCGGCGCGCA AAGCGTATTA 
ACTCAGCCGC CGAGCGTGAG CGCAGCCCCT GGGCAGAAAG TCACCATTTC 
ATGCAGCGGC TCCTCCAGCG ATATCGGCAA CAATTACGTG TCCTGGTATC 
AGCAGCTGCC TGGCACTGCG CCGAAGCTGT TGATTTATGA CAACAATAAG 
CGTCCCTCGG GTATTCCAGA TCGTTTTTCT GGCTCTAAAA GCGGGACATC 
AGCGACACTG GGCATCACCG GGCTGCAGAC GGGGGATGAA GCCGATTATT 
ACTGCGGGAC CTGGGATAGT TCCCTGAGCG CGTGGGTGTT TGGCGGGGGC 
ACCAAACTCA CCGTGCTGGG GGCGGCGGCG CACCATCACC ATCACCACTA  
ACTCGAG 
Appendix 8.25: DNA sequence of WFL_scFv. NdeI and XhoI restriction sites are shown in 
gold and orange, respectively. Additional GAAA amino acid codons are shown in pink with 
the hexa-histag shown in green. Codons for positions 30, 31 and 57 are highlighted in yellow. 
Start and stop codons are underlined. 
 
MQVQLVQSGA EVKKPGSSVK VSCKASGGTF WFGAFTWVRQ APGQGLEWMG 
GIIPIFGLTN LAQNFQGRVT ITADESTSTV YMELSSLRSE DTAVYYCARS 
SRIYDLNPSL TAYYDMDVWG QGTMVTVSSG GGSSGGGGSG GGGGAQSVLT 
QPPSVSAAPG QKVTISCSGS SSDIGNNYVS WYQQLPGTAP KLLIYDNNKR 
PSGIPDRFSG SKSGTSATLG ITGLQTGDEA DYYCGTWDSS LSAWVFGGGT 
KLTVLGAAAH HHHHH 
 
Appendix 8.26: Protein sequence of WFL_scFv. Additional GAAA amino acids are shown in 
pink with the hexa-histag shown in green. Residues 30, 31 and 57 are highlighted in yellow. 
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Appendix 8.27: Table of WFL_scFv properties. 
Amino acids Base pairs MW pI ε 
265 795 27,629.6 Da 6.57 55,140 
 
 
 
Appendix 8.28: Plasmid map of pET23a WFL-scFv. 
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8.2.2 SFL_scFv 
CATATGCAGG TTCAGCTGGT TCAGAGTGGT GCGGAGGTCA AAAAACCCGG 
CAGCTCTGTA AAAGTTAGCT GCAAAGCGAG TGGCGGTACG TTTTCCTTTG 
GGGCCTTTAC TTGGGTTCGT CAAGCGCCGG GCCAGGGCTT GGAATGGATG 
GGTGGCATTA TCCCTATTTT CGGCCTCACA AACCTGGCGC AAAACTTTCA 
AGGTCGCGTT ACCATTACGG CGGACGAAAG CACCAGTACC GTCTATATGG 
AGCTGTCAAG CCTGCGCTCA GAAGACACCG CAGTTTACTA CTGTGCGCGT 
AGCAGCCGCA TTTACGACTT GAATCCTAGC CTCACAGCGT ACTACGACAT 
GGATGTGTGG GGGCAGGGCA CCATGGTTAC GGTGTCGAGT GGTGGTGGGA 
GCAGTGGTGG AGGTGGGTCC GGGGGCGGCG GCGGCGCGCA AAGCGTATTA 
ACTCAGCCGC CGAGCGTGAG CGCAGCCCCT GGGCAGAAAG TCACCATTTC 
ATGCAGCGGC TCCTCCAGCG ATATCGGCAA CAATTACGTG TCCTGGTATC 
AGCAGCTGCC TGGCACTGCG CCGAAGCTGT TGATTTATGA CAACAATAAG 
CGTCCCTCGG GTATTCCAGA TCGTTTTTCT GGCTCTAAAA GCGGGACATC 
AGCGACACTG GGCATCACCG GGCTGCAGAC GGGGGATGAA GCCGATTATT 
ACTGCGGGAC CTGGGATAGT TCCCTGAGCG CGTGGGTGTT TGGCGGGGGC 
ACCAAACTCA CCGTGCTGGG GGCGGCGGCG CACCATCACC ATCACCACTA  
ACTCGAG 
Appendix 8.29: DNA sequence of SFL_scFv. NdeI and XhoI restriction sites are shown in gold 
and orange, respectively. Additional GAAA amino acid codons are shown in pink with the 
hexa-histag shown in green. Codons for positions 30, 31 and 57 are highlighted in yellow. 
Start and stop codons are underlined. 
 
MQVQLVQSGA EVKKPGSSVK VSCKASGGTF SFGAFTWVRQ APGQGLEWMG 
GIIPIFGLTN LAQNFQGRVT ITADESTSTV YMELSSLRSE DTAVYYCARS 
SRIYDLNPSL TAYYDMDVWG QGTMVTVSSG GGSSGGGGSG GGGGAQSVLT 
QPPSVSAAPG QKVTISCSGS SSDIGNNYVS WYQQLPGTAP KLLIYDNNKR 
PSGIPDRFSG SKSGTSATLG ITGLQTGDEA DYYCGTWDSS LSAWVFGGGT 
KLTVLGAAAH HHHHH 
 
Appendix 8.30: Protein sequence of SFL_scFv. Additional GAAA amino acids are shown in 
pink with the hexa-histag shown in green. Residues 30, 31 and 57 are highlighted in yellow. 
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Appendix 8.31: Table of SFL_scFv properties. 
Amino acids Base pairs MW pI ε 
265 795 27,530.5 Da 6.57 49,640 
 
 
Appendix 8.32: Plasmid map of pET23a SFL-scFv. 
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8.2.3 STT_scFv 
CATATGCAGG TTCAGCTGGT TCAGAGTGGC GCGGAGGTTA AGAAACCGGG 
GTCAAGTGTT AAGGTGTCTT GCAAAGCGAG CGGCGGCACC TTCTCCACCG 
GAGCGTTTAC GTGGGTGCGT CAGGCGCCGG GCCAGGGTTT GGAATGGATG 
GGCGGTATCA TCCCGATTTT TGGGACGACG AACCTGGCCC AAAATTTCCA 
GGGGCGGGTG ACGATCACGG CAGATGAGAG TACATCGACT GTGTATATGG 
AACTGTCCAG CTTGCGCAGT GAAGACACGG CGGTGTATTA CTGCGCCCGC 
TCCAGCCGGA TCTACGACTT GAACCCATCC CTGACCGCCT ATTATGATAT 
GGATGTATGG GGCCAAGGCA CGATGGTGAC GGTGAGCTCT GGCGGCGGGT 
CAAGTGGGGG AGGGGGTTCG GGGGGTGGTG GAGGCGCACA GTCTGTTTTA 
ACCCAGCCCC CGAGTGTGAG CGCCGCACCC GGGCAGAAAG TGACAATCTC 
GTGTTCGGGT AGCTCTAGCG ACATCGGCAA TAATTATGTC AGCTGGTACC 
AACAGCTGCC GGGAACTGCG CCTAAATTGC TGATCTACGA TAATAACAAA 
CGTCCGAGTG GAATCCCTGA CCGCTTCTCC GGGTCAAAAA GCGGCACCAG 
CGCCACGTTA GGGATTACTG GCCTGCAAAC GGGGGATGAA GCAGACTATT 
ATTGTGGCAC GTGGGATAGC AGTTTAAGTG CCTGGGTTTT TGGGGGCGGC 
ACTAAACTGA CCGTTCTGGC GGCAGCGCAC CATCACCATC ACCACTAACT  
CGAG 
Appendix 8.33: DNA sequence of STT_scFv. NdeI and XhoI restriction sites are shown in gold 
and orange, respectively. Additional AAA amino acid codons are shown in pink with the 
hexa-histag shown in green. Codons for positions 30, 31 and 57 are highlighted in yellow. 
Start and stop codons are underlined. 
 
MQVQLVQSGA EVKKPGSSVK VSCKASGGTF STGAFTWVRQ APGQGLEWMG 
GIIPIFGTTN LAQNFQGRVT ITADESTSTV YMELSSLRSE DTAVYYCARS 
SRIYDLNPSL TAYYDMDVWG QGTMVTVSSG GGSSGGGGSG GGGGAQSVLT 
QPPSVSAAPG QKVTISCSGS SSDIGNNYVS WYQQLPGTAP KLLIYDNNKR 
PSGIPDRFSG SKSGTSATLG ITGLQTGDEA DYYCGTWDSS LSAWVFGGGT 
KLTVLAAAHH HHHH 
 
Appendix 8.34: Protein sequence of SFL_scFv. Additional AAA amino acids are shown in pink 
with the hexa-histag shown in green. Residues 30, 31 and 57 are highlighted in yellow. 
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Appendix 8.35: Table of STT_scFv properties. 
Amino acids Base pairs MW pI ε 
264 792 27,415.3 Da 6.57 49,640 
 
 
Appendix 8.36: Plasmid map of pET23a STT_scFv.  
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8.3 Cross-links identified using StavroX 
Appendix 8.37: Cross-linked peptides identified using StavroX for the cross-linked monomer 
sample of WFL with a score above 100. 
WFL cross-linked monomer 
Peptide 1 Peptide 2 
ADSSPVK AGVETTTPSK 
ADSSPVKAGVETTPSK YAASSYLSLTPEQWKSHR 
ADSSPVKAGVETTPSK SYSBQVTHEGSTVEK 
ADSSPVKAGVETTPSK GPSVFPLAPSSKSTSGGTAALGBLVK 
GPSVFPLAPSSK STSGGTAALGBLVK 
LTVDKSR ADSSPVKAGVETTPSK 
LTVDKSR EEMTKNQVSLTBLVK 
QSNNK YAASSYLSLTPEQWK 
RPSGIPDR LLIYDNNKR 
SBDK THTBPPBPAPEFEGGPSVFLFPPKPK 
TISKAK ADSSPVKAGVETTPSK 
TISKAK LTVDKSR 
VDKR ADSSPVKAGVETTTPSK 
VEPKSBDK ADSSPVKAGVETTPSK 
VSNKALPASIEK ADSSPVKAGVETTPSK 
 
 
Appendix 8.38: Cross-linked peptides identified using StavroX for the cross-linked dimer 
sample of WFL with a score about 100. Blue = unique cross-link to the dimer sample (this was 
not identified in repeat samples).  
WFL cross-linked dimer 
Peptide 1 Peptide 2 
ADSSPVK AGVETTTPSK 
ADSSPVKAGVETTPSK YAASSYLSLTPEQWKSHR 
ADSSPVKAGVETTPSK GPSVFPLAPSSKSTSGGTAALGBLVK 
GPSVFPLAPSSK STSGGTAALGBLVK 
LTVDKSR ADSSPVKAGVETTPSK 
LTVDKSR EEMTKNQVSLTBLVK 
LTVDKSR LTVDKSR 
QSNNK YAASSYLSLTPEQWK 
RPSGIPDR LLIYDNNKR 
SBDK THTBPPBPAPEFEGGPSVFLFPPKPK 
TISKAK ADSSPVKAGVETTPSK 
VDKR ADSSPVKAGVETTTPSK 
VEPKSBDK ADSSPVKAGVETTPSK 
VSNKALPASIEK ADSSPVKAGVETTPSK 
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Appendix 8.39: Cross-linked peptides identified using StavroX for the cross-linked monomer 
sample of STT with a score above 100. 
STT cross-linked monomer 
Peptide 1 Peptide 2 
ADSSPVK AGVETTTPSK 
ADSSPVKAGVETTPSK YAASSYLSLTPEQWKSHR 
ADSSPVKAGVETTPSK SYSBQVTHEGSTVEK 
ADSSPVKAGVETTPSK GPSVFPLAPSSKSTSGGTAALGBLVK 
AKGQPR ADSSPVKAGVETTPSK 
GPSVFPLAPSSK STSGGTAALGBLVK 
KPGSSVKVSBK ATLVBLISDFYPGAVTVAWKADSSPVK 
LTVDKSR EEMTKNQVSLTBLVK 
QSNNK YAASSYLSLTPEQWK 
SBDK THTBPPBPAPEFEGGPSVFLFPPKPK 
TISK ALPASIEK 
TISKAK ADSSPVKAGVETTPSK 
TISKAK LTVDKSR 
VDKR ADSSPVKAGVETTTPSK 
VSBK KPGSSVK 
VSNKALPASIEK ADSSPVKAGVETTPSK 
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8.4 Results from the in vivo assay 
 
Appendix 8.41: Plates showing the in vivo results of (a) WFL, (b) SFL and (c) STT. 
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